<SEC-DOCUMENT>0001493152-22-026706.txt : 20220923
<SEC-HEADER>0001493152-22-026706.hdr.sgml : 20220923
<ACCEPTANCE-DATETIME>20220923170247
ACCESSION NUMBER:		0001493152-22-026706
CONFORMED SUBMISSION TYPE:	DEF 14A
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20220923
FILED AS OF DATE:		20220923
DATE AS OF CHANGE:		20220923

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Enveric Biosciences, Inc.
		CENTRAL INDEX KEY:			0000890821
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				954484725
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DEF 14A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38286
		FILM NUMBER:		221262917

	BUSINESS ADDRESS:	
		STREET 1:		4851 TAMIAMI TRAIL N, SUITE 200
		CITY:			NAPLES
		STATE:			FL
		ZIP:			34103
		BUSINESS PHONE:		239-302-1707

	MAIL ADDRESS:	
		STREET 1:		4851 TAMIAMI TRAIL N, SUITE 200
		CITY:			NAPLES
		STATE:			FL
		ZIP:			34103

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AMERI Holdings, Inc.
		DATE OF NAME CHANGE:	20150527

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SPATIALIZER AUDIO LABORATORIES INC
		DATE OF NAME CHANGE:	19950323
</SEC-HEADER>
<DOCUMENT>
<TYPE>DEF 14A
<SEQUENCE>1
<FILENAME>formdef14a.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 4pt solid; border-bottom: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>UNITED
STATES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>SECURITIES
AND EXCHANGE COMMISSION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt"><B>Washington,
D.C. 20549</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>SCHEDULE
14A</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Proxy
Statement Pursuant to Section 14(a) of the Securities</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exchange
Act of 1934 (Amendment No. )</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filed
by the Registrant &#9746;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filed
by a Party other than the Registrant &#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Check
the appropriate box:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.35in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Preliminary
    Proxy Statement</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Confidential,
    For Use of the Commission Only (as permitted by Rule 14a-6(e)(2))</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Definitive
    Proxy Statement</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Definitive
    Additional Materials</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Soliciting
    Material Under &sect;240.14a-12</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>ENVERIC
BIOSCIENCES, INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Name
of Registrant as Specified in Its Charter)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">-<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Name
of Person(s) Filing Proxy Statement, if Other Than the Registrant)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Payment
of Filing Fee (Check all boxes that apply):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
                                            fee required.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fee
                                            paid previously with preliminary materials</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fee
                                            computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and
                                            0-11.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid; border-bottom: Black 4pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ENVERIC
BIOSCIENCES, INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>4851
Tamiami Trail N., Suite 200</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Naples,
Florida 34103</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">September
23, 2022</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dear
Stockholders:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
cordially invite you to attend the 2022 Annual Meeting of Stockholders (the &ldquo;<U>Annual Meeting</U>&rdquo;) of Enveric Biosciences,
Inc., a Delaware corporation (&ldquo;<U>we</U>,&rdquo; &ldquo;<U>us</U>,&rdquo; &ldquo;<U>our</U>&rdquo; or the &ldquo;<U>Company</U>&rdquo;),
which will be held on October 28, 2022, at 10:00 a.m. Eastern Time at www.virtualshareholdermeeting.com/ENVB2022. In light of the ongoing
developments related to the novel coronavirus, the Company has determined that the Annual Meeting will be a virtual meeting conducted
exclusively via live webcast. You or your proxyholder will be able to attend the virtual Annual Meeting online, vote and view
the list of stockholders entitled to vote at the Annual Meeting by visiting www.virtualshareholdermeeting.com/ENVB2022 and entering the
16-digit control number on your proxy card or voting instruction form, as applicable. To register and receive access to the virtual Annual
Meeting, registered stockholders and beneficial stockholders (those holding shares through a stock brokerage account or by a bank or
other holder of record) will need to follow the instructions applicable to them provided in the accompanying proxy statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Details
regarding the Annual Meeting and the business to be conducted at the Annual Meeting are more fully described in the accompanying Notice
of Annual Stockholders Meeting and proxy statement. You are entitled to vote at our Annual Meeting and any adjournments, continuations
or postponements thereof only if you were a stockholder as of September 14, 2022.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Your
vote is very important, regardless of the number of shares of our voting securities that you own. Whether or not you expect to attend
the Annual Meeting online, please vote as promptly as possible by following the instructions in the accompanying proxy statement to ensure
your representation and the presence of a quorum at the Annual Meeting. As an alternative to voting online during the Annual Meeting,
you may vote via the Internet, by telephone, or by signing, dating and returning the accompanying proxy card.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
your shares are held in the name of a broker, trust, bank or other nominee, and you receive these materials through your broker or through
another intermediary, please complete and return the materials in accordance with the instructions provided to you by such broker or
other intermediary, or you may also virtually attend the meeting and vote online during the meeting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
behalf of the board of directors, I urge you to submit your vote as soon as possible, even if you currently plan to attend the Annual
Meeting online.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
you have any questions regarding the attached proxy statement or need assistance in voting your shares of common stock or preferred stock,
please contact our proxy solicitor, Kingsdale Advisors, by telephone at 1-866-851-2468 (stockholders) and 646-854-7795 (brokers,
banks and other nominees), or by email at contactus@kingsdaleadvisors.com.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Thank
you for your ongoing support of our Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 47%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">order
    of the Board of Directors,</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Joseph Tucker</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Joseph
    Tucker, PhD</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Chief
    Executive Officer</I></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 3in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ENVERIC
BIOSCIENCES, INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>4851
Tamiami Trail N, Suite 200</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Naples,
FL 34103</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notice
of Annual Meeting of Stockholders</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
Be Held on October 28, 2022</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notice
is hereby given that the 2022 Annual Meeting of Stockholders (the &ldquo;<U>Annual Meeting</U>&rdquo;) of Enveric Biosciences, Inc.,
a Delaware corporation (the &ldquo;<U>Company</U>&rdquo;), will be held on October 28, 2022, at 10:00 a.m. Eastern Time via a live webcast
on the Internet. You will be able to virtually attend the Annual Meeting online and vote during the Annual
Meeting by visiting www.virtualshareholdermeeting.com/ENVB2022 during the meeting. Only stockholders of record of our common stock or
preferred stock on September 14, 2022 (the &ldquo;<U>Record Date</U>&rdquo;) will be entitled to vote at the Annual Meeting and any adjournments,
continuations or postponements thereof that may take place. We are holding the Annual Meeting for the following purposes, which are more
fully described in the accompanying proxy statement:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    election of seven directors, to serve until the Company&rsquo;s 2023 annual meeting of stockholders or until their successors are
    duly elected and qualified (&ldquo;<U>Election of Directors</U>&rdquo;);</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
    non-binding advisory vote to approve the compensation of the Company&rsquo;s named executive officers (the &ldquo;<U>Say-on-Pay Proposal</U>&rdquo;);
    and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    ratification of the appointment of Marcum LLP as the Company&rsquo;s independent registered public accounting firm for the
    fiscal year ending December 31, 2022 (the &ldquo;<U>Auditor Ratification Proposal</U>&rdquo;).</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stockholders
are referred to the proxy statement accompanying this notice for more detailed information with respect to the matters to be considered
at the Annual Meeting. After careful consideration, the Board has determined that each proposal listed above is in the best interests
of the Company and its stockholders and has approved each proposal. <B>The Board recommends a vote FOR each of the board of directors&rsquo;
seven nominees that are standing for election to the board of directors (Proposal 1), FOR the Say-on-Pay Proposal (Proposal 2), and FOR
the Auditor Ratification Proposal (Proposal 3)</B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Board has fixed the close of business on September 14, 2022 as the Record Date for the Annual Meeting. Only stockholders of record on
the Record Date are entitled to receive notice of the Annual Meeting and to vote at the Annual Meeting or at any postponement(s) or,
continuations(s), or adjournment(s) of the Annual Meeting. A complete list of registered stockholders entitled to vote at the Annual
Meeting will be available for inspection at our offices during regular business hours for the 10 calendar days prior to the Annual Meeting
and online during the Annual Meeting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>Your
vote at the annual meeting is important.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Whether
or not you plan to attend the Annual Meeting online, we urge you to vote your shares as promptly as possible by Internet, telephone or
mail.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
behalf of our entire Board of Directors, we thank you for your continued support.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 47%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">order
    of the Board of Directors,</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/<I>s</I>/
    <I>Joseph Tucker</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Joseph
    Tucker, PhD</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Chief
    Executive Officer</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Naples,
    Florida</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">September
    23, 2022</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 3in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iii<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Table
of Contents</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#n_001"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notice of Annual Meeting of Stockholders</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">v</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_001">Questions and Answers About the Annual Meeting</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_002">Proposal 1: Election of Directors</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_003">Corporate Governance</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_004">Executive Compensation</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">22</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_005">Director Compensation</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">39</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_006">Related Person Transactions and Section 16(a) Beneficial Ownership Reporting Compliance</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">40</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_007">Proposal 2: Advisory Vote to Approve Executive Compensation</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">51</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_008">Report of the Audit Committee</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">52</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_009">Proposal 3: Ratification of Appointment of Independent Auditors</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">54</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_010">Security Ownership of Certain Beneficial Owners and Management</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">57</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_011">Other Matters</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">59</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_012">Deadline for Receipt of Stockholder Proposals</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">59</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_013">Annual Report</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">59</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_014">Stockholders Sharing the Same Address</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">60</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iv<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="n_001"></A>ENVERIC
BIOSCIENCES, INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>4851
Tamiami Trail N., Suite 200</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Naples,
FL 34103</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="border-top: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Proxy
Statement</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>for</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>Annual
Meeting of Stockholders</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>To
Be Held on October 28, 2022</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="border-top: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
the context otherwise requires, references in this proxy statement to &ldquo;<U>we</U>,&rdquo; &ldquo;<U>us</U>,&rdquo; &ldquo;<U>our</U>,&rdquo;
the &ldquo;<U>Company</U>&rdquo; or &ldquo;<U>Enveric</U>&rdquo; refer to Enveric Biosciences, Inc. (formerly known as Ameri Holdings,
Inc.), a Delaware corporation and its consolidated subsidiary as a whole. In addition, unless the context otherwise requires, references
to &ldquo;stockholders&rdquo; are to the holders of our common stock, par value $0.01 per share (&ldquo;<U>Common Stock</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying proxy is solicited by the Board of Directors (the &ldquo;<U>Board</U>&rdquo;) on behalf of Enveric Biosciences, Inc. to
be voted at the Company&rsquo;s 2022 Annual Meeting of Stockholders (the &ldquo;<U>Annual Meeting</U>&rdquo;) to be held on October 28,
2022, and at any adjournment, continuation or postponement thereof, for the purposes set forth in the accompanying Notice of Annual Meeting
of Stockholders (the &ldquo;<U>Notice</U>&rdquo;). The Annual Meeting will be held virtually via a live webcast on the Internet on October
28, 2022 at 10:00 a.m. Eastern Time. This proxy statement and accompanying form of proxy are dated September 23, 2022 and are
expected to be first sent or given to stockholders along with a copy of our annual report on Form 10-K for the year ended December 31,
2021 (the &ldquo;2021 Annual Report&rdquo;) on or about September 23, 2022.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
you held shares of our Common Stock at the close of business on September 14, 2022 (the &ldquo;<U>Record Date</U>&rdquo;), you are invited
to attend the Annual Meeting virtually at www.virtualshareholdermeeting.com/ENVB2022 and if you held shares of our Common Stock at the
close of business on the Record Date, you are invited to vote on the proposals described in this proxy statement applicable to the class
of stock which you held.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
executive offices of the Company are located at, and the mailing address of the Company is, 4851 Tamiami Trail N., Suite 200, Naples,
FL 34103.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company will pay the costs of soliciting proxies from stockholders. We have retained Kingsdale Advisors to assist in the solicitation
of proxies for a fee of $8,500, plus reimbursement of expenses. In addition to solicitation by mail and by Kingsdale Advisors,
our directors, officers and employees may solicit proxies on behalf of the Company, without additional compensation, by telephone, facsimile,
mail, on the Internet or in person.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Important
Notice Regarding the Availability of Proxy Materials for the Enveric Biosciences, Inc. 2022 Annual Meeting of Stockholders to be Held
on October 28, 2022</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Notice of Annual Meeting of Stockholders and Proxy Statement and 2021 Annual Report are available to stockholders at <B>www.proxyvote.com</B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->v<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="a_001"></A>Questions
and Answers About the Annual Meeting</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">What
is a proxy?</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
proxy is another person that you legally designate to vote your stock. If you designate someone as your proxy in a written document,
that document is also called a &ldquo;proxy&rdquo; or a &ldquo;proxy card.&rdquo; By using the methods discussed below, you will be appointing
Joseph Tucker as your proxy. The proxy agent will vote on your behalf, and will have the authority to appoint a substitute to act as
proxy. If you are unable to attend the Annual Meeting, please vote by proxy so that your shares may be voted.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">What
is a proxy statement?</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
proxy statement is a document that regulations of the Securities and Exchange Commission (&ldquo;<U>SEC</U>&rdquo;) require that we give
to you when we ask you to sign a proxy card to vote your stock at the Annual Meeting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">What
is the purpose of the Annual Meeting?</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
the Annual Meeting, stockholders will act upon the following proposals:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    election of seven directors, to serve until the Company&rsquo;s 2023 annual meeting of stockholders or until their successors are
    duly elected and qualified (&ldquo;<U>Election of Directors</U>&rdquo;);</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
    non-binding advisory vote to approve the compensation of the Company&rsquo;s named executive officers (the &ldquo;<U>Say-on-Pay Proposal</U>&rdquo;);
    and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    ratification of the appointment of Marcum LLP  as the Company&rsquo;s independent registered public
    accounting firm for the fiscal year ending December 31, 2022 (the &ldquo;<U>Auditor Ratification Proposal</U>&rdquo;).</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">What
is the record date and what does it mean?</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Record Date to determine the stockholders entitled to notice of and to vote at the Annual Meeting is the close of business on September
14, 2022. The Record Date is established by the Board as required by Delaware law. On the Record Date, 2,078,271 shares of Common Stock
were issued and outstanding and entitled to vote.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Who
is entitled to vote at the Annual Meeting?</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holders
of record of our Common Stock as of the close of business on the Record Date will be entitled to notice of and to vote at the Annual
Meeting and at any adjournments or postponements thereof. Holders of record of shares of Common Stock have the right to vote on all matters
brought before the Annual Meeting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
do not need to attend the Annual Meeting to vote your shares. Instead, you may vote your shares by marking, signing, dating and returning
the enclosed proxy card or voting through the Internet.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 6; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">What
are the voting rights of the stockholders?</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
share of our Common Stock outstanding as of the record date is entitled to one vote per share on all matters properly brought before
the Annual Meeting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">When
and where is the Annual Meeting and what do I need to be able to attend online?</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Annual Meeting will be held on October 28, 2022, at 10:00 a.m. Eastern Time at www.virtualshareholdermeeting.com/ENVB2022. Any stockholder
who owns our Common Stock on the Record Date can attend the Annual Meeting online.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
will be able to attend the Annual Meeting online, vote and view the list of stockholders entitled to vote at the Annual Meeting by visiting www.virtualshareholdermeeting.com/ENVB2022. To participate in the virtual
meeting, you will need a 16-digit control number included on your proxy card or voting instruction form, as applicable. The meeting webcast
will begin promptly at 10:00 a.m. Eastern Time. We encourage you to access the meeting prior to the start time and you should allow ample
time for the check-in procedures. Because the Annual Meeting will be a completely virtual meeting, there will be no physical location
for stockholders to attend.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">How
do I cast my vote?</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
you are a stockholder of record, there are four ways to vote:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By
    Internet at <U>www.proxyvote.com</U> 24 hours a day, seven days a week, until 11:59 p.m. Eastern Time on October 27, 2022 (have your
    16-digit stockholder control number, which can be found on your proxy card, in hand when you access the website);</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By
    toll-free telephone at 1-800-690-6903, until 11:59 p.m. Eastern Time on October 27, 2022 (have your 16-digit stockholder control
    number, which can be found on your proxy card, in hand when you call);</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By
    completing, signing, dating and mailing your proxy card in the postage-paid envelope we have provided or returning it to Vote Processing,
    c/o Broadridge, 51 Mercedes Way, Edgewood, NY 11717; or</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Online
    during the Annual Meeting at www.virtualshareholdermeeting.com/ENVB2022. You will need your 16-digit stockholder control number,
    which can be found on your proxy card, in hand when you vote online during the Annual Meeting.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By
completing and submitting a proxy, you will direct the designated persons (known as &ldquo;proxies&rdquo;) to vote your stock at the
Annual Meeting in accordance with your instructions. The Board has appointed Joseph Tucker, our Chief Executive Officer to serve as the
proxies for the Annual Meeting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
order to be counted, proxies submitted by telephone or Internet must be received by 11:59 p.m. Eastern Time on October 27, 2022. Proxies
submitted by U.S. mail must be received before the start of the Annual Meeting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Your
proxy will be voted according to your instructions. If you are a stockholder of record and do not vote via the Internet or telephone
or by returning a signed proxy card, your shares will not be voted unless you virtually attend the Annual Meeting and vote your shares
online. If you vote via the Internet or telephone and do not specify contrary voting instructions, your shares will be voted in accordance
with the recommendations of our Board on all matters, and in the discretion of proxy holders as to any other matters that may properly
come before the meeting or any adjournment, continuation or postponement thereof. Similarly, if you sign and submit your proxy card with
no instructions, your shares will be voted in accordance with the recommendations of our Board on all matters, and in the discretion
of proxy holders as to any other matters that may properly come before the meeting or any adjournment, continuation or postponement thereof.
We know of no other business to be considered at the Annual Meeting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
your shares are registered in the name of a broker, bank or other nominee (typically referred to as being held in &ldquo;street name&rdquo;),
there are four ways to vote:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By
    Internet at <U>www.proxyvote.com</U> 24 hours a day, seven days a week, until 11:59 p.m. Eastern Time on October 27, 2022 (have your
    16-digit stockholder control number, which can be found on your voting instruction form, in hand when you access the website);</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By
    toll-free telephone at 1-800-454-8683, until 11:59 p.m. Eastern Time on October 27, 2022 (have your 16-digit stockholder control
    number, which can be found on your voting instruction form, in hand when you call);</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By
    completing, signing, dating and mailing your voting instruction form in the postage-paid envelope provided to you; or</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Online
    during the Annual Meeting at www.virtualshareholdermeeting.com/ENVB2022. You will need your 16-digit shareholder control number,
    which can be found on your voting instruction form, in hand when you vote online during the Annual Meeting.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the event you do not provide instructions on how to vote, your broker will have authority to vote your shares with respect to the Auditor
Ratification Proposal. Under the rules that govern brokers who are voting with respect to shares that are held in street name, brokers
have the discretion to vote such shares on &ldquo;routine&rdquo; matters, but not on &ldquo;non-routine&rdquo; matters. The Auditor Ratification
Proposal is considered a &ldquo;routine&rdquo; matter. Accordingly, your broker, bank or other nominee may vote your shares without receiving
instructions from you on Proposal 3 (Auditor Ratification Proposal). A failure to instruct your broker, bank or other nominee on how
to vote your shares will not necessarily count as a vote against Proposal 3 (Auditor Ratification Proposal). The Election of Directors
and the Say-on-Pay Proposal are not considered routine matters. Accordingly, your broker, bank or other nominee does not have discretionary
authority to vote your shares with respect to Proposal 1 (Election of Directors) or Proposal 2 (Say-on-Pay Proposal).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Who
counts the votes?</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
votes will be tabulated by the inspector of election appointed for the Annual Meeting. Each proposal will be tabulated separately.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">What
are my choices when voting?</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">When
    you cast your vote on:</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Proposal
    1:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
    may vote <FONT STYLE="text-transform: uppercase"><B>for</B></FONT> all director nominees or may <FONT STYLE="text-transform: uppercase"><B>withhold
    </B></FONT>your vote as to one or more director nominees</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Proposal
    2:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
    may vote <B>FOR </B>the proposal, <B>AGAINST</B> the proposal or <B>ABSTAIN</B>.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Proposal
    3:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
    may vote <B>FOR </B>the proposal, <B>AGAINST</B> the proposal or <B>ABSTAIN</B>.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">How
does the Board recommend I vote on the proposals?</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Board recommends you vote:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>FOR</B>&rdquo;
    all seven director nominees;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>FOR</B>&rdquo;
    the Say-on-Pay Proposal; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>FOR</B>&rdquo;
    the Auditor Ratification Proposal.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">What
is a &ldquo;quorum?&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
quorum is the minimum number of shares required to be present or represented by proxy at the Annual Meeting to properly hold a meeting
of stockholders and conduct business under our bylaws and Delaware law. The presence, in person or by proxy, of one-third of the voting
power of the stock issued, outstanding and entitled to vote at the Annual Meeting will constitute a quorum at the Annual Meeting. Abstentions
and broker non-votes will be counted as shares present and entitled to vote for the purposes of determining a quorum for the Annual Meeting.
&ldquo;Broker non-votes&rdquo; occur when brokers, banks or other nominees that hold shares on behalf of beneficial owners do not receive
voting instructions from the beneficial owners prior to the meeting and do not have discretionary voting authority to vote those shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">What
vote is required to approve each item?</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table sets forth the voting requirement with respect to each of the proposals:</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Proposal
    1 &mdash; Election of Directors.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Directors
                                            are elected by a plurality of the voting power of the shares present in person or represented
                                            by proxy at the meeting and entitled to vote on the election of directors. The seven nominees
                                            who receive the greatest number of affirmative &ldquo;<B>FOR</B>&rdquo; votes of the holders
                                            of the Common Stock cast in the Election of Directors at the Annual Meeting will be elected
                                            directors to serve until the next annual meeting of stockholders and until their successors
                                            are duly elected and qualified. Broker non-votes and abstentions will have no effect on this
                                            proposal.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Proposal
    2 &mdash; Say-on-Pay Proposal.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
    be approved by stockholders, this proposal must receive the affirmative &ldquo;<B>FOR</B>&rdquo; vote of a majority of the voting
    power of the shares present in person (which would include voting online at the virtual Annual Meeting) or represented by proxy at
    the meeting and entitled to vote on the proposal. Abstentions will have the same effect as a vote cast &ldquo;AGAINST&rdquo; the
    approval of such proposal. Broker non-votes will have no effect on this proposal.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Proposal
    3 &mdash; Auditor Ratification Proposal.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
    be approved by stockholders, this proposal must receive the affirmative &ldquo;<B>FOR</B>&rdquo; vote of a majority of the voting
    power of the shares present in person (which would include voting online at the virtual Annual Meeting) or represented by proxy at
    the meeting and entitled to vote on the proposal. Abstentions will have the same effect as a vote cast &ldquo;AGAINST&rdquo; the
    approval of such proposal. The approval of the Auditor Ratification Proposal is a routine proposal on which a broker or other nominee
    is generally empowered to vote in the absence of voting instructions from the beneficial owner, so broker non-votes are unlikely
    to result from this proposal.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">How
are abstentions and broker non-votes treated?</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Abstentions
are included in the determination of the number of shares of Common Stock present at the Annual Meeting for determining a quorum at the
meeting. An abstention is not an &ldquo;affirmative vote,&rdquo; but an abstaining stockholder is considered &ldquo;entitled to vote&rdquo;
at the Annual Meeting. Accordingly, an abstention will have the effect of a vote against Proposals 2 and 3.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Broker
non-votes will be included in the determination of the number of shares of Common Stock present at the Annual Meeting for determining
a quorum at the meeting. Broker non-votes, to the extent applicable, will have the effect of a vote against Proposal 3. Because your
broker will have discretionary voting authority with respect to Proposal 3, a broker non-vote would only arise in the event that your
broker does not receive your voting instructions and chooses not to exercise its discretionary voting authority with respect to such
matter. Broker non-votes will have no effect on upon the approval of Proposal 1 and Proposal 2 as broker non-votes are not considered
&ldquo;entitled to vote.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
your shares are held in the name of a bank, broker or other nominee, you should check with your bank, broker or other nominee and follow
the voting instructions provided. Attendance at the Annual Meeting alone will not revoke your proxy.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Can
I revoke or change my proxy?</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
may revoke your proxy and change your vote at any time before the final vote at the Annual Meeting. You may vote again on a later date
via the Internet or by telephone (only your latest Internet or telephone proxy submitted prior to the Annual Meeting will be counted),
by signing and returning a proxy card or voting instructions form with a later date, or by attending the Annual Meeting and voting via
the virtual meeting website. However, your attendance at the Annual Meeting will not automatically revoke your proxy unless you vote
again at the Annual Meeting or specifically request that your prior proxy is revoked by delivering to the Company&rsquo;s corporate secretary
at 4851 Tamiami Trail N., Suite 200, Naples, Florida 34103 a written notice of revocation prior to the Annual Meeting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Do
I have any dissenters&rsquo; or appraisal rights with respect to any of the matters to be voted on at the Annual Meeting?</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No.
None of the stockholders has any dissenters&rsquo; or appraisal rights with respect to the matters to be voted on at the Annual Meeting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">What
does it mean if I get more than one set of voting materials?</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Your
shares are probably registered in more than one account. Please follow the separate voting instructions that you received for your shares
of Common Stock held in each of your different accounts to ensure that all of your shares are voted.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">What
are the solicitation expenses and who pays the cost of this proxy solicitation?</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Board is asking for your proxy and we will pay all of the costs of asking for stockholder proxies. We will reimburse brokerage houses
and other custodians, nominees and fiduciaries for their reasonable out-of-pocket expenses for forwarding solicitation material to the
beneficial owners of Common Stock and collecting voting instructions. We may use officers and employees of the Company to ask for proxies,
as described below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Is
this Proxy Statement the only way that proxies are being solicited?</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No.
In addition to the solicitation of proxies, we have engaged Kingsdale Advisors, the proxy solicitation firm hired by the Company, at
an approximate cost of $8,500, plus reimbursement of expenses, to solicit proxies on behalf of our Board. Kingsdale Advisors may
solicit the return of proxies, either by mail, telephone, telecopy, e-mail or through personal contact. The fees of Kingsdale Advisors
as well as the reimbursement of expenses of Kingsdale Advisors will be borne by us. Our officers, directors and employees may also solicit
the return of proxies, either by mail, telephone, telecopy, e-mail or through personal contact. These officers and employees will not
receive additional compensation for their efforts but will be reimbursed for out-of-pocket expenses. Brokerage houses and other custodians,
nominees and fiduciaries, in connection with shares of the Common Stock registered in their names, will be requested to forward solicitation
material to the beneficial owners of shares of Common Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Are
there any other matters to be acted upon at the Annual Meeting?</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
does not intend to present any business at the Annual Meeting for a vote other than the matters set forth in the Notice and has no information
that others will do so. If other matters requiring a vote of the stockholders properly come before the Annual Meeting, it is the intention
of the persons named in the form of proxy to vote the shares represented by the proxies held by them in accordance with applicable law
and their judgment on such matters.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Where
can I find the voting results of the Annual Meeting?</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preliminary voting results will be announced at the Annual Meeting. The final results will be published in a Current Report on Form 8-K
to be filed by us with the SEC within four business days of the meeting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Whom
do I call if I have questions?</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
you have any questions, need additional material, or need assistance in voting your shares, please feel free to contact the firm assisting
us in the solicitation of proxies, Kingsdale Advisors. Brokers, banks and other nominees may call 646-854-7795. Stockholders may
call toll free at 1-866-851-2468. Or you may contact Kingsdale Advisors by email at contactus@kingsdaleadvisors.com.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="a_002"></A>Proposal
1:<BR>
Election of Directors</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nominees
for Election</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Board, upon the recommendation of the Nominating and Corporate Governance Committee, has nominated the following seven individuals to
serve as directors (collectively, the &ldquo;Company Nominees&rdquo;):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="CENTER" STYLE="font: 10pt Times New Roman, Times, Serif; width: 90%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 30%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Name</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 10%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Age</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Position</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">George
    Kegler</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">65</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director
    and Chair of the Audit Committee</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Douglas
    Lind, M.D.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">62</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bevin
    O&rsquo;Neil</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">45</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Frank
    Pasqualone</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">66</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Marcus
    Schabacker, M.D., Ph.D.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">58</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director
    and Chair of the Compensation Committee</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Joseph
    Tucker, Ph.D.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">54</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer and Director</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Michael
    D. Webb</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">64</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Board has previously fixed the size of the Board to be nine directors. Two of our current directors, David Johnson and Solomon Mayer,
will not stand for reelection at the 2022 Annual Meeting. The Board has resolved to reduce the size of the Board from nine directors
to seven directors upon the election of directors at the Annual Meeting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
elected, respectively, these nominees will serve until our 2023 annual meeting of stockholders or until their successors are elected
and qualified or until their earlier incapacity, removal or resignation. Our Board believes that all of the Company Nominees possess
personal and professional integrity, good judgment, a high level of ability and business acumen.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
a quorum is present, the Company Nominees will be elected by a plurality of the voting power of the shares present in person or represented
by proxy at the meeting and entitled to vote on the election of directors. Abstentions and broker non-votes have no effect on the vote.
The seven Company Nominees receiving the highest number of affirmative votes will be elected directors of the Company. Shares of voting
stock represented by executed proxies will be voted, if authority to do so is not withheld, for the election of the seven nominees named
above. Should any Company Nominee become unable or unwilling to accept nomination or election, the proxy holders may vote the proxies
for the election, in his or her stead, of any other person the Board may nominate or designate. Each Company Nominee has agreed to serve,
if elected, and the Board has no reason to believe that any Company Nominee will be unable to serve.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
biographies of the Company Nominees are as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>George
Kegler</I> has served as a non-employee director of the Company since December 30, 2020. Mr. Kegler was employed by Mallinckrodt Pharmaceuticals
from January 2013 to June 2019, serving as the Executive Vice President and Chief Financial Officer, Interim from December 2018 to May
2019, where he had responsibility for the global finance function and was a member of the executive committee, Vice President Finance
from November 2016 to November 2018, President Specialty Generics (Interim) and Vice President Finance from July 2016 to October 2016,
and Vice President, Finance from January 2013 to June 2016. He has served in various consulting roles since June 2019, which ended in
March 2020. Mr. Kegler has 40 years of experience in financial planning and analysis, corporate finance, controllership and business
development. Previously Mr. Kegler served as the vice president of commercial finance for various businesses within Mallinckrodt and
was also interim president of the company&rsquo;s specialty generics business. Prior to joining Mallinckrodt, he was the chief financial
officer for Convatec a private equity-owned company that was purchased from Bristol-Myers Squibb. He worked in various finance roles
within Bristol-Myers Squibb including commercial, International, technical operations, research &amp; development as well as the assistant
controller of internal controls. Mr. Kegler holds a bachelor&rsquo;s degree in accounting from the University of Missouri, an MBA from
Saint Louis University and completed the Certified Public Accountant exam in Missouri. Mr. Kegler&rsquo;s experience as an officer at
several companies and extensive knowledge of corporate finance qualify him to be a director of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Dr.
Douglas Lind</I> has served as a non-employee director of the Company since March 17, 2021. Dr. Lind is a co-founder and Managing Partner,
since 2013, at Biomark Capital, a Greenwich, CT-based healthcare venture firm. There, his investment focus has included cellular therapy,
medical imaging, peripheral vascular disease, and oncology. Dr. Lind has more than 30 years of experience in a variety of life science
related professions, ranging from former practicing physician to senior Wall Street equity research analyst at Morgan Stanley. Dr. Lind
is a graduate of the University of Iowa, College of Medicine. He was a practicing physician in Brookline, Massachusetts. He served as
an attending physician at St. Elizabeth&rsquo;s Hospital in Boston, a major teaching affiliate of Tufts University School of Medicine,
where he completed his residency training in Internal Medicine. Dr. Lind&rsquo;s medical background and relevant industry experience
qualify him to be a director of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><I>Bevin O&rsquo;Neil</I> has
served as a non-employee director of the Company since June 13, 2022. Ms. O&rsquo;Neil has served at ECRI, a nonprofit organization
focused on advancing effective, evidenced-based healthcare globally since 2021, first as VP, Strategy and currently as Chief Strategy
Officer. Prior to ECRI, O&rsquo;Neil was the founder and managing partner of Incline GEP from 2014 until 2021. From 2011 to 2013, O&rsquo;Neil
served on the drug access team of Clinton Health Access Initiative (CHAI), responsible for improving sustainable access to pediatric
HIV drugs and diagnostics for the developing world utilizing a market-based approach. Earlier in her career, O&rsquo;Neil was a Principal
at Avista Capital Partners, founded by former DLJ Merchant Banking partners. At Avista, O&rsquo;Neil launched the consumer silo and executed
five private equity investments and related tack-on acquisitions in healthcare and consumer, four of which were corporate carve-outs
requiring intense operational and infrastructure building. Prior to Avista, O&rsquo;Neil was a senior manager in business development at Tumi,
an Oaktree Capital Management portfolio company. In addition, O&rsquo;Neil served various roles in the private equity groups of Guggenheim
Partners, Oaktree Capital Management, and DLJ Merchant Banking. O&rsquo;Neil received a BBA from the University of Michigan. Ms. O&rsquo;Neil&rsquo;s
expertise in business operations and fundraising experience qualify her to be a director of the Company.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Frank
Pasqualone</I> has served as a non-employee director of the Company since July 13, 2022. Mr. Pasqualone has served as Senior Vice President,
Chief Business Officer of Theravance Biopharma, Inc. since November 2020 and joined Theravance Biopharma as Senior Vice President, Operations
in June 2014 in connection with its spin-off from Innoviva. Mr. Pasqualone held the position of Senior Vice President, Operations at
Innoviva since January 2014. From 2010 to 2012, he served as President of Intercontinental Region: Latin America, Middle East and Africa
and also as President of Southern Europe from 2009 to 2010, at Bristol-Myers Squibb (BMS). Over a 25-year period with BMS, Mr. Pasqualone
held senior management positions in the U.S. and globally. In the U.S., he was responsible for the Oncology/Virology business and led
the marketing group in the Diabetes business. After leaving Bristol-Myers Squibb and prior to joining Theravance, Mr. Pasqualone was
self-employed as a part-time consultant. Mr. Pasqualone holds an M.B.A. from University of Dayton and a B.S. in Marketing from Bowling
Green State University in Ohio. Mr. Pasqualone&rsquo;s relevant industry experience as an officer at several companies qualifies him
to be a director of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Dr.
Marcus Schabacker</I> has served as a non-employee director of the Company since December 30, 2020. Since January 2018, Dr. Schabacker
has served as president and chief executive officer of the ECRI Institute, a non-profit organization with 500 employees and an operating
budget of $80 million focusing on advancing evidenced-based, effective healthcare globally. Prior to joining ECRI, Dr. Schabacker worked
at Baxter Healthcare Corporation, serving as corporate vice president and chief scientific officer from July 2015 to May 2017, chairman
of the executive quality council from March 2014 to May 2017, Chief Scientific Officer, Medical Products from July 2014 to July 2015,
and Vice President, R&amp;D, Medical Products from March 2011 to July 2014. During his clinical years, and his time as an industry thought
leader, Dr. Schabacker was focused on patient safety and enhancing patient care. For over a decade Dr. Schabacker has served on numerous
boards of small and midsize companies and organizations, providing management with guidance and expertise to strategically accelerate
growth and to build successful and sustainable high performing management teams. Dr. Schabacker&rsquo;s medical background and relevant
research and development experience qualify him to be a director of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Dr.
Joseph. Tucker</I> has served as Chief Executive Officer and a Director of the Company since September 16, 2022. Prior to joining Enveric,
Dr. Tucker was the Chief Executive Officer, President and Director of MagicMed Industries, from its founding in May 2020 to September
2021. Dr. Tucker was the Executive Chairman of Willow Biosciences Inc. from March 2014 to March 2020. Dr. Tucker was a founder and Chief
Executive Officer of Stem Cell Therapeutics, which he took public on the TSX (TSX: SSS). Trillium Therapeutics (Nasdaq: TRIL, TSX: TRIL)
acquired Stem Cell Therapeutics in 2013. Dr. Tucker has also held the position of Co-Founder and Chief Executive Officer of Epimeron
Inc., a University of Calgary start-up acquired in the creation of Willow Biosciences Inc. (TSX: WLLW). At Willow, Dr. Tucker served
as Executive Chairman and Chief Operating Officer. Prior to founding companies, Dr. Tucker was a healthcare analyst with two investment
banks and has also worked in technology commercialization for a university technology transfer office. Dr. Tucker received his Ph.D.
in Biochemistry and Molecular Biology from the University of Calgary. Dr. Tucker&rsquo;s relevant industry experience qualifies him to
be a director of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><I>Michael D. Webb</I> has served
as a non-employee director of the Company since June 13, 2022. Mr. Webb is the President and CEO of CXL Ophthalmics, LLC and a member
of its board of directors, positions he has held since 2017. He has served as a director at iQure Pharma Inc. since 2022, at GMDx Genomics
since 2021, at RIFFIT, Inc. since 2019, at Videokawa since 2018, and at DeuteRx, LLC since 2012. Mr. Webb is also a Principal and IntrinsicBio
Life Sciences Consulting LLC, a position he has held since 2016. He has been a founder and CEO of biotechnology companies, taking them
from seed round funding through venture financing and NASDAQ IPO. Mr. Webb began his career in Booz, Allen &amp; Hamilton&rsquo;s Chicago
office, specializing in healthcare and life sciences and subsequently at CIBA-Geigy (now Novartis) where has was last a senior vice president.
Mr. Webb holds Bachelors degrees in Biochemistry and Economics from the University of Kansas, summa cum laude and an MA in International
Relations from Sussex University in the UK. In addition, he holds an MBA degree from Kellogg with a concentration in healthcare management.
He is a past Chairman of the Massachusetts Biotechnology Council. Mr. Webb&rsquo;s relevant industry experience qualifies him to
be a director of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Family
Relationships</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
are no family relationships between any of our officers or directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vote
Required</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
a quorum is present and voting, the seven Company Nominees receiving the highest number of votes will be elected as directors. Abstentions
and broker non-votes will not have any effect on the outcome of the vote.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Board
Recommendation</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>The
Board recommends that you vote &ldquo;<I>FOR</I>&rdquo; each Company Nominee.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="a_003"></A>Corporate
Governance</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Composition
of the Board of Directors</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
amended and restated certificate of incorporation and amended and restated bylaws provide that our Board of Directors will consist of
such number of directors as determined from time to time by resolution adopted by the board of directors. The size of the Board of Directors
is currently fixed at nine directors. The Board has resolved to reduce the number of directors from nine to seven upon the election of
directors at the Annual Meeting. Subject to any rights applicable to any then-outstanding shares of preferred stock, any vacancies or
newly created directorships resulting from an increase in the authorized number of directors may be filled by a majority of the directors
then in office. Stockholders vote to elect directors with a term then expiring each year at our annual meeting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have no formal policy regarding board diversity. The Board of Directors believes that each director should have a basic understanding
of the principal operational and financial objectives and plans and strategies of the Company, our results of operations and financial
condition and relative standing in relation to our competitors. We take into consideration the overall composition and diversity of the
board and areas of expertise that director nominees may be able to offer, including business experience, knowledge, abilities and customer
relationships. Generally, we will strive to assemble a board that brings to us a variety of perspectives and skills derived from business
and professional experience as we may deem are in our and our stockholders&rsquo; best interests. In doing so, we will also consider
candidates with appropriate non-business backgrounds. Pursuant to Rules 5605(f) and 5606 of the Nasdaq Listing Rules, we have made our
board diversity matrix available on our website at www.enveric.com in the &ldquo;Corporate Governance&rdquo; section under &ldquo;Investors.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director
Nomination Process</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director
Qualifications</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
evaluating director nominees, the Nominating and Corporate Governance Committee of the Board of Directors considers the appropriate size
of the Board of Directors, as well as the qualities and skills of individual candidates. Factors considering include the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="width: 0.4in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
    history illustrating personal and professional integrity and ethics;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Independence;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Successful
    business management experience;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Public
    company experience, as officer or board member;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Relevant
    professional experience;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Diversity;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Educational
    background.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Nominating and Corporate Governance Committee&rsquo;s goal is to assemble a board of directors that brings the Company a diversity of
perspectives and skills derived from the factors considered above. The Nominating and Corporate Governance Committee also considers candidates
with relevant non-business experience and training.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Board of Directors believes that it is necessary for each of our directors to possess many qualities and skills. When searching for new
candidates, the Nominating and Corporate Governance Committee considers the evolving needs of the board of directors and searches for
candidates that fill any current or anticipated future gap. The Board of Directors also believes that all directors must possess a considerable
amount of business management (such as experience as a chief executive or chief financial officer) and educational experience. The Nominating
and Corporate Governance Committee first considers a candidate&rsquo;s management experience and then considers issues of judgment, background,
stature, conflicts of interest, integrity, ethics and commitment to the goal of maximizing stockholder value when considering director
candidates. The Nominating and Corporate Governance Committee also focuses on issues of diversity, such as diversity of gender, race
and national origin, education, professional experience and differences in viewpoints and skills. The Nominating and Corporate Governance
Committee does not have a formal policy with respect to diversity; however, the Board of Directors and the Nominating and Corporate Governance
Committee believe that it is essential that the directors represent diverse viewpoints. In considering candidates for the Board of Directors,
the Nominating and Corporate Governance Committee considers the entirety of each candidate&rsquo;s credentials in the context of these
standards. With respect to the nomination of continuing directors for re-election, the individual&rsquo;s contributions to the Board
of Directors are also considered.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
than the foregoing background factors that are considered in selecting director candidates, there are no stated minimum qualifications
for director nominees, although the Nominating and Corporate Governance Committee may also consider such other facts as it may deem are
in the best interests of the Company and our stockholders. The Nominating and Corporate Governance Committee does believe it appropriate
for at least one, and preferably several, members of the Board of Directors to meet the criteria for an &ldquo;Audit Committee financial
expert&rdquo; as defined by the rules of the SEC, and that a majority of the members of the Board of Directors meet the definition of
an &ldquo;independent director&rdquo; under the listing standards of the Nasdaq Stock Market.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Identification
and Evaluation of Nominees for Directors</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Nominating and Corporate Governance Committee identifies nominees for director by first evaluating the current members of the Board of
Directors willing to continue their service on the Board of Directors. Current members with qualifications and skills that are consistent
with the Nominating and Corporate Governance Committee&rsquo;s criteria for service on the Board of Directors and who are willing to
continue their service are considered for re-nomination, balancing the value of continuity of service by existing members of the Board
of Directors with that of obtaining new perspectives. If any member of the Board of Directors does not wish to continue his or her service
or if the Board of Directors decides not to re-nominate a member for re-election, the Nominating and Corporate Governance Committee identifies
the desired skills and experience of a new nominee in light of the criteria above. The Nominating and Corporate Governance Committee
generally polls the Board of Directors and members of management for their recommendations regarding potential new nominees. The Nominating
and Corporate Governance Committee may also review the composition and qualification of the boards of directors of our competitors, and
may seek input from our stockholders, industry experts or analysts. The Nominating and Corporate Governance Committee reviews the qualifications,
experience and background of the candidates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Final
candidates are interviewed by some or all of our independent directors and our Chief Executive Officer. In making its determinations,
the Nominating and Corporate Governance Committee evaluates each individual in the context of the Board of Directors as a whole, with
the objective of assembling a group that can best attain success for the Company and represent stockholder interests through the exercise
of sound judgment. After review and deliberation of all feedback and data, the Nominating and Corporate Governance Committee makes its
recommendation to the Board of Directors. Historically, the Nominating and Corporate Governance Committee has not relied on third-party
search firms to identify board candidates. The Nominating and Corporate Governance Committee may in the future choose to do so in those
situations where particular qualifications are required or where existing contacts are not sufficient to identify and acquire an appropriate
candidate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Nominating and Corporate Governance Committee does not have a formal policy regarding consideration of director candidate recommendations
from our stockholders. Any recommendations received from stockholders have been and will continue to be evaluated in the same manner
as potential nominees suggested by members of the Board of Directors or management. Stockholders wishing to suggest a candidate for director
should write to our Corporate Secretary at our corporate headquarters. In order for us to effectively consider a recommendation for a
nominee for a director position, stockholders must provide the following information in writing: (i) the stockholder&rsquo;s name and
contact information; (ii) the class and number of shares beneficially owned by the stockholder; (iii) a statement that the stockholder
is proposing a candidate for consideration as a director nominee to the Nominating and Corporate Governance Committee of the Board of
Directors; (iv) the name, age, business address and residence address of the candidate and confirmation that the candidate is willing
to be considered and serve as a director of the Company if elected; (v) a description of all arrangements and understandings and the
relationship between the stockholder making the recommendation and the candidate being recommended and between the candidate and any
customer, supplier, or competitor of the Company; (vi) the principal occupation and educational background of the candidate; (vii) a
statement of the value that the candidate would add to the Board of Directors, including addressing the factors that the Board of Directors
normally considers in assessing board candidates as stated above; and (viii) at least three character references with complete contact
information. In order to give the Nominating and Corporate Governance Committee sufficient time to evaluate a recommended candidate,
any such recommendation should be received by our Corporate Secretary at our corporate headquarters not later than the 120th calendar
day before the one year anniversary of the date our proxy statement was mailed to stockholders in connection with the previous year&rsquo;s
annual meeting of stockholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Board
Leadership Structure</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Currently,
the positions of Chairman of the Board and Chief Executive Officer of the Company are held by separate persons. The Board of Directors
does not have a policy as to whether the roles of Chairman of the Board and CEO should be separate or combined; however, in the event
that they are combined, the independent directors may appoint an independent director to serve in a lead capacity in specific circumstances.
The lead independent director would then coordinate the activities of the other non-management directors and perform such other duties
and responsibilities as the Board of Directors may determine. Our Board currently believes the division of responsibility between separate
individuals serving as Chairman and Chief Executive Officer, respectively, is an effective approach for addressing the risks we face
and increasing management accountability and improving the ability of the board to monitor whether management&rsquo;s actions are in
the best interests of the Company and its stockholders. This approach is subject to the evolving needs of the Company, as the goal of
the Board of Directors is to ensure the best possible management structure for the Company at any given time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Board
Meeting Attendance</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2021, the Board held 14 meetings and acted by written consent on seven occasions. We expect our directors
to attend board meetings, meetings of any committees and subcommittees on which they serve and each annual meeting of stockholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director
Independence</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are currently listed on the Nasdaq Stock Market and therefore rely on the definition of independence set forth in the Nasdaq Listing
Rules (&ldquo;Nasdaq Rules&rdquo;). Under the Nasdaq Rules, a director will only qualify as an &ldquo;independent director&rdquo; if,
in the opinion of our board, that person does not have a relationship that would interfere with the exercise of independent judgment
in carrying out the responsibilities of a director.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
upon information requested from and provided by each director concerning his background, employment, and affiliations, including family
relationships, the Board of Directors has determined that Mr. Kegler, Dr. Lind, Ms. O&rsquo;Neil, Mr. Pasqualone, Dr. Schabacker and
Mr. Webb have no material relationships with us that would interfere with the exercise of independent judgment and are &ldquo;independent
directors&rdquo; as that term is as currently defined in Rule 5605(a)(2) of the Nasdaq listing rules. In determining the independence
of our directors, the Board of Directors considered all transactions in which the Company and any director had any interest. The independent
directors meet as often as necessary to fulfill their responsibilities, including meeting at least twice annually in executive session
without the presence of non-independent directors and management.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director
Attendance at the Annual Meeting</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
we do not have a formal policy regarding attendance by members of the Board of Directors at the Annual Meeting, we encourage all of our
directors to attend.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 19; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Committees
of the Board of Directors</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Board of Directors delegates various responsibilities and authority to different board committees. Committees regularly report on their
activities and actions to the full board. Currently, the board has established an Audit Committee, a Compensation Committee and a Nominating
and Corporate Governance Committee. Committee assignments are re-evaluated annually. Each of these standing committees operates under
a charter that has been approved by the Board of Directors. The current charter of each of these committees is available on our website
at www.enveric.com in the &ldquo;Corporate Governance&rdquo; section under &ldquo;Investors.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth the membership of each of the board committees listed above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 28%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Name</B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Audit<BR>
    Committee</B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Compensation<BR>
    Committee</B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 34%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Nominating
    and<BR>
    Corporate Governance<BR>
    Committee</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">David
    Johnson</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">George
    Kegler</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">X</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">X</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sol
    Mayer</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">X</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
    Marcus Schabacker</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">X</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
    Douglas Lind</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">X</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bevin
    O&rsquo;Neil</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">X</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Frank
    Pasqualone</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Joseph
    Tucker, Ph.D.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Michael
    D. Webb</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Audit
Committee</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of September 23, 2022, the members of our Audit Committee were George Kegler (chairman), Dr. Douglas Lind, and Bevin O&rsquo;Neil.
All members of the Audit Committee (i) are independent directors (as currently defined in Rule 5605(a)(2) of the Nasdaq listing rules);
(ii) meet the criteria for independence set forth in Rule 10A-3(b)(1) under the Exchange Act; (iii) have not participated in the preparation
of the financial statements of the Company or any current subsidiary of the Company at any time during the past three years; and (iv)
are able to read and understand fundamental financial statements. Mr. Kegler qualifies as an &ldquo;Audit Committee financial expert&rdquo;
as defined in the rules and regulations established by the SEC. The Audit Committee is governed by a written charter approved by the
Board of Directors. The functions of the Audit Committee include, among other things:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Approving
    and retaining the independent auditors to conduct the annual audit of our financial statements;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reviewing
    the proposed scope and results of the audit;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reviewing
    and pre-approving audit and non-audit fees and services;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reviewing
    accounting and financial controls with the independent auditors and our financial and accounting staff;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reviewing
    and approving transactions between us and our directors, officers and affiliates;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Recognizing
    and preventing prohibited non-audit services;</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 20; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Establishing
    procedures for complaints received by us regarding accounting matters;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Overseeing
    internal audit functions, if any; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Preparing
    the report of the audit committee that the rules of the SEC require to be included in our annual meeting proxy statement.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Both
our independent registered public accounting firm and internal financial personnel regularly meet privately with our Audit Committee
and have unrestricted access to the Audit Committee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Audit Committee met four times during the year ended December 31, 2021.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compensation
Committee</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of September 23, 2022, the members of our Compensation Committee were Dr. Marcus Schabacker (chairman), Sol Mayer and George
Kegler. The Board of Directors has determined that Dr. Schabacker, Mr. Mayer and Mr. Kegler are independent in accordance with
Nasdaq Rules. The Compensation Committee is governed by a written charter approved by the Board of Directors. The charter of the Compensation
Committee permits the Compensation Committee to engage outside consultants and to consult with our human resources department when appropriate
to assist in carrying out its responsibilities. Compensation consultants have not been engaged by the Company to recommend or assist
in determining the amount or form of compensation for any current executive officers or directors of the Company. The Committee may also
obtain advice and assistance from internal or external legal, accounting, or other advisers selected by the Committee. The functions
of the Compensation Committee include, among other things:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reviewing
    and recommending the compensation arrangements for management, including the compensation for our president and chief executive officer;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Establishing
    and reviewing general compensation policies with the objective to attract and retain superior talent, to reward individual performance
    and to achieve our financial goals;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Administering
    our stock incentive plans; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Preparing
    the report of the compensation committee that the rules of the SEC require to be included in our annual meeting proxy statement.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Compensation Committee met one time during the year ended December 31, 2021 and acted by written consent on one occasion.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 21; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nominating
and Corporate Governance Committee</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of September 23, 2022, the members of our Nominating and Corporate Governance Committee were Sol Mayer (chairman), Dr. Marcus
Schabacker and George Kegler. The Board of Directors has determined that Mr. Mayer, Dr. Schabacker and Mr. Kegler are independent in
accordance with Nasdaq Rules. The Nominating and Corporate Governance Committee is governed by a written charter approved by the Board
of Directors. The functions of the Nominating and Corporate Governance Committee include, among other things:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Evaluating
    the current composition, organization and governance of the board and its committees, and making recommendations for changes thereto;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reviewing
    each director and nominee annually;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Determining
    desired board member skills and attributes and conducting searches for prospective members accordingly;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Evaluating
    nominees, and making recommendations to the Board concerning the appointment of directors to board committees, the selection of board
    committee chairs, proposal of the slate of directors for election to the board, and the termination of membership of individual directors
    in accordance with the board&rsquo;s governance principles;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Overseeing
    the process of succession planning for the chief executive officer and, as warranted, other senior officers of the Company;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Developing,
    adopting and overseeing the implementation of a code of business conduct and ethics; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Administering
    the annual board performance evaluation process.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Nominating and Corporate Governance Committee met one time during the year ended December 31, 2021.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Board of Directors&rsquo; Role in Risk Oversight</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Board of Directors, as a whole and also at the committee level, has an active role in managing enterprise risk. The members of the Board
of Directors participate in our risk oversight assessment by receiving regular reports from members of senior management and the Company
compliance officer appointed by the Board of Directors on areas of material risk to us, including operational, financial, legal and regulatory,
and strategic and reputational risks. The Compensation Committee is responsible for overseeing the management of risks relating to our
executive compensation plans and arrangements. The Audit Committee oversees management of financial risks, as well as our policies with
respect to risk assessment and risk management. The Nominating and Corporate Governance Committee manages risks associated with the independence
of the Board of Directors and potential conflicts of interest. Members of the management team report directly to the Board of Directors
or the appropriate committee. The directors then use this information to understand, identify, manage, and mitigate risk. Once a committee
has considered the reports from management, the chairperson will report on the matter to the full Board of Directors at the next meeting
of the Board of Directors, or sooner if deemed necessary. This enables the Board of Directors and its committees to effectively carry
out its risk oversight role.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 22; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Communications
with the Board of Directors</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
stockholder may send correspondence to the Board of Directors, c/o Enveric Biosciences, Inc., 4851 Tamiami Trail N, Suite 200, Naples,
FL 34103. Our Corporate Secretary will review all correspondence addressed to the Board of Directors, or any individual director, and
forward all such communications to the Board of Directors or the appropriate director prior to the next regularly scheduled meeting of
the Board of Directors following the receipt of the communication, unless the Corporate Secretary decides the communication is more suitably
directed to Company management and forwards the communication to Company management. Our Corporate Secretary will summarize all stockholder
correspondence directed to the Board of Directors that is not forwarded to the Board of Directors and will make such correspondence available
to the Board of Directors for its review at the request of any member of the Board of Directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Code
of Business Conduct and Ethics</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have adopted a Code of Corporate Conduct and Ethics and Whistleblower Policy that applies to our directors, officers, employees and certain
persons performing services for us. The Code of Corporate Conduct and Ethics and Whistleblower Policy addresses, among other things,
competition and fair dealing, conflicts of interest, protection and proper use of Company assets, government relations, compliance with
laws, rules and regulations and the process for reporting violations of the Code of Corporate Conduct and Ethics and Whistleblower Policy,
employee misconduct, improper conflicts of interest or other violations. Our Code of Corporate Conduct and Ethics and Whistleblower Policy
is available on our website at www.enveric.com in the &ldquo;Corporate Governance&rdquo; section found under the &ldquo;Investors&rdquo;
tab. We intend to disclose any amendments to, or waivers from, our Code of Corporate Conduct and Ethics and Whistleblower Policy at the
same website address provided above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anti-Hedging
and Anti-Pledging Policies</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
our Insider Trading Policy, Company personnel, including directors, officers, employees and consultants of the Company, as well as certain
family members, other members of a person&rsquo;s household and entities controlled by Company personnel, are prohibited from engaging
in short sales of the Company&rsquo;s securities, using the Company&rsquo;s securities to secure a margin or other loan, engaging in
transactions in publicly-traded options relating to the Company&rsquo;s securities, and engaging in similar risk reduction or hedging
transactions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Corporate
Governance Documents Available Online</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
corporate governance documents, including the Audit Committee charter, Compensation Committee charter, Nominating and Corporate Governance
Committee charter and Ethics Codes, are available free of charge on the &ldquo;Investors&rdquo; section of our website (www.enveric.com)
under the tab &ldquo;Corporate Governance&rdquo;. Information contained on our website is not incorporated by reference in, or considered
part of, this Proxy Statement. Stockholders may also request paper copies of these documents free of charge upon written request to the
Corporate Secretary at Enveric Biosciences, Inc., 4851 Tamiami Trail N, Suite 200, Naples, FL 34103.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 23; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director
Term Limits</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
ENVB board of directors does not currently have a term limit policy limiting the number of years a director may serve on the Board of
Directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Executive
Officers</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
names of our executive officers, their ages, their positions with the Company, and other biographical information as of September 14,
2022, are set forth below. There are no family relationships among our directors and executive officers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Name</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Age</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 46%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Position(s)</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">David
    Johnson</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">65</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Executive
    Chairman</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Joseph
    Tucker, PhD</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">54</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer and Director</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Avani
    Kanubaddi</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">51</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">President
    and Chief Operating Officer</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
    Bob Dagher</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">54</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Medical Officer</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Peter
    Facchini, PhD</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">59</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Innovation Officer</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Robert
    Dickey*</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">66</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*
Robert Dickey was appointed as the Company&rsquo;s Chief Financial Officer on an interim basis effective September 9, 2022. Prior to
that date, the position of Chief Financial Officer was held by Carter Ward.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>David
Johnson</I> has served as our Executive Chairman since September 2021. From December 2020 until September 2021, Mr. Johnson served as
Chairman and Chief Executive Officer of Enveric. Mr. Johnson also has served on the board of directors and as the Chief Executive Officer
of Aquamed Technologies, Inc. since April 2019. Mr. Johnson formerly served on the board of directors and as the President and Chief
Executive Officer of Alliqua BioMedical, Inc. from November 2012 until April 2019. Mr. Johnson was formerly President of the ConvaTec
Division of Bristol-Myers Squibb, Inc. until 2008 when he orchestrated a sale of the division from its pharmaceutical parent to Avista
Capital Partners and Nordic Capital in a deal valued at $4.1 billion. Concurrently, he acquired and integrated the assets of Copenhagen-based
Unomedical to expand ConvaTec Inc.&rsquo;s manufacturing and infrastructure into Europe. From 2008 through 2012, Mr. Johnson served as
the Chief Executive Officer of ConvaTec Inc. Prior to his tenure with ConvaTec Inc., Mr. Johnson held several senior positions in the
U.S., Europe and Canada with Zimmer Inc., Fisher Scientific, and Baxter Corporation. He served as a member of ConvaTec Inc.&rsquo;s board
of directors and the board of the Advanced Medical Technology Association (AdvaMed), where he chaired the Global Wound Sector Team for
four years. Mr. Johnson received an Undergraduate Business Degree in Marketing from the Northern Alberta Institute of Technology in Edmonton,
Alberta, Canada, completed the INSEAD Advanced Management Program in Fontainbleau, France, and is a fellow from the Wharton School of
the University of Pennsylvania. Mr. Johnson&rsquo;s extensive experience in the pharmaceutical and biotechnology fields, as well as his
executive leadership experience, make him an asset that will serve as a bridge between the board of directors and our executive officers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<!-- Field: Page; Sequence: 24; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Dr.
Joseph. Tucker</I> is a seasoned executive who has built several publicly traded biotechnology companies. Prior to joining Enveric, Dr.
Tucker was the Chief Executive Officer, President and Director of MagicMed Industries, from its founding in May 2020 to September 2021.
Dr. Tucker was the Executive Chairman of Willow Biosciences Inc. from March 2014 to March 2020. Dr. Tucker was a founder and Chief Executive
Officer of Stem Cell Therapeutics, which he took public on the TSX (TSX: SSS). Trillium Therapeutics (Nasdaq: TRIL, TSX: TRIL) acquired
Stem Cell Therapeutics in 2013. Dr. Tucker has also held the position of Co-Founder and Chief Executive Officer of Epimeron Inc., a University
of Calgary start-up acquired in the creation of Willow Biosciences Inc. (TSX: WLLW). At Willow, Dr. Tucker served as Executive Chairman
and Chief Operating Officer. Prior to founding companies, Dr. Tucker was a healthcare analyst with two investment banks and has also
worked in technology commercialization for a university technology transfer office. Dr. Tucker received his Ph.D. in Biochemistry and
Molecular Biology from the University of Calgary.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Avani
Kanubaddi</I> has served as our President since October 2021 and Chief Operating Officer since December 30, 2020. Mr. Kanubaddi is an
entrepreneur and business leader who has a passion for health and healing. From September 2019 through December 2020, Mr. Kanubaddi was
the President &amp; Chief Operating Officer of NEXGEL, Inc. (&ldquo;NEXGEL&rdquo;), an FDA registered, ISO certified advanced hydrogel
manufacturer serving the OTC, cosmetic and medical device markets around the world. At NEXGEL, Mr. Kanubaddi led the rebranding, repositioning
and overall strategy for the company to accelerate growth and drive innovation. This included rebranding the company as NEXGEL, branding
the company&rsquo;s unique hydrogels, developing a robust white label catalog, architecting an innovation engine to fill the pipeline
with new concepts and guiding the company&rsquo;s first-ever branded product launches. In addition to NEXGEL, since August 2018, Mr.
Kanubaddi has also served as the Senior Partner at IQ/EQ Brand Strategy, where he assists companies in developing &ldquo;go to market&rdquo;
strategies, branding and naming exercises and new product innovation for consumer, medical device and prescription companies. Prior to
his consulting career, from February 2007 to September 2019, Mr. Kanubaddi was the Founder and Chief Executive Officer of Welmedix Healthcare,
where he developed innovative skin and wound care solutions to improve health and healing with an eye towards whole person wellness.
During his tenure, he led the company to develop three unique brands with patented solutions, gaining distribution in over 20,000 retail
outlets, including Walmart, Walgreens, CVS and others. After building some of the fastest growing brands in their respective categories,
Welmedix sold its leading brands to a private-equity backed healthcare company. Before his entrepreneurial venture, Mr. Kanubaddi began
his 25+ year career in the healthcare industry at two leading companies &ndash; Wyeth (now Pfizer) and Bristol Myers Squibb&rsquo;s ConvaTec
Division. While working with market leading brands like Centrum, Advil and Chapstick; medical devices and hospital businesses including
Aloe Vesta, DuoDerm and Sur-Fit Natura, Mr. Kanubaddi held positions of increasing responsibility across the functional areas of brand
management, sales, new product development and new ventures. Mr. Kanubaddi holds an MBA from Columbia Business School and BS in Marketing
from Miami University. Mr. Kanubaddi also served on the Board of Directors for the Consumer Healthcare Products Association (CHPA), the
leading industry trade group for consumer healthcare in the United States.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 25; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Dr.
Bob Dagher</I> has served as our Chief Medical Officer since December 2021. Dr. Dagher has over twenty years of experience in clinical
development in the pharmaceutical industry and as a past board-certified physician from the American Board of neurology and psychiatry.
He has an extensive therapeutic background concentrated in the neuroscience space which includes a focus on psychotic, affective and
anxiety disorders, as well as neuroimmunology, neurodegeneration and movement disorders. Furthermore, Dr. Dagher has supported and driven
successful drug development programs from preclinical stages through Phase 4 clinical trials. Following his early experience treating
patients in academic and private practice settings, Dr. Dagher started his career in the pharmaceutical industry at GlaxoSmithKline,
followed by Sanofi/Genzyme working on neurology, psychiatry, and urology indications. Prior to joining Enveric, Dr. Dagher served as
the Chief Medical Officer at WCG MedAvante-ProPhase from December 2019 to December 2021 and Cadent Therapeutics from January 2018 to
June 2019. Prior to that, he was Senior Medical Director at LabCorp-Covance from October 2013 to January 2018. In both these organizations,
he Dr. Dagher helped forge and develop compelling scientific solutions to match industry challenges and developed innovative programs
targeting movement and cognitive disorders. Dr. Dagher brings extensive experience working in the pharmaceutical industry with a focus
and passion for drug development for neurological and mental health indications.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Dr.
Peter Facchini</I> has served as our Chief Innovation Officer since joining the Company in September 2021. Dr. Facchini has been
a Professor of Plant Biochemistry in the Department of Biological Sciences at the University of Calgary since 1995, during which he held
the Canada Research Chair in Plant Metabolic Processes Biotechnology, was a Parex Resources Innovation Fellow, and received the 2021
Faculty of Science Innovation Excellence Award. Dr. Facchini co-founded and was the Chief Scientific Officer of Willow Biosciences Inc.
and Epimeron Inc. Dr. Facchini was the Chief Scientific Officer at MagicMed Industries Inc. from May 2020 to September 2021. Prior to
that, Dr. Facchini was the Chief Scientific Officer of Willow Biosciences from 2014 to 2020. Dr. Facchini has published over 165 scientific
papers and co-invented over 45 patents. Dr. Facchini is an international leader in the biochemistry and biotechnology fields of natural
product metabolism.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Robert
Dickey</I> has served as our Chief Financial Officer since September 9, 2022. Mr. Dickey has served as Managing Director at Foresite
Advisors since March 2020 and was previously a Managing Director at Danforth Advisors from August 2018 to March 2020. Foresite Advisors
provides finance support and strategy for life science companies, including CFO advisory, financial analysis, and transactional support/execution
for fundraising and M&amp;A. Mr. Dickey has served on the boards of Angiogenex, Inc., a publicly traded biopharmaceutical company, since
2020 and SFA Therapeutics, a privately held developing microbiome-derived therapies, since 2022. He has been on the leadership team of
Cell One Partners a strategic consulting services company focused on cell and gene therapy since 2018 and BCI LifeSciences, an advisory
firm affiliated with a broker-dealer, since 2021. Mr. Dickey served as a member on the board of directors and audit committee chair at
Emmaus Life Sciences, Inc., a publicly traded biopharmaceutical company, from 2018 to 2022 and member on the board of directors of Sanuthera,
Inc., a privately held medical device company, from 2013 to 2017. Previously, he was employed as CFO of Motif Bio Plc., a NASDAQ and
London AIM exchange-listed antibiotics company, from January 2017 to February 2018. He also was previously employed with several other
biotechnology companies, including as the CFO of Tyme Technologies, Inc. from May 2015 to January 2017, the CFO of NeoStem, Inc. from
August 2013 to January 2015 and the Senior Vice President of Hemispherx Biopharma, Inc. from November 2008 to August 2013. Prior to that
time, among other things, Mr. Dickey served as a Managing Director at Legg Mason Wood Walker, Inc., Senior Vice President at Lehman Brothers
and Co-Founder/Partner at The Middle Market Group, an affiliate of Lehman Brothers. He received his undergraduate degree from Princeton
University and an M.B.A. from The Wharton School of the University of Pennsylvania.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 26; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="a_004"></A>Executive
Compensation</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 14, 2022, we filed an amendment to our Amended and Restated Certificate of Incorporation to effect a reverse stock split (the &ldquo;<U>Reverse
Stock Split</U>&rdquo;) of the issued and outstanding shares of our common stock, at a ratio of one share for fifty shares. All share
amounts in this proxy statement have been adjusted to give effect to the Reverse Stock Split.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Role
and Authority of Compensation Committee</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of September 23, 2022, the members of our Compensation Committee were Dr. Marcus Schabacker (chairman), Sol Mayer and George
Kegler. Our Board of Directors has determined that Dr. Schabacker, Mr. Mayer, Mr. Kegler and Mr. Pasqualone are independent in accordance
with Nasdaq rules. The Compensation Committee has the authority to delegate to subcommittees of the Compensation Committee any of the
responsibilities of the full committee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Compensation Committee is responsible for discharging the responsibilities of the Board of Directors with respect to the compensation
of our executive officers. The Compensation Committee recommends overall compensation of our executive officers to the Board of Directors.
The Board of Directors approves all compensation of our executive officers. The Compensation Committee also periodically reviews director
compensation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
charter of the Compensation Committee permits the Compensation Committee to engage outside consultants and to consult with our human
resources department when appropriate to assist in carrying out its responsibilities. In 2021, the Compensation Committee engaged
Meridian Compensation Partners, LLC (&ldquo;Meridian&rdquo;) to provide input, analysis, and advice about our compensation programs for
executive officers and non-employee directors, including compensation philosophy and design and peer group data. The Compensation Committee
selected Meridian as its compensation consultant based on, among other things, Meridian&rsquo;s reputation and substantial insight and
experience with executive compensation programs in our industry. Meridian reported directly to the Compensation Committee and did not
perform work for the Company in 2021 except under its engagement by the Compensation Committee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Committee may also obtain advice and assistance from internal or external legal, accounting, or other advisers selected by the Committee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Elements
of Executive Compensation</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
executive compensation consists of the following elements:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Base
    Salary</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Annual
    Bonus</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Long-Term
    Incentives; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Retirement
    benefits under 401(k) plan and generally available benefit programs.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 27; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Base
Salary</I>. The base salary for each executive is initially established through negotiation at the time the executive is hired, taking
into account his or her scope of responsibilities, qualifications, experience, prior salary, and competitive salary information within
our industry. Year-to-year adjustments to each executive officer&rsquo;s base salary are determined by an assessment of his or her sustained
performance against individual goals, including leadership skills and the achievement of high ethical standards, the individual&rsquo;s
impact on our business and financial results, current salary in relation to the salary range designated for the job, experience, demonstrated
potential for advancement, and an assessment against base salaries paid to executives for comparable jobs in the marketplace.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Annual
Bonus</I>. Annual bonus payments under our executive employment agreements are based on the discretion of our Board of Directors. We
believe that such bonuses provide our executives with an incentive to achieve goals that are aligned with our stockholders&rsquo; interests,
with the achievement of such goals being measurable in terms of revenue and income or other financial objectives. An executive officer&rsquo;s
failure to achieve measurable performance goals can affect his or her bonus amount. We believe that offering significant potential income
in the form of bonuses allows us to attract and retain executives and to align their interests with those of our stockholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Long-Term
Incentives</I>. The Compensation Committee has the ability to grant equity instruments to our executives under our 2020 Long-Term Incentive
Plan (the &ldquo;2020 Plan&rdquo;). The 2020 Plan provides for the granting of incentive stock options, nonqualified stock options, stock
appreciation rights, restricted stock, restricted stock units, performance awards, dividend equivalent rights and other awards which
may be granted singly, in combination or in tandem, and which may be paid in shares of our Common Stock. We believe that our executive
compensation program must include long-term incentives such as stock options and restricted stock units if we wish to hire and retain
high-level executive talent. We also believe that stock options and restricted stock units help to provide a balance to the overall executive
compensation program as base salary and bonus awards focus only on short-term compensation. In addition, the vesting period of stock
options and restricted stock units encourages executive retention and the preservation of stockholder value. Finally, we believe that
aligning at least a portion of restricted stock units vesting provisions to financial performance measures further aligns executive compensation
to stockholder value; if performance targets are not achieved, then the awards do not vest. We base the number of equity units granted
on the type and responsibility level of the executive&rsquo;s position, the executive&rsquo;s performance in the prior year and the executive&rsquo;s
potential for continued sustained contributions to our long-term success and the long-term interests of our stockholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>401(k)
and Other Benefits</I>. During 2020, our executive officers were eligible to receive certain benefits generally available to all our
employees on the same terms, including medical, dental and vision insurance, long-term and short-term disability insurance, life and
accidental death and dismemberment insurance, health and dependent care flexible spending accounts, educational and employee assistance,
paid-time-off, and certain other benefits. During 2020, we also maintained a tax-qualified 401(k) Plan, which provides for broad-based
employee participation. During 2020, under the 401(k) Plan, at the Company&rsquo;s discretion, all employees were eligible to receive
matching contributions from the Company of (i) 100% of their first 3% of employee contributions and (ii) 50% of the next 2% of employee
contributions up to an aggregate maximum of $10,600 per employee, per year, subject to vesting provisions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 28; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Compensation
Risk Assessment</I>. In establishing and reviewing our overall compensation program, the Compensation Committee considers whether the
program and its various elements encourage or motivate our executives or other employees to take excessive risks. We believe that our
compensation program and its elements are designed to encourage our employees to act in the long-term best interests of the Company and
are not reasonably likely to have a material adverse effect on our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Summary
Compensation Table</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth total compensation paid to the named executive officers for the years ended December 31, 2021 and 2020, comprised
of (i) all individuals who served as our Chief Executive Officer during the 2021 fiscal year, (ii) the two most highly compensated executive
officers other than the Chief Executive Officer who were serving as an executive officer at the end of the 2021 fiscal year and whose
salary, as determined by Regulation S-K, Item 402, exceeded $100,000 and (iii) up to two most highly compensated former executive officers
who were no longer serving as an executive officer at the end of the 2021 fiscal year. The stock awards listed below have been adjusted
to give effect to the Reverse Stock Split.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Name and Principal Position</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Salary<BR> ($)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Bonus<BR> ($)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Stock<BR> ($) <SUP>(1)</SUP></B></FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total<BR> ($)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 35%; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>David Johnson<SUP>(2)</SUP></B></FONT></TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">2021</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">250,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">168,750</TD><TD STYLE="width: 1%; text-align: left"><SUP>(3)</SUP></TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">6,469,066</TD><TD STYLE="width: 1%; text-align: left"><SUP>(4)</SUP></TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">6,887,816</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-style: italic; text-align: left">Executive Chairman, Director, and Former Chief Executive Officer</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2020</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">200,000</TD><TD STYLE="text-align: left"><SUP>(3)</SUP></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">200,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Joseph Tucker<SUP>(5)</SUP></B></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2021</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">92,083</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">159,063</TD><TD STYLE="text-align: left"><SUP>(7)</SUP></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,226,992</TD><TD STYLE="text-align: left"><SUP>(8)</SUP></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,478,138</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-style: italic; text-align: left">Chief Executive Officer and Director</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2020</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Avani Kanubaddi<SUP>(9)</SUP></B></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2021</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">302,500</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">144,570</TD><TD STYLE="text-align: left"><SUP>(6)</SUP></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,789,523</TD><TD STYLE="text-align: left"><SUP>(10)</SUP></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,236,593</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-style: italic; text-align: left">President and Chief Operating Officer</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2020</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">60,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">60,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Dr. Peter Facchini<SUP>(11)</SUP></B></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2021</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">68,269</TD><TD STYLE="text-align: left"><SUP>(12)</SUP></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">69,429</TD><TD STYLE="text-align: left"><SUP>(13)</SUP></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,566,910</TD><TD STYLE="text-align: left"><SUP>(14)</SUP></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,704,608</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-style: italic; text-align: left">Chief Innovation Officer</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2020</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Dr. Robert Wilkins<SUP>(15)</SUP></B></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2021</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">186,211</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,541,180</TD><TD STYLE="text-align: left"><SUP>(16)</SUP></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,727,391</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-style: italic; text-align: left">Former Chief Medical Officer</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2020</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 29; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock
    compensation consists of Restricted Stock Unit Award (&ldquo;<U>RSUs</U>&rdquo;) and Restricted Stock Awards (&ldquo;<U>RSA&rsquo;s</U>&rdquo;).
    RSUs and RSA&rsquo;s may contain vesting conditions that include, without limitation, continued employment or engagement with the
    Company, achievement of defined stock price levels or achievement of defined performance milestones, termination of the employee
    without cause, resignation of the employee for good cause or change in control. Please also note there are no assurances that such
    vesting conditions will be met and accordingly there are no assurances that any unvested RSUs or RSA&rsquo;s will become vested prior
    to being forfeited on the expiration date defined in the relevant award agreements. Furthermore, RSUs require that the recipient&rsquo;s
    employment with the Company be terminated, or that a change of control occur, as a prerequisite of conversion of vested restricted
    stock units into shares of Common Stock. RSA&rsquo;s have no such condition of termination or change of control as a prerequisite
    of conversion of vested restricted stock awards into shares of Common Stock.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
                                            Johnson was appointed Chairman and Chief Executive Officer on December 30, 2020.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
    Johnson resigned as Chief Executive Officer and was appointed Executive Chairman of the Board of Directors on September 16, 2021.</FONT></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
                                            Johnson&rsquo;s bonus for 2021 was paid in February 2022.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
    Johnson&rsquo;s bonus for 2020 was paid in two increments of $100,000 each in December 2020 and in February of 2021.</FONT></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
    Johnson&rsquo;s stock compensation consists of an aggregate of 26,955 RSUs valued at $6,469,066, with such valuation being
    based on the Company&rsquo;s closing price per share of $240.00 on the grant date of such RSUs. As of December 31, 2021, all of these
    RSUs are vested. Mr. Johnson&rsquo;s stock compensation excludes an aggregate of 426 RSUs, with a grant date value of $102,130,
    due to such RSUs being forfeited due to non-achievement of specific performance milestones.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
    Tucker was appointed Chief Executive Officer on September 16, 2021.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bonus
    for 2021 was paid in February 2022.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(7)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bonus
    consists of $100,000 paid in September 2021 and $59,063 attributable to 2021 paid in February 2022.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(8)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
    Tucker&rsquo;s stock compensation consists of an aggregate of 16,375 RSUs, valued at $2,226,992, with such valuation being
    based on the Company&rsquo;s closing price per share of $136.00 on the RSU grant date. All of these RSUs are unvested as of December
    31, 2021, with no assurances of these RSUs vesting in the future.</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 30; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(9)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
                                            Kanubaddi served as Chief Operating Officer from December 30, 2020 through September 30,
                                            2021.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
    Kanubaddi was appointed President on October 1, 2021.</FONT></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(10)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
    Kanubaddi&rsquo;s stock compensation consists of an aggregate of 15,790 RSUs, valued at $3,789,523, with such valuation being
    based on the Company&rsquo;s closing price per share of $240.00 on the RSU grant date. All of these RSUs are vested.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(11)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
    Facchini has served as Chief Innovation Officer since September 16, 2021.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(12)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Salaries
    and bonus paid in Canadian Dollars and translated to United States Dollars equivalent.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(13)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bonus
    consists of $40,390 paid in September 2021 and $29,039 attributable to 2021 paid in February 2022.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(14)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
    Facchini&rsquo;s stock compensation consists of an aggregate of 11,522 RSUs, valued at $1,556,910, with such valuation being
    based on the Company&rsquo;s closing price per share of $136.00 on the RSU grant date. All of these RSUs are unvested as of December
    31, 2021, with no assurances of these RSUs vesting in the future.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(15)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
    Wilkins served as Chief Medical Officer from December 30, 2020 to November 30, 2021.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(16)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
    Wilkins&rsquo; stock compensation consists of an aggregate of 10,520 RSUs, valued at $1,541,180, with such valuation being based
    on the Company&rsquo;s closing price per share of $146.50 on the RSU grant date. 3,507 of these RSUs are vested, with Common Shares
    to be issued during June 2022. The remaining 7,014 RSUs were unvested and forfeited upon Dr. Wilkins&rsquo; resignation.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Narrative
Disclosure to Summary Compensation Table</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior
to the completion of our tender offer to purchase all of the outstanding common shares of Jay Pharma Inc. (&ldquo;<U>Jay Pharma</U>&rdquo;)
on December 30, 2020 (&ldquo;<U>Offer</U>&rdquo;), and in connection with the execution of that certain Amalgamation Agreement, dated
January 10, 2020, by and among the Company (f/k/a &ldquo;<U>Ameri</U>&rdquo;), Jay Pharma, Jay Pharma Merger Sub, Inc., 1236567 B.C.
Unlimited Liability Company and Barry Kostiner, as the Company representative, which predates the Tender Agreement related to the Offer
(the &ldquo;<U>Tender Agreement</U>&rdquo;), Jay Pharma entered into an employment agreement with Mr. Johnson, whereby Mr. Johnson would
serve as the Chief Executive Officer and Chairman of the Company upon the completion of the Offer (the &ldquo;<U>Johnson Employment Agreement</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 31; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Johnson
Employment Agreement</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Johnson Employment Agreement, dated January 10, 2020, Mr. Johnson served in the position of Chief Executive Officer and Chairman
of the Company following the completion of the Offer. Mr. Johnson was entitled to a base salary of $250,000 and an annual bonus in the
amount of $100,000 (provided, however, that if Mr. Johnson&rsquo;s position was changed such that he no longer serves as Chief Executive
Officer and only serves as Chairman of the Company, he would only be entitled to a base salary of $100,000 beginning with the first day
of the month following such change). Mr. Johnson was also eligible to receive annual performance bonuses based on satisfaction of performance
criteria/financial results, as determined by the Board of the Company in its sole discretion. Within 30 days after the completion of
the Offer, Mr. Johnson was granted an award of restricted stock units (&ldquo;<U>RSUs</U>&rdquo;) that represent, in the aggregate, 5%
of the Company&rsquo;s issued and outstanding common stock determined on a fully diluted basis as of the date of grant. Mr. Johnson was
eligible to receive additional equity awards, as determined by the Company in its sole discretion.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the terms of the Johnson Employment Agreement, Mr. Johnson&rsquo;s employment may have been terminated by either the Company or Mr. Johnson
at any time and for any reason with 30 days&rsquo; advance written notice. Upon termination of Mr. Johnson&rsquo;s employment, Mr. Johnson
would have received (i) his fully earned but unpaid base salary through the date of termination, (ii) any accrued and unpaid time off
or similar pay to which Mr. Johnson was entitled as a matter of law or Company policy, (iii) any amounts due to Mr. Johnson under the
terms of the benefit plans, and (iv) any unreimbursed expenses properly incurred prior to the date of termination (the &ldquo;<U>Johnson
Accrued Obligations</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the Company terminated Mr. Johnson&rsquo;s employment for cause or Mr. Johnson resigns without good reason (as defined below), the Company,
at its sole discretion, may have shortened the notice period and determine the date of termination without any obligation to pay any
additional compensation other than the Johnson Accrued Obligations and without triggering a termination of Mr. Johnson&rsquo;s employment
without cause. If the Company terminated Mr. Johnson&rsquo;s employment without cause or Mr. Johnson resigned for good reason at any
time, Mr. Johnson would have been entitled to the following severance payments and benefits: (i) his full annual base salary less applicable
deductions and withholdings; plus (ii) any earned but unpaid annual bonus and performance bonus, if any, for the year of the termination.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Johnson Employment Agreement also contained certain standard non-solicitation, non-disparagement and confidentiality requirements for
Mr. Johnson.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2021, Mr. Johnson has been awarded an aggregate of 26,955 RSUs, all of which are vested. Mr. Johnson will be eligible
to convert these vested RSUs into an equivalent number of shares of Common Stock on the first day of the seventh month subsequent to
either his termination of employment with the Company, or in the event of a change in control, and provided compliance with all terms
and conditions of the Incentive Plan, including, without limitation, the availability of shares approved by the Company&rsquo;s shareholders
for such issuance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tucker
Employment Agreement</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 24, 2021, Dr. Joseph Tucker entered into an employment agreement (the &ldquo;<U>Tucker Employment Agreement</U>&rdquo;) with the
Company pursuant to which he will become the Company&rsquo;s Chief Executive Officer, effective as of the September 16, 2021 closing
date of the Amalgamation (the &ldquo;<U>Tucker Effective Date</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 32; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Tucker Employment Agreement, Dr. Tucker receives a base salary of $350,000 annually (&ldquo;<U>Tucker Base Salary</U>&rdquo;).
Dr. Tucker also received, upon entering into the Tucker Employment Agreement, a one-time signing bonus of $100,000 and 1,375 RSUs,
of which half are subject to time-based vesting and the other half subject to performance-based vesting. Pursuant to the Tucker Employment
Agreement, upon entering into the agreement, Dr. Tucker also received an initial equity compensation received grant of 15,000 RSUs, of
which half are subject to time-based vesting and the other half subject to performance-based vesting. The RSUs are subject to the terms
and conditions of the Company&rsquo;s Incentive Plan. The Tucker time-based RSUs vest in quarters on each of the first four anniversaries
of the Tucker Effective Date, and the Tucker performance-based RSUs shall vest based on the achievement of performance milestones established
by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Beginning
in calendar year 2022, Dr. Tucker became eligible to receive annual performance bonuses of up to 75% of the Tucker Base Salary, as determined
from time to time by the Company&rsquo;s Board.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Tucker Employment Agreement will remain in effect until terminated by either party, unless the Company or Dr. Tucker delivers advance
written notice of termination to the other party at least 30 days prior. In addition, the Tucker Employment Agreement is subject to early
termination by him or the Company in accordance with the terms of the Tucker Employment Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Tucker Employment Agreement, if Dr. Tucker&rsquo;s employment is terminated by the Company without cause or by Dr. Tucker for
good reason, then the Company must pay Dr. Tucker, in addition to any then-accrued and unpaid obligations owed to him, 12 months of the
then-current Tucker Base Salary.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Tucker Employment Agreement also contains covenants restricting Dr. Tucker from soliciting the Company&rsquo;s employees or customers
for a period of 12 months after the termination of Dr. Tucker&rsquo;s employment with the Company and prohibiting him from disclosure
of confidential information regarding the Company at any time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2021, Dr. Tucker has been awarded an aggregate of 16,375 RSUs, with all being unvested. Vesting conditions include,
without limitation, continued employment or engagement with the Company, achievement of defined stock price levels, termination of the
employee without cause, resignation of the employee for good cause or change in control and there can be no assurances of any of these
vesting conditions being achieved and accordingly no assurances of any of these RSUs vesting. Furthermore, in the event that any or all
of these RSUs do vest, Dr. Tucker will be eligible to convert any vested RSUs into an equivalent number of shares of Common Stock on
the first day of the seventh month subsequent to either his termination of employment with the Company or in the event of a change in
control and provided compliance with all terms and conditions of the Incentive Plan, including, without limitation, the availability
of shares approved by the Company&rsquo;s shareholders for such issuance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 33; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Kanubaddi
Employment Agreement</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior
to the completion of the Offer, and contingent and effective upon the completion of the Offer, the Company entered into an employment
agreement with Mr. Kanubaddi (the &ldquo;<U>Kanubaddi Employment Agreement</U>&rdquo;). Pursuant to the Kanubaddi Employment Agreement,
dated December 2, 2020, Mr. Kanubaddi serves in the position of Chief Operating Officer. Mr. Kanubaddi is entitled to a base salary of
$295,000 and a closing bonus in the amount of $60,000. Mr. Kanubaddi is also eligible to receive annual performance bonuses of up to
50% of his base salary based on satisfaction of performance criteria/financial results, as determined by the Board in its sole discretion.
Within 30 days after the completion of the Offer, Mr. Kanubaddi was granted an award of restricted stock units that represent, in the
aggregate, 3% of the Company&rsquo;s issued and outstanding common stock determined on a fully diluted basis as of the date of grant.
Mr. Kanubaddi is also eligible to receive additional equity awards, as determined by the Company in its sole discretion.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the terms of the Kanubaddi Employment Agreement, Mr. Kanubaddi&rsquo;s employment may be terminated by either the Company or Mr. Kanubaddi
at any time and for any reason with 30 days&rsquo; advance written notice. Upon termination of Mr. Kanubaddi&rsquo;s employment, Mr.
Kanubaddi will receive (i) his fully earned but unpaid base salary through the date of termination, (ii) any accrued and unpaid time
off or similar pay to which Mr. Kanubaddi is entitled as a matter of law or Company policy, (iii) any amounts due to Mr. Kanubaddi under
the terms of the benefit plans, and (iv) any unreimbursed expenses properly incurred prior to the date of termination (the &ldquo;<U>Kanubaddi
Accrued Obligations</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the Company terminates Mr. Kanubaddi&rsquo;s employment for cause or Mr. Kanubaddi resigns without good reason (as defined below), the
Company, at its sole discretion, may shorten the notice period and determine the date of termination without any obligation to pay any
additional compensation other than the Kanubaddi Accrued Obligations and without triggering a termination of Mr. Kanubaddi&rsquo;s employment
without cause. If the Company terminates Mr. Kanubaddi&rsquo;s employment without cause or Mr. Kanubaddi resigns for good reason at any
time, Mr. Kanubaddi is entitled to the following severance payments and benefits: (i) his full annual base salary less applicable deductions
and withholdings; plus (ii) any earned but unpaid performance bonus, if any, for the year of the termination.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Kanubaddi Employment Agreement also contains certain standard non-solicitation, non-disparagement and confidentiality requirements for
Mr. Kanubaddi.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2021, Mr. Kanubaddi has been awarded an aggregate of 15,790 RSUs, all of which are vested. Mr. Kanubaddi will
be eligible to convert these vested RSUs into an equivalent number of shares of Common Stock on the first day of the seventh month subsequent
to either his termination of employment with the Company, or in the event of a change in control, and provided compliance with all terms
and conditions of the Incentive Plan, including, without limitation, the availability of shares approved by the Company&rsquo;s shareholders
for such issuance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 34; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Facchini
Employment Agreement</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 24, 2021, Dr. Peter Facchini entered into an employment agreement (the &ldquo;<U>Facchini Employment Agreement</U>&rdquo;) with the
Company pursuant to he serves as the Company&rsquo;s Chief Innovation Officer, effective as of the September 16, 2021 closing
date of the Amalgamation (the &ldquo;<U>Facchini Effective Date</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Facchini Employment Agreement, as of the Facchini Effective Date, Dr. Facchini has received a base salary of C$295,000 annually
(&ldquo;<U>Facchini Base Salary</U>&rdquo;). Dr. Facchini also received a one-time signing bonus of C$50,000 and up to 2,600 RSUs, based
on the price of the Company&rsquo;s shares at the Facchini Effective Date. Half of any such RSUs are subject to time-based vesting, and
the remaining half of any such RSUs are subject to performance-based vesting. Beginning in calendar year 2022, Dr. Facchini became eligible
to receive annual performance bonuses of up to 50% of the Facchini Base Salary, as determined from time to time by the Board. Additionally,
Dr. Facchini received 10,500 RSUs as equity compensation. 5,250 of such RSUs are subject to time-based vesting, and the remaining 5,250
of such RSUs are subject to performance-based vesting. The RSUs are subject to the terms and conditions of the Company&rsquo;s Incentive
Plan. The RSUs are subject to time-based vesting and shall vest in quarters on each of the first four anniversaries of the Facchini Effective
Date, and the RSUs shall vest based on the achievement of performance milestones established by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Facchini Employment Agreement will remain in effect until terminated by either party, unless the Company delivers advance written notice
of termination to Dr. Facchini or Dr. Facchini delivers advance written notice of termination to the Company at least 30 days prior.
In addition, the Facchini Employment Agreement is subject to early termination by him or the Company in accordance with the terms of
the Facchini Employment Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Facchini Employment Agreement, if Dr. Facchini&rsquo;s employment is terminated by the Company without cause or by Dr. Facchini
for good reason, then the Company must pay Dr. Facchini, in addition to any then-accrued and unpaid obligations owed to him, 12 months
of the then-current Facchini Base Salary.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Facchini Employment Agreement also contains covenants restricting Dr. Facchini from soliciting the Company&rsquo;s employees or customers
for a period of 12 months after the termination of Dr. Facchini&rsquo;s employment with the Company and prohibiting him from disclosure
of confidential information regarding the Company at any time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2021, Dr. Facchini has been awarded an aggregate of 11,522 RSUs, with all being unvested. Vesting conditions include,
without limitation, continued employment or engagement with the Company, achievement of defined stock price levels, termination of the
employee without cause, resignation of the employee for good cause or change in control and there can be no assurances of any of these
vesting conditions being achieved and accordingly no assurances of any of these RSUs vesting. Furthermore, in the event that any or all
of these RSUs do vest, Dr. Facchini will be eligible to convert any vested RSUs into an equivalent number of shares of Common Stock on
the first day of the seventh month subsequent to either his termination of employment with the Company, or in the event of a change in
control, and provided compliance with all terms and conditions of the Incentive Plan, including, without limitation, the availability
of shares approved by the Company&rsquo;s shareholders for such issuance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 35; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Wilkins
Employment Agreement</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 22, 2020, Dr. Robert Wilkins entered into an employment agreement (the &ldquo;<U>Wilkins Employment Agreement</U>&rdquo;) with
the Company pursuant to which he became the Company&rsquo;s Chief Medical Officer, effective as of the December 30, 2020 (the &ldquo;<U>Wilkins
Effective Date</U>&rdquo;). Dr. Wilkins resigned from his position with the Company on November 30, 2021.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Wilkins Employment Agreement, Dr. Wilkins served in the position of Chief Medical Officer of the Company. Dr. Wilkins received
a base annual salary of $185,000. Dr. Wilkins was also eligible to receive annual performance bonuses of up to 50% of his base salary
based on satisfaction of performance criteria/financial results, as determined by the Board in its sole discretion. The Wilkins Employment
Agreement provided for the awarding of 10,520 RSUs to Dr. Wilkins, with 3,507 of such RSUs being immediately vested and 7,014
RSUs vesting upon the achievement of specific volume weighted average prices being achieved by the Company&rsquo;s Common Stock during
specified measurement periods. Dr. Wilkins was also eligible to receive additional equity awards, as determined by the Company in its
sole discretion.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Wilkins Employment Agreement also contains certain standard non-solicitation, non-disparagement and confidentiality requirements for
Dr. Wilkins.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
Wilkins resigned from his position with the Company on November 30, 2021. As of the date of his resignation, Dr. Wilkins had been awarded
an aggregate of 10,520 RSUs, with 3,507 of such RSUs being vested and 7,014 of such RSUs being unvested, forfeited and cancelled.
Dr. Wilkins will be eligible to convert these vested RSUs into an equivalent number of shares of Common Stock on the first day of the
seventh month subsequent to the date of his resignation, provided compliance with all terms and conditions of the Incentive Plan, including,
without limitation, the availability of shares approved by the Company&rsquo;s shareholders for such issuance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Independent
Contractor Agreement with David Johnson</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jay
Pharma entered into an independent contractor agreement with Mr. Johnson on January 2, 2020. Pursuant to the agreement, Mr. Johnson provided
certain consulting services in connection with the Offer beginning on January 1, 2020 through the completion of the Offer. Mr. Johnson
was entitled to (i) $15,000 per month, and (ii) $100,000 on the closing date. The agreement was terminable by Jay Pharma and Mr. Johnson
for any reason upon 30 days&rsquo; written notice.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 36; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding
Equity Awards at Fiscal Year-End</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0.5in">The following table sets
forth information concerning outstanding equity awards held by each of our named executive officers as of December 31, 2021</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 9pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: justify">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="10" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Option Awards</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Stock Awards</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font-weight: bold">Name</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Grant Date</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of securities underlying unexercised options <BR>(#) exercisable</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Option exercise price <BR>($)</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Option expiration date</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Equity incentive plan awards: Number of unearned shares, units or other rights that have not vested <BR>(#)(1)</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Equity incentive plan awards: Market or payout value of unearned shares, units or other rights that have not vested <BR>($)</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">David Johnson</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 40%; text-align: left">Dr. Joseph Tucker</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 8%; text-align: right">9/16/2021</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 6%; text-align: right">3,987</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 6%; text-align: right">94.00</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 6%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">4/5/2026</FONT></TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 6%; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 6%; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">10/13/2021</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">16,375</TD><TD STYLE="text-align: left">(2)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">761,391</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Avani Kanubaddi</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Dr. Peter Facchini</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">9/16/2021</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,993</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">94.00</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">4/5/2026</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">10/13/2021</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">11,522</TD><TD STYLE="text-align: left">(3)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">535,727</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Dr. Robert Wilkins</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vested
    restricted stock units are eligible for conversion into an equivalent number of shares of Common Stock on the first day of the seventh
    month subsequent to either the employee&rsquo;s termination of employment with the Company, or in the event of a change in control,
    and provided compliance with all terms and conditions of the Incentive Plan, including, without limitation, the availability of shares
    approved by the Company&rsquo;s shareholders for such issuance.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Potential
Payments Upon Termination of Employment or Change in Control</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">None
of our named executive officers has a contract in place for change in control payments.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
employment agreements of Mr. David Johnson, Dr. Joseph Tucker, Mr. Avani Kanubaddi, and Dr. Peter Facchini include provisions for severance
pay equal to twelve months of salary upon termination by the Company without cause, as defined in the employment agreements or termination
by the employee for good reason, as defined in the employment agreements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
of our named executive officers have also been granted RSUs which are currently either fully vested or contain conditions providing for
vesting upon change of control. Vested RSUs are eligible for conversion to an equivalent number of shares of Common Stock upon termination
of the employee by either the Company without cause, termination by the employee for good reason or an event of change of control, and
provided the Company&rsquo;s compliance with all terms and conditions of the Incentive Plan, including, without limitation, the availability
of shares approved by the Company&rsquo;s shareholders for such issuances.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 37; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incentive
Plans</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Enveric
Biosciences, Inc. 2020 Long-Term Incentive Plan</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Purpose</I>.
The purpose of the Incentive Plan is to enable us to remain competitive and innovative and aid our ability to attract and retain the
services of key employees, key contractors, and non-employee directors. The Incentive Plan provides for the granting of incentive stock
options, nonqualified stock options, stock appreciation rights, restricted stock, restricted stock units, performance awards, dividend
equivalent rights, and other awards, which may be granted singly, in combination, or in tandem, and which may be paid in cash or shares
of our common stock. The Incentive Plan provides flexibility to the Company with regard to its compensation methods in order to adapt
the compensation of its key employees, key contractors, and non-employee directors to a changing business environment, after giving due
consideration to competitive conditions and the impact of applicable tax laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Effective
Date and Expiration</I>. The Incentive Plan was adopted on December 31, 2020 pursuant to the Tender Agreement and was effective as of
December 31, 2020 (the &ldquo;<U>Incentive Plan Effective Date</U>&rdquo;). The Incentive Plan will terminate on the tenth anniversary
of the Incentive Plan Effective Date, unless sooner terminated by our Board. No award may be made under the Incentive Plan after its
termination date, but awards made prior to the termination date may extend beyond that date in accordance with their terms.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Share
Authorization</I>. Subject to certain adjustments, as of January 1, 2022, the total number of shares of the Company&rsquo;s common stock
that were reserved and able to be issued pursuant to awards under the Incentive Plan was 53,918 shares. On May 3, 2022, our Board
adopted the First Amendment (the &ldquo;<U>Plan Amendment</U>&rdquo;) to Incentive Plan to (i) increase the aggregate number of shares
available for the grant of awards by 146,083 shares to a total of 200,000 shares, and (ii) add an &ldquo;evergreen&rdquo; provision whereby
the number of shares authorized for issuance pursuant to awards under the Incentive Plan will be automatically increased on the first
trading date immediately following the date the Company issues any share of Common Stock (defined below) to any person or entity, to
the extent necessary so that the number of shares of the Company&rsquo;s Common Stock authorized for issuance under the Incentive Plan
will equal the greater of (x) 200,000 shares, and (y) 15% of the total number of shares of the Company&rsquo;s Common Stock outstanding
as of such issuance date. The Plan Amendment was approved by the Company&rsquo;s stockholders at a special meeting of the Company&rsquo;s
stockholders held on July 14, 2022.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Administration</I>.
The Incentive Plan shall be administered by the Board or such committee of the Board as it designated by it to administer the Incentive
Plan (the &ldquo;<U>Committee</U>&rdquo;). At any time that there is no Committee to administer the Plan, any reference to the Committee
is a reference to the board of directors of the Company. The Committee will determine the persons to whom awards are to be made; determine
the type, size, and terms of awards; interpret the Incentive Plan; establish and revise rules and regulations relating to the Incentive
Plan; establish performance goals for awards and certify the extent of their achievement; and make any other determinations that it believes
are necessary for the administration of the Incentive Plan. The Committee may delegate certain of its duties to one or more officers
of the Company as provided in the Incentive Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 38; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Eligibility</I>.
Employees (including any employee who is also a director or an officer), contractors, and non-employee directors of the Company or any
of its subsidiaries, whose judgment, initiative, and efforts contributed to or may be expected to contribute to its successful performance,
are eligible to participate in the Incentive Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Stock
Options</I>. The Committee may grant either incentive stock options (&ldquo;<U>ISOs</U>&rdquo;) qualifying under Section 422 of the Internal
Revenue Code of 1986, as amended (the &ldquo;<U>Code</U>&rdquo;), or nonqualified stock options, provided that only employees of the
Company and our subsidiaries (excluding subsidiaries that are not corporations) are eligible to receive ISOs. Stock options may not be
granted with an option price less than 100% of the fair market value of a share of common stock on the date the stock option is granted.
If an ISO is granted to an employee who owns or is deemed to own more than 10% of the combined voting power of all classes of our stock
(or of any parent or subsidiary), the option price shall be at least 110% of the fair market value of a share of common stock on the
date of grant. The Committee will determine the terms of each stock option at the time of grant, including, without limitation, the methods
by or forms in which shares will be delivered to participants or registered in their names. The maximum term of each option, the times
at which each option will be exercisable, and provisions requiring forfeiture of unexercised options at or following termination of employment
or service generally are fixed by the Committee, except that the Committee may not grant stock options with a term exceeding ten (10)
years or, in the case of an ISO granted to an employee who owns or is deemed to own more than 10% of the combined voting power of all
classes of our stock (or of any parent or subsidiary), a term exceeding five (5) years.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Recipients
of stock options may pay the option price (i) in cash, check, bank draft, or money order payable to the order of the Company; (ii) by
delivering to us shares of common stock (included restricted stock) already owned by the participant having a fair market value equal
to the aggregate option price and that the participant has not acquired from the Company within six months prior to the exercise date;
(iii) by delivering to the Company or its designated agent an executed irrevocable option exercise form, together with irrevocable instructions
from the participant to a broker or dealer, reasonably acceptable to the Company, to sell certain of the shares purchased upon the exercise
of the option or to pledge such shares to the broker as collateral for a loan from the broker and to deliver to us the amount of sale
or loan proceeds necessary to pay the purchase price; (iv) by requesting us to withhold the number of shares otherwise deliverable upon
exercise of the stock option by the number of shares having an aggregate fair market value equal to the aggregate option price at the
time of exercise (<I>i.e., </I>a cashless net exercise); and (v) by any other form of valid consideration that is acceptable to the Committee
in its sole discretion.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Stock
Appreciation Rights</I>. The Committee is authorized to grant stock appreciation rights (&ldquo;<U>SARs</U>&rdquo;) as a stand-alone
award, or freestanding SARs, or in conjunction with options granted under the Incentive Plan, or tandem SARs. SARs entitle a participant
to receive an amount equal to the excess of the fair market value of a share of common stock on the date of exercise over the fair market
value of a share of Company common stock on the date of grant. The grant price of a SAR cannot be less than 100% of the fair market value
of a share of Company common stock on the date of grant. The Committee will determine the terms of each SAR at the time of the grant,
including, without limitation, the methods by or forms in which shares will be delivered to participants or registered in their names.
The maximum term of each SAR, the times at which each SAR will be exercisable, and provisions requiring forfeiture of unexercised SARs
at or following termination of employment or service generally are fixed by the Committee, except that no freestanding SAR may have a
term exceeding ten (10) years and no tandem SAR may have a term exceeding the term of the option granted in conjunction with the tandem
SAR. Distributions to the recipient may be made in common stock, cash, or a combination of both as determined by the Committee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 39; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Restricted
Stock and Restricted Stock Units.</I> The Committee is authorized to grant restricted stock and restricted stock units. Restricted stock
consists of shares of Company common stock that may not be sold, assigned, transferred, pledged, hypothecated, encumbered, or otherwise
disposed of, and that may be forfeited in the event of certain terminations of employment or service, prior to the end of a restricted
period as specified by the Committee. Restricted stock units are the right to receive shares of common stock at a future date in accordance
with the terms of such grant upon the attainment of certain conditions specified by the Committee, which include a substantial risk of
forfeiture and restrictions on their sale or other transfer by the participant. The Committee determines the eligible participants to
whom, and the time or times at which, grants of restricted stock or restricted stock units will be made; the number of shares or units
to be granted; the price to be paid, if any; the time or times within which the shares covered by such grants will be subject to forfeiture;
the time or times at which the restrictions will terminate; and all other terms and conditions of the grants. Restrictions or conditions
could include, but are not limited to, the attainment of performance goals (as described below), continuous service with the Company,
the passage of time, or other restrictions or conditions. Except as otherwise provided in the Incentive Plan or the applicable award
agreement, a participant shall have, with respect to shares of restricted stock, all of the rights of a stockholder of the Company holding
the class of common stock that is the subject of the restricted stock, including, if applicable, the right to vote the common stock and
the right to receive any dividends thereon.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Dividend
Equivalent Rights</I>. The Committee is authorized to grant a dividend equivalent right to any participant, either as a component of
another award or as a separate award, conferring on the participant the right to receive credits based on the cash dividends that would
have been paid on the shares of common stock specified in the award as if such shares were held by the participant. The terms and conditions
of the dividend equivalent right shall be specified in the grant. Dividend equivalents credited to the holder of a dividend equivalent
right may be paid currently or may be deemed to be reinvested in additional shares. Any such reinvestment shall be at the fair market
value at the time thereof. A dividend equivalent right may be settled in cash, shares, or a combination thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Performance
Awards</I>. The Committee may grant performance awards payable at the end of a specified performance period in cash, shares of common
stock, units, or other rights based upon, payable in, or otherwise related to our common stock. Payment will be contingent upon achieving
pre-established performance goals (as discussed below) by the end of the applicable performance period. The Committee will determine
the length of the performance period, the maximum payment value of an award, and the minimum performance goals required before payment
will be made, so long as such provisions are not inconsistent with the terms of the Incentive Plan, and to the extent an award is subject
to Section 409A of the Code, are in compliance with the applicable requirements of Section 409A of the Code and any applicable regulations
or guidance. In certain circumstances, the Committee may, in its discretion, determine that the amount payable with respect to certain
performance awards will be reduced from the maximum amount of any potential awards. If the Committee determines, in its sole discretion,
that the established performance measures or objectives are no longer suitable because of a change in the Company&rsquo;s business, operations,
corporate structure, or for other reasons that the Committee deems satisfactory, the Committee may modify the performance measures or
objectives and/or the performance period.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 40; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Performance
Goals</I>. Awards of restricted stock, restricted stock units, performance awards, and other awards under the Incentive Plan may be made
subject to the attainment of performance goals relating to one or more business criteria which shall consist of one or more or any combination
of the following criteria (&ldquo;<U>Performance Criteria</U>&rdquo;): cash flow; cost; revenues; sales; ratio of debt to debt plus equity;
net borrowing, credit quality, or debt ratings; profit before tax; economic profit; earnings before interest and taxes; earnings before
interest, taxes, depreciation, and amortization; gross margin; earnings per share (whether on a pre-tax, after-tax, operational, or other
basis); operating earnings; capital expenditures; expenses or expense levels; economic value added; ratio of operating earnings to capital
spending or any other operating ratios; free cash flow; net profit; net sales; net asset value per share; the accomplishment of mergers,
acquisitions, dispositions, public offerings, or similar extraordinary business transactions; sales growth; price of the shares; return
on assets, equity, or stockholders&rsquo; equity; market share; inventory levels, inventory turn or shrinkage; or total return to stockholders.
Any Performance Criteria may be used to measure our performance as a whole or of any of our business units and may be measured relative
to a peer group or index. Any Performance Criteria may include or exclude (i) events that are of an unusual nature or indicate infrequency
of occurrence, (ii) gains or losses on the disposition of a business; (iii) changes in tax or accounting regulations or laws; (iv) the
effect of a merger or acquisition, as identified in the Company&rsquo;s quarterly and annual earnings releases; or (v) other similar
occurrences. In all other respects, Performance Criteria shall be calculated in accordance with the Company&rsquo;s financial statements,
under GAAP, or under a methodology established by the Committee prior to the issuance of an award, which is consistently applied and
identified in the Company&rsquo;s audited financial statements, including in notes thereto, or the Compensation Discussion and Analysis
section of the Company&rsquo;s Annual Report on Form 10-K.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Other
Awards</I>. The Committee may grant other forms of awards, based upon, payable in, or that otherwise relate to, in whole or in part,
shares of our common stock, if the Committee determines that such other form of award is consistent with the purpose and restrictions
of the Incentive Plan. The terms and conditions of such other form of award shall be specified in the grant. Such other awards may be
granted for no cash consideration, for such minimum consideration as may be required by applicable law, or for such other consideration
as may be specified in the grant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Vesting,
Forfeiture and Recoupment, Assignment</I>. The Committee, in its sole discretion, may determine that an award will be immediately vested,
in whole or in part, or that all or any portion may not be vested until a date, or dates, subsequent to its date of grant, or until the
occurrence of one or more specified events, subject in any case to the terms of the Incentive Plan. If the Committee imposes conditions
upon vesting, then, subsequent to the date of grant, the Committee may, in its sole discretion, accelerate the date on which all or any
portion of the award may be vested.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 41; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Committee may impose on any award at the time of grant or thereafter, such additional terms and conditions as the Committee determines,
including terms requiring forfeiture of awards in the event of a participant&rsquo;s termination of service. The Committee will specify
the circumstances on which performance awards may be forfeited in the event of a termination of service by a participant prior to the
end of a performance period or settlement of awards. Except as otherwise determined by the Committee, restricted stock will be forfeited
upon a participant&rsquo;s termination of service during the applicable restriction period. In addition, we may recoup all or any portion
of any shares or cash paid to a participant in connection with any award in the event of a restatement of the Company&rsquo;s financial
statements as set forth in the Company&rsquo;s clawback policy, if any, as such policy may be approved or modified by the Board from
time to time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Awards
granted under the Incentive Plan generally are not assignable or transferable except by will or by the laws of descent and distribution,
except that the Committee may, in its discretion and pursuant to the terms of an award agreement, permit transfers of nonqualified stock
options or SARs to (i) the spouse (or former spouse), children, or grandchildren of the participant (&ldquo;<U>Immediate Family Members</U>&rdquo;);
(ii) a trust or trusts for the exclusive benefit of such Immediate Family Members; (iii) a partnership in which the only partners are
(1) such Immediate Family Members and/or (2) entities which are controlled by the participant and/or his or her Immediate Family Members;
(iv) an entity exempt from federal income tax pursuant to Section 501(c)(3) of the Code or any successor provision; or (v) a split interest
trust or pooled income fund described in Section 2522(c)(2) of the Code or any successor provision, provided that (x) there shall be
no consideration for any such transfer, (y) the applicable award agreement pursuant to which such nonqualified stock options or SARs
are granted must be approved by the Committee and must expressly provide for such transferability, and (z) subsequent transfers of transferred
nonqualified stock options or SARs shall be prohibited except those by will or the laws of descent and distribution.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Adjustments
Upon Changes in Capitalization</I>. In the event that any dividend or other distribution (whether in the form of cash, shares of Company
common stock, other securities or other property), recapitalization, stock split, reverse stock split (including the proposed Reverse
Stock Split, to the extent it is implemented after the Annual Meeting), rights offering, reorganization, merger, consolidation, split-up,
spin-off, split-off, combination, subdivision, repurchase, or exchange of shares of common stock or other securities of the Company,
issuance of warrants or other rights to purchase shares of common stock or other securities of the Company, or other similar corporate
transaction or event affects the fair value of an award, then the Committee shall adjust any or all of the following so that the fair
value of the award immediately after the transaction or event is equal to the fair value of the award immediately prior to the transaction
or event: (i) the number of shares and type of common stock (or the securities or property) which thereafter may be made the subject
of awards; (ii) the number of shares and type of common stock (or other securities or property) subject to outstanding awards; (iii)
the number of shares and type of common stock (or other securities or property) specified as the annual per-participant limitation under
the Incentive Plan; (iv) the option price of each outstanding stock option; (v) the amount, if any, we pay for forfeited shares in accordance
with the terms of the Incentive Plan; and (vi) the number of or exercise price of shares then subject to outstanding SARs previously
granted and unexercised under the Incentive Plan, to the end that the same proportion of our issued and outstanding shares of common
stock in each instance shall remain subject to exercise at the same aggregate exercise price; provided, however, that the number of shares
of common stock (or other securities or property) subject to any award shall always be a whole number. Notwithstanding the foregoing,
no such adjustment shall be made or authorized to the extent that such adjustment would cause the Incentive Plan or any stock option
to violate Section 422 of the Code or Section 409A of the Code. All such adjustments must be made in accordance with the rules of any
securities exchange, stock market, or stock quotation system to which we are subject.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 42; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Amendment
or Discontinuance of the Incentive Plan</I>. The Board may, at any time and from time to time, without the consent of participants, alter,
amend, revise, suspend, or discontinue the Incentive Plan in whole or in part; provided, however, that (i) no amendment that requires
stockholder approval in order for the Incentive Plan and any awards under the Incentive Plan to continue to comply with Sections 421
and 422 of the Code (including any successors to such sections or other applicable law) or any applicable requirements of any securities
exchange or inter-dealer quotation system on which our stock is listed or traded, shall be effective unless such amendment is approved
by the requisite vote of our stockholders entitled to vote on the amendment; and (ii) unless required by law, no action by our Board
regarding amendment or discontinuance of the Incentive Plan may adversely affect any rights of any participants or obligations of the
Company to any participants with respect to any outstanding awards under the Incentive Plan without the consent of the affected participant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equity
Compensation Plan Information</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table provides information regarding the weighted-average exercise price of options issued by the Company as of December 31,
2021. Such issuances were approved by the Board outside of an equity compensation plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; border-bottom: Black 1.5pt solid">Plan category</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of securities to be issued upon exercise of outstanding options, warrants and rights</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted-average exercise price of outstanding options, warrants and rights (3)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of securities remaining for issuance under equity compensation plans (excluding securities reflected in the first column)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 46%; text-align: left">Equity compensation plans approved by security holders (1)</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 14%; text-align: right">121,883</TD><TD STYLE="width: 1%; text-align: left">(2)</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 14%; text-align: right">172.50</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 14%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">(4)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Equity compensation plans not approved by security holders</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,870</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">111.50</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Total</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">123,753</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">133.00</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 43; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consists
    of the Incentive Plan.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif">Represents
                                            2,482 shares of Common Stock to be issued pursuant to the exercise of outstanding options,
                                            642 shares of Common Stock to be issued pursuant to vested restricted stock awards,
                                            1,031 shares of Common stock to be issued pursuant to unvested restricted stock awards,
                                            55,717 vested restricted stock units representing 55,717 shares of Common Stock,
                                            62,013 unvested restricted stock units representing 62,013 shares of Common
                                            Stock. There can be no assurances of the achievement of vesting conditions related to those
                                            unvested restricted stock awards and unvested restrict stock units.</P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Represents
    the weighted-average exercise price of outstanding options and is calculated without taking into account the shares of common stock
    subject to outstanding restricted stock awards and outstanding restricted stock units.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif">As
                                            of the end of the fiscal year ended December 31, 2021, there were 117,729 shares of
                                            common stock underlying outstanding restricted stock units, of which (i) 55,717 shares
                                            are underlying vested restricted stock units and issuable, subject to certain conditions
                                            for settlement, which include termination of employment or the event of a change in control,
                                            and of which 5,953 shares could not be issued until Incentive Plan, which as of that
                                            date had no shares available for issuance and was short of shares to cover all of the outstanding
                                            restricted stock units, was amended to increase the number of shares authorized for issuance
                                            of awards under the Incentive Plan upon approval by our stockholders and (ii) 62,013
                                            shares are issuable upon the vesting of such restricted stock units, subject to achievement
                                            of vesting conditions, either termination of employment with the Company, or a change in
                                            control, and is further subject to the increase in the number of shares authorized for issuance
                                            of awards under the Incentive Plan upon approval by our stockholders.</P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="a_005"></A>Director
Compensation</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents the total compensation for each person who served as a member of our Board during the fiscal year ended December
31, 2021. Other than set forth in the table and described more below, we did not pay any compensation, reimburse any expense of, make
any equity awards or non-equity awards to, or pay any other compensation to any of the other members of our Board in 2021.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; border-bottom: Black 1.5pt solid">Name</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Fees earned<BR> or paid in<BR> cash<BR> ($)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Equity<BR> awards<BR> ($)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total<BR> ($)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 46%; text-align: left">George Kegler</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 14%; text-align: right">38,500</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 14%; text-align: right">76,594</TD><TD STYLE="width: 1%; text-align: left"><SUP>(1)</SUP></TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 14%; text-align: right">115,094</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Sol Mayer</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">34,250</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">76,594</TD><TD STYLE="text-align: left"><SUP>(2)</SUP></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">110,844</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Marcus Schabacker</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">37,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">76,594</TD><TD STYLE="text-align: left"><SUP>(3)</SUP></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">113,594</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Douglas Lind</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">24,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">32,432</TD><TD STYLE="text-align: left"><SUP>(4)</SUP></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">56,432</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Bradley Thompson*</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8,958</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">25,000</TD><TD STYLE="text-align: left"><SUP>(5)</SUP></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">33,958</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*Resigned
from the board of directors effective May 3, 2022.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 44; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consists
    of RSA&rsquo;s equivalent to 320 shares of Common Stock, valued at $240.00 per share (the closing price per share on the date
    of the award). As of December 31, 2021, George Kegler had outstanding 320 RSA&rsquo;s.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consists
    of RSA&rsquo;s equivalent to 320 shares of Common Stock, valued at $240.00 per share (the closing price per share on the date
    of the award). As of December 31, 2021, Sol Mayer had outstanding 320 RSA&rsquo;s.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consists
    of RSA&rsquo;s equivalent to 320 shares of Common Stock, valued at $240.00 per share (the closing price per share on the date
    of the award). As of December 31, 2021, Marcus Schabacker had outstanding 320 RSA&rsquo;s.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consists
    of RSA&rsquo;s equivalent to 182 shares of Common Stock, valued at $179.00 per share (the closing price per share on the date
    of the award). As of December 31, 2021, Douglas Lind had outstanding 182 RSA&rsquo;s.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consists
    of RSA&rsquo;s equivalent to 260 shares of Common Stock, valued at $96.50 per share (the closing price per share on the date
    of the award). As of December 31, 2021, Bradley Thompson had outstanding 260 RSA&rsquo;s.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="a_006"></A>Related
Person Transactions and<BR>
Section 16(<FONT STYLE="text-transform: none">a</FONT>) Beneficial Ownership Reporting Compliance</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Described
below are transactions occurring since January 1, 2021 and any currently proposed transactions to which the Company was a party and in
which:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    amounts involved exceeded or will exceed the lesser of (i) $120,000, or (ii) 1% of the average of the Company&rsquo;s total assets
    at December 31, 2020 and December 30, 2021; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    director, executive officer, holder of more than 5% of the Company&rsquo;s outstanding capital stock, or any member of such person&rsquo;s
    immediate family had or will have a direct or indirect material interest, excluding compensation arrangements described above.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amalgamation
Agreement with MagicMed Industries Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 24, 2021, the Company entered into an Amalgamation Agreement (the &ldquo;Amalgamation Agreement&rdquo;) with 1306432 B.C. Ltd., a
corporation existing under the laws of the Province of British Columbia and a wholly-owned subsidiary of the Company (&ldquo;HoldCo&rdquo;),
1306436 B.C. Ltd., a corporation existing under the laws of the Province of British Columbia and a wholly-owned subsidiary of HoldCo
(&ldquo;Purchaser&rdquo;), and MagicMed Industries Inc., a corporation existing under the laws of the Province of British Columbia (&ldquo;MagicMed&rdquo;),
pursuant to which, among other things, the Company, indirectly through Purchaser, acquired all of the outstanding securities of MagicMed
in exchange for securities of the Company by way of an amalgamation under the British Columbia Business Corporations Act, upon the terms
and conditions set forth in the Amalgamation Agreement, such that, upon completion of the Amalgamation (as defined herein), the amalgamated
corporation (&ldquo;Amalco&rdquo;) will be an indirect wholly-owned subsidiary of the Company. The Amalgamation was completed on September
16, 2021.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MagicMed
shareholders on the date of Amalgamation Agreement included Joseph Tucker, Peter Facchini and Jillian Hagel, all of whom became employees
of the Company as of the September 16, 2021 completion of the Amalgamation. At the time of and prior to entering into the Amalgamation
Agreement, MagicMed, Joseph Tucker, Peter Facchini and Jillian Hagel were not related parties of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 45; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Employment
and Consulting Agreements</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Independent
Contractor Agreement with Barry Kostiner</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jay
Pharma and Barry Kostiner entered into an independent contractor agreement on January 10, 2020 (the &ldquo;January Agreement&rdquo;).
Pursuant to the January Agreement, Mr. Kostiner agreed to provide consulting services to Jay Pharma effective December 1, 2019. The January
Agreement was terminated effective April 30, 2020. Mr. Kostiner earned $10,000 per month over the term of the January Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Agreements
with Tikkun</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assignment
and Assumption Agreements</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 10, 2020, Jay Pharma entered into two assignment and assumption agreements, pursuant to which, upon the satisfaction of all closing
conditions to the Offer, affiliates of Tikkun would assign to Jay Pharma all of such affiliates&rsquo; in-licensed and developed rights
based on certain Amended and Restated Sublicense Agreements, effective January 12, 2018, pursuant to which Jay Pharma entered into two
in-licensing U.S. and rest of world rights to the limited pharmaceutical business (including cancer) from TOP and TOCI, respectively,
each as amended by a First Amendment entered January 10, 2020, with:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
TOP and Tikkun regarding all of Tikkun&rsquo;s (i) in-licensed rights and obligations to commercialize pharmaceutical products related
to GVHD under the relevant Sublicense in the U.S. and (ii) certain skincare business and all of Tikkun&rsquo;s rights related thereto
as of the January 10, 2020 effective date. Jay Pharma agreed to issue 8,288,006 common shares of Jay Pharma to Tikkun in exchange for
these rights; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
TOCI and Tikkun regarding all of Tikkun&rsquo;s in-licensed rights and obligations to commercialize pharmaceutical products related to
GVHD under the relevant sublicense anywhere in the world outside the U.S. Jay Pharma agreed to issue 2,072,001 common shares of Jay Pharma
to Tikkun in exchange for these rights.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 12, 2020, Jay Pharma and the applicable Tikkun affiliates entered into the First Amendment to the Tikkun Agreements, pursuant
to which all references to the Original Amalgamation Agreement and the amalgamation were revised to be references to the Tender Agreement
and the Offer, as applicable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 2, 2020, Jay Pharma and the applicable Tikkun affiliates entered into the Second Amendment to the Tikkun Agreements, pursuant
to which the effective date of the transactions was revised to occur as of October 2, 2020.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 46; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">License
Agreement</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jay
Pharma, TO LLC and TOH entered into a license agreement dated on January 10, 2020, pursuant to which Jay Pharma would acquire certain
in-licensed and owned intellectual property rights related to the cannabis products in the United States (presently excluding the state
of New York) from TO LLC and TOH, each of which is an affiliate of TO Holdings, in exchange for royalty payments of (i) four percent
(4.0%) of net sales of OTC cancer products made via consumer channels; (ii) five percent (5.0%) of net sales of beauty products made
via consumer channels; and (iii) three percent (3.0%) of net sales of OTC cancer products made via professional channels, along with
a minimum net royalty payment starting in January 1, 2022 and progressively increasing up to a cap of $400,000 maximum each year for
the first 10 years, then $600,000 maximum each year for the next 5 years, and an annual maximum cap of $750,000 each year thereafter
during the term of the agreement. The licensed intellectual property rights relate to beauty products and OTC cancer products, and branding
rights related thereto. The beauty products include any topical or transdermal cannabis-containing or cannabis-derived (including hemp-based)
skin care or body care beauty products, and the OTC cancer products means any cancer-related products, in each case excluding those regulated
as a drug, medicine, or controlled substance by the FDA or any other relevant governmental authority, such as the USDA.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 12, 2020, Jay Pharma, TO LLC and TOH entered into the First Amendment to the License Agreement, pursuant to which all references
to the Original Amalgamation Agreement and the amalgamation were revised to be references to the Tender Agreement and the Offer, as applicable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 2, 2020, Jay Pharma, TO LLC and TOH entered into the Second Amendment to the License Agreement, pursuant to which the effective
date of the transactions was revised to occur as of October 2, 2020.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Agreements
with Alpha</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Alpha
Bridge Loan</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
the signing of the Original Amalgamation Agreement, Jay Pharma issued the Original Note to Alpha, dated as of January 10, 2020, pursuant
to which Alpha loaned $1,500,000 to Jay Pharma in connection with, and as a condition to, the Original Amalgamation Agreement. The Original
Note was amended on June 23, 2020 (as discussed further below) to reflect an additional investment of $500,000, resulting in a total
principal amount of $2,000,000 (the &ldquo;Second Note Amendment&rdquo;). The Original Note was further amended on August 12, 2020 (as
discussed further below), to account for the termination of the Original Amalgamation Agreement and the change in the structure of the
transaction from an amalgamation to a stock-for-stock exchange offer (the &ldquo;Third Note Amendment&rdquo;). The terms described in
the following paragraphs reflect the terms of the Original Note as amended by the Second Note Amendment and the Third Note Amendment.
The Note was secured, pursuant to the Security Agreement, by all of the assets of Jay Pharma. The Note carried an annual interest rate
of 7%, calculated daily.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 47; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
the closing of the Offer, the Note was converted into the right to receive 2,473,848 common shares of Jay Pharma and warrants to purchase
2,333,970 common shares of Jay Pharma at an exercise price of $1.03 per share immediately prior to the Offer. In connection with the
Offer, such common shares and warrants of Jay Pharma acquired by Alpha upon conversion of the Note were converted into the right to receive
(i) 547,278 shares of Series B Preferred Stock that are convertible into up to 10,946 shares of Common Stock, after giving effect to
a one-for-four reverse stock split (the &ldquo;<U>2020 Reverse Stock Split</U>&rdquo;) and the subsequent 1-for-50 Reverse Stock Split
(together, the &ldquo;<U>Reverse Stock Splits</U>&rdquo;), and (ii) warrants to purchase up to 10,327 shares of Common Stock at an exercise
price of $232.00 per share, after giving effect to the 2020 Reverse Stock Split,</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jay
Pharma was obligated by certain covenants set forth in the Note, including, but not limited to, the obligation (i) to provide certain
financial information, (ii) to use the proceeds in a specifically agreed to manner, (iii) to not incur any new indebtedness other than
as allowed under the terms of the Note, (iv) to not enter into any business, except those in which Jay Pharma is already engaged or that
are reasonably related thereto, (v) to not make any distributions to its shareholders or creditors, (vi) to not make any changes to its
capital structure, authorize or issue any equity interest of Jay Pharma, and (vii) to not take or suffer any act not permitted under
the Tender Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Events
of default under the Note included, but were not limited to, (i) breaches of representations and warranties made by Jay Pharma, in the
Note or the Security Agreement, (ii) breaches of covenants made by Jay Pharma, (iii) bankruptcy and insolvency of Jay Pharma, and (iv)
the failure to consummate the Offer by a certain date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Note and the Security Agreement also provided certain customary representations and warranties of Jay Pharma. If the Tender Agreement
had been terminated without Alpha&rsquo;s prior written consent and without meeting certain other conditions in the Tender Agreement,
Jay Pharma would have been required to repay the entire outstanding principal balance of the Note plus all accrued and unpaid interest
thereon and any other sums payable to Alpha directly in connection with the Note.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">First
Note Amendment</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 6, 2020, Jay Pharma and Alpha entered into the First Note Amendment. The First Note Amendment revised the maturity date of the Note.
Prior to the First Note Amendment, the maturity date of the Note was the earlier of (i) July 6, 2020 and (ii) an event of default that
accelerates the maturity of the Note. Following the First Note Amendment, the maturity date of the Note was revised to be the earlier
of (i) September 30, 2020 and (ii) an event of default that accelerates the maturity of the Note. The First Note Amendment also revised
the event of default regarding a failure of the amalgamation to be consummated by March 31, 2020 to extend such date to September 30,
2020.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Second
Note Amendment</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 23, 2020, Jay Pharma and Alpha entered into the Second Note Amendment. The Second Note Amendment revised the principal amount of
the Note from $1,500,000 to $2,000,000, which was deemed advanced as the of date of the Second Note Amendment. The rights and securities
granted to Alpha under the terms of the Note were extended to the additional $500,000 advance contemplated by the Second Note Amendment
pursuant to the terms of the Second Note Amendment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 48; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Third
Note Amendment</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 12, 2020, Jay Pharma and Alpha entered into the Third Note Amendment. The Third Note Amendment extended the maturity date to be
the earlier of (a) January 1, 2021 and (b) an event of default that accelerates the maturity of the Note. The Third Note Amendment also
revised the Note to account for the change in structure from an amalgamation to a stock-for-stock exchange offer. As a result, references
to the Original Amalgamation Agreement and the amalgamation were revised to be references to the Tender Agreement and the Offer. The
Third Note Amendment also revised the event of default regarding a failure of the amalgamation to be consummation by March 31, 2020 to
be an event of default if the Offer was not completed by January 1, 2021.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Series
B Warrants</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
the completion of the Offer, the Company provided Alpha with the Series B Warrants to purchase the number of pre-2020 Reverse Stock Split
shares of common stock of the Company equal to the product of (i) 8,100,000 and (ii) the Exchange Ratio of 0.8849 at an exercise price
of $0.01 to Alpha, as set forth in, and pursuant to the terms of, the Series B Common Stock Purchase Warrant. The Series B Warrants had
a five-year term beginning on the 90th day after the later of the last day of the lock-up/leak-out period. If Alpha chooses to exercise
the Series B Warrants, Alpha may elect, at its own option, to exercise the Series B Warrants on a cashless basis. Alpha may not exercise
the Series B Warrants to the extent such exercise would result in Alpha and its affiliates owning more than 9.99% of the Company. The
number of shares issuable under the terms of the Series B Common Stock Purchase Warrant are adjustable for stock dividends and splits.
Additionally, Alpha shall have the right to participate in subsequent rights offerings or pro rata distributions with respect to the
equity of the Company or any fundamental transaction involving the Company as more fully described in the Series B Common Stock Purchase
Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Alpha
Investment</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
the signing of the Original Amalgamation Agreement, Alpha entered into the Original Alpha Securities Purchase Agreement, pursuant to
which Alpha agreed, subject to the terms and conditions thereof, to purchase common shares of Jay Pharma and Jay Pharma Series A Warrants
to purchase Jay Pharma&rsquo;s common shares for an aggregate total purchase price of $3,500,000. The Alpha Securities Purchase Agreement
was amended on August 12, 2020 (as discussed further below), to account for the termination of the Original Amalgamation Agreement and
the change in the structure of the transaction from an amalgamation to a stock-for-stock exchange offer (the &ldquo;Third Alpha SPA Amendment&rdquo;).
The terms described in the following paragraphs reflect the terms of the Alpha Securities Purchase Agreement as amended by the Third
Alpha SPA Amendment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 49; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
closing of the Alpha Investment is conditioned upon the satisfaction or waiver of the conditions set forth in the Tender Agreement. The
obligations of Alpha under the Alpha Securities Purchase Agreement in connection with the closing of the Alpha Investment are also subject
to the condition that, from the date of the Alpha Securities Purchase Agreement to the date of closing of the Alpha Investment, trading
in Ameri&rsquo;s common stock shall not have been suspended by the SEC or Nasdaq, and, at any time prior to the closing date of the Alpha
Investment, trading in securities generally as reported by Bloomberg L.P. shall not have been suspended or limited, or minimum prices
shall not have been established on securities whose trades are reported by such service, or on any trading market, nor shall a banking
moratorium have been declared either by the U.S. or New York State authorities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Alpha Securities Purchase Agreement provides certain customary covenants, conditions, representations and warranties, and other agreements
by and between Jay Pharma and Alpha. In addition, Jay Pharma has agreed to use commercially reasonable efforts to complete the Offer,
and as a condition to closing of the Offer, to cause Ameri to assume all of Jay Pharma&rsquo;s obligations under the warrants and the
Securities Purchase Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the terms of the Alpha Securities Purchase Agreement, from the closing date of the Offer until 120 days thereafter, Jay Pharma agreed
to not permit or allow Ameri or any of its subsidiaries to issue, enter into agreement to issue, or announce the issuance or proposed
issuance of any shares of Ameri common stock. Additionally, for a period of 18 months following the closing date of the Offer, Ameri
is prohibited from effecting or entering into an agreement to effect any issuance by Ameri or any of its subsidiaries of their respective
common stock or common stock equivalent involving a variable rate transaction. A &ldquo;variable rate transaction&rdquo; means a transaction
in which Ameri (i) issues or sells any debt or equity securities that are convertible into, exchangeable or exercisable for, or include
the right to receive additional shares of common stock either (A) at a conversion price, exercise price or exchange rate or other price
that is based upon and/or varies with the trading prices of or quotations for the shares of common stock at any time after the initial
issuance of such debt or equity securities, or (B) with a conversion, exercise or exchange price that is subject to being reset at some
future date after the initial issuance of such debt or equity security or upon the occurrence of specified or contingent events directly
or indirectly related to the business of Ameri or the market for the common stock, or (ii) enters into, or effects a transaction under,
any agreement, including, but not limited to, an equity line of credit, whereby Ameri may issue securities at a future determined price.
Additionally, from the closing date of the Offer until such time as Alpha holds less than one-fifth of the shares issued in connection
with the Alpha Investment, Alpha will hold certain anti-dilution rights outlined in the Alpha Securities Purchase Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
the closing of the Alpha Investment under the Alpha Securities Purchase Agreement immediately prior to the Offer, Alpha received approximately
3,500,954 common shares of Jay Pharma and Jay Pharma Series A Warrants to purchase 3,500,954 common shares of Jay Pharma at an exercise
price of $1.03 per common share (the &ldquo;Alpha Investment Securities&rdquo;). In connection with the Offer, such common shares and
warrants of Jay Pharma acquired by Alpha in the Alpha Investment were converted into, as applicable, the right to receive (i) 774,499
shares of Series B Preferred Stock that are convertible into up to 15,490 shares of Common Stock, after giving effect to the Reverse
Stock Splits, and (ii) warrants to purchase up to 15,490 shares of Common Stock at an exercise price of $232.00 per share, after giving
effect to the Reverse Stock Splits. The Company warrants will be immediately exercisable and will expire on the fifth anniversary of
the original issuance date. The exercise price and number of shares of Company common stock issuable upon exercise is subject to appropriate
adjustment in the event of stock dividends, stock splits, reorganizations or similar events affecting the Company common stock and the
exercise price. The Series B Preferred Stock of the Company and the warrants to purchase Company common stock to be issued to Alpha are
convertible or exercisable, as applicable, subject to a 9.99% beneficial ownership blocker.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 50; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">First
Amendment to Alpha Securities Purchase Agreement</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 23, 2020, Jay Pharma and Alpha entered into the Second Note Amendment. The Second Note Amendment also amended the Alpha Securities
Purchase Agreement to reduce the amount of the investment in Jay Pharma&rsquo;s common shares and Jay Pharma Series A Warrants from $3,500,000
to $3,000,000.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Second
Amendment to Alpha Securities Purchase Agreement</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 12, 2020, Jay Pharma and Alpha entered into a second amendment to the Alpha Securities Purchase Agreement (the &ldquo;Second Alpha
SPA Amendment&rdquo;). The Second Alpha SPA Amendment revised the formula regarding the securities to be issued to Alpha in connection
with the closing of the amalgamation to match the formula set forth in the Original Amalgamation Agreement. Additionally, the Second
Alpha SPA amended the termination rights under the Alpha Securities Purchase Agreement to extend the termination date from July 7, 2020
to September 30, 2020.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Third
Amendment to Alpha Securities Purchase Agreement</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 12, 2020, Jay Pharma and Alpha entered into a third amendment to the Alpha Securities Purchase Agreement (the &ldquo;Third Alpha
SPA Amendment&rdquo;). The Third Alpha SPA Amendment revised the references to the Original Amalgamation Agreement and amalgamation to
be references to the Tender Agreement and the Offer, as applicable, in order to account for the change in transaction structure from
an amalgamation to a stock-for-stock exchange offer. Additionally, the Third Alpha SPA Amendment amended the termination rights under
the Alpha Securities Purchase Agreement to extend the termination date from September 30, 2020 to January 1, 2021.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Company
Warrants</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
noted above, in connection with conversion of the Note and the closing of the Alpha Investment, which occurred immediately prior to the
closing of the Offer, Alpha received warrants to purchase common shares of Jay Pharma. Further, as noted above, in connection with the
Offer and pursuant to the terms of the Tender Agreement and the Alpha Exchange Agreement, these warrants were exchanged for Company warrants
to purchase pre-2020 Reverse Stock Split shares of Company common stock equal to the number of common shares of Jay Pharma underlying
such outstanding Jay Pharma warrants multiplied by the Exchange Ratio, with the exercise price of such converted warrants determined
by dividing the exercise price of the Jay Pharma warrant by the Exchange Ratio. The Company warrants will be immediately exercisable
and will expire on the fifth anniversary of the original issuance date. The exercise price and number of shares of Company common stock
issuable upon exercise is subject to appropriate adjustment in the event of stock dividends, stock splits, reorganizations or similar
events affecting Jay Pharma common stock and the exercise price.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 51; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If,
at the time Alpha exercises its Company common stock warrants, a registration statement registering the issuance of the shares of Company
common stock underlying the Company common stock warrants under the Securities Act is not then available for the issuance of such shares,
then in lieu of making the cash payment otherwise contemplated to be made to the Company upon such exercise in payment of the aggregate
exercise price, Alpha may elect instead to receive upon such exercise (either in whole or in part) the net number of shares of Company
common stock determined according to a formula set forth in the Company common stock warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Alpha
(together with its affiliates) may not exercise any portion of the Company common stock warrant to the extent that Alpha would own more
than 9.99% of the outstanding Company common stock immediately after exercise; provided, however, that upon notice to the Company, Alpha
may increase or decrease the beneficial ownership limitation, provided that in no event shall the beneficial ownership limitation exceed
9.99% and any increase in the beneficial ownership limitation will not be effective until 61 days following notice of such increase from
Alpha to the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the Company, at any time while the Company common stock warrant is outstanding, sells or grants any option to purchase, or sells or grants
any right to reprice, or otherwise dispose of or issue (or announce any offer, sale, grant or any option to purchase or other disposition)
any Company common stock (or common stock equivalents), at an effective price per share less than the exercise price then in effect,
then simultaneously with the consummation (or, if earlier, the announcement) of each such dilutive issuance, the exercise price will
be reduced to equal the exercise price then in effect, subject to certain exceptions, which includes issuance of securities issued pursuant
to acquisitions or strategic transactions approved by a majority of the disinterested directors of the Company and not for the primary
purpose of raising capital.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the event of a fundamental transaction, as described in the common warrants and generally including any reorganization, recapitalization
or reclassification of the Company&rsquo;s common stock, the sale, transfer or other disposition of all or substantially all of Company&rsquo;s
properties or assets, the Company&rsquo;s consolidation or merger with or into another person, the acquisition of more than 50% of the
Company&rsquo;s outstanding common stock, or any person or group becoming the beneficial owner of 50% of the voting power represented
by the Company&rsquo;s outstanding common stock, Alpha will be entitled to receive upon exercise of such warrants the kind and amount
of securities, cash or other property that Alpha would have received had they exercised the Company&rsquo;s common stock warrants immediately
prior to such fundamental transaction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 52; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nominal
Share Purchase Agreement</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the Offer, Jay Pharma entered into a series of assignment and assumption agreements with a third party, Tikkun Pharma,
Inc. (&ldquo;Tikkun&rdquo;), pursuant to which Tikkun assigned to Jay Pharma all of Tikkun&rsquo;s (i) rights to certain skin care treatment
assets and (ii) intellectual property rights to certain formulations for the development of therapeutic candidates for the prevention,
management and treatment of graft versus host disease (GVHD) in exchange for an aggregate of 10,360,007 common shares of Jay Pharma,
which were issued in October 2020.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
Alpha required additional shares of the Company, at no or a nominal cost, for Alpha to consummate the Alpha Bridge Loan and the Alpha
Investment at the planned valuation, Alpha entered into an agreement with Tikkun pursuant to which, immediately following such assignment,
but prior to the Offer, Tikkun sold 7,774,463 of these common shares of Jay Pharma to Alpha for the nominal aggregate purchase price
of $10.00 (the &ldquo;Alpha Nominal Shares&rdquo;), leaving Tikkun with 2,585,544 common shares of Jay Pharma (the &ldquo;Tikkun Shares&rdquo;).
In connection with the Offer, the Tikkun Shares were converted into the right to receive 11,440 shares of common stock of the Company,
after giving effect to the Reverse Stock Splits and the Alpha Nominal Shares were converted into the right to receive 1,719,906 shares
of Series B Preferred Stock of the Company that are convertible into up to 34,399 shares of common stock of the Company after giving
effect to the Reverse Stock Splits.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Alpha
December Investment</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 4, 2020, Jay Pharma and Alpha executed a securities purchase agreement whereby Alpha purchased an additional 1,000,000 common
shares of Jay Pharma and warrants to purchase 500,000 common shares of Jay Pharma at an exercise price of $0.30 per share for an aggregate
purchase price of $300,000 (the &ldquo;Alpha December Investment&rdquo;). In connection with the Offer, such shares were exchanged for
4,425 shares of Common Stock, after giving effect to the Reverse Stock Splits, and such warrants were exchanged for warrants to purchase
2,213 shares of common stock of the Company at $68.00 per share after giving effect to the Reverse Stock Splits.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities
Exchange Agreements</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Option
Exchange Agreements</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the terms of the Tender Agreement, prior to the closing of the Offer, the Company entered into exchange agreements with each of the
holders of Jay Pharma options (the &ldquo;Option Exchange Agreements&rdquo;). Pursuant to the terms of the Option Exchange Agreements,
each outstanding Jay Pharma option was exchanged for Company options to purchase a number of shares of Company common stock equal to
the Exchange Ratio on substantially the same terms as those contained in the stock option plan of the Company, and each such Jay Pharma
option was cancelled. The exercise price for each share of Company common stock underlying a Company option was equal to the exercise
price per share of Jay Pharma common stock under the Jay Pharma option in effect immediately prior to the completion of the Offer, as
adjusted to reflect the 2020 Reverse Stock Split and Exchange Ratio and applicable currency exchange ratio. Jay Pharma and Ameri intended
that the exchange of all Jay Pharma options for Resulting Issuer options would occur on a rollover basis pursuant to subsection 7(1.4)
of the Tax Act and that any relevant adjustments to the exercise price of the Company options would be made to reflect this intention,
and that the foregoing treatment of Jay Pharma options was fair and reasonable in light of the circumstances of the transaction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 53; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrant
Exchange Agreements</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the terms of the Tender Agreement, prior to the closing of the Offer, the Company entered into exchange agreements with the holders
of Jay Pharma warrants (the &ldquo;Warrant Exchange Agreements&rdquo;). Pursuant to the terms of the Warrant Exchange Agreements, each
outstanding Jay Pharma warrant was exchanged for Company warrants to purchase the number of shares of Company common stock equal to the
Exchange Ratio on substantially economically equivalent terms and each such Jay Pharma warrant shall be cancelled. The exercise price
for each share of Company common stock underlying a Company warrant will be equal to the exercise price per share of Jay Pharma common
stock under the Jay Pharma warrant in effect immediately prior to the completion of the Offer, as adjusted to reflect the 2020 Reverse
Stock Split and Exchange Ratio and the applicable currency exchange ratio.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Alpha
Exchange Agreement</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the terms of the Tender Agreement, prior to the closing of the Offer, the Company entered into an exchange agreement with Alpha (the
&ldquo;Alpha Exchange Agreement&rdquo; and, together with the Option Exchange Agreements and Warrant Exchange Agreements, the &ldquo;Securities
Exchange Agreements&rdquo;). Pursuant to the terms of the Alpha Exchange Agreement, the Jay Note Securities and the Alpha Investment
Securities were exchanged for (i) the number of shares of Series B Preferred Stock convertible into 65,259 shares of Company common stock,
(ii) warrants to purchase 25,817 shares of common stock of the Company at $232.00 per share, and (iii) warrants to purchase up to 2,213
shares of common stock of the Company at an exercise price of $68.00 per share, in each case, after giving effect to the Reverse Stock
Splits. The Series B Preferred Stock of the Company and the warrants to purchase Company common stock issued to Alpha are convertible
or exercisable, as applicable, subject to a 9.99% beneficial ownership blocker.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Relationships
with Tikkun and Jay Pharma</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Solomon
Eisenberg</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Solomon
Eisenberg was both a board member and shareholder of Tikkun and a board member of Jay Pharma. His role with both companies might have
created a conflict of interest in connection with Jay Pharma&rsquo;s strategic relationship with Tikkun.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Barry
Farkas</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Barry
Farkas was both a board member and shareholder of Tikkun and a board member of Jay Pharma. His role with both companies might have created
a conflict of interest in connection with Jay Pharma&rsquo;s strategic relationship with Tikkun.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 54; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lorne
Gertner</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lorne
Gertner was both a board member of Tikkun and a board member of Jay Pharma. His role with both companies might have created a conflict
of interest in connection with Jay Pharma&rsquo;s strategic relationship with Tikkun.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">David
Stefansky</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">David
Stefansky was both a board member of Tikkun and a board member and an executive officer of Jay Pharma. His role with both companies might
have created a conflict of interest in connection with Jay Pharma&rsquo;s strategic relationship with Tikkun. On May 6, 2020, Mr. Stefansky
resigned as an executive officer and director of Jay Pharma.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Abstention</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
order to avoid any potential conflicts of interest amongst the Jay Pharma board of directors in light of the transactions described above,
on January 7, 2020, each of Solomon Eisenberg and Barry Farkas, both of whom were board members and shareholders of Tikkun, resigned
from the Jay Pharma board. In addition, Lorne Gertner, who also served on the board of both Jay Pharma and Tikkun, agreed to abstain
from any votes regarding the Original Amalgamation Agreement, the Side Transactions and all matters related to such transactions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yaron
Conforti Letter Agreement</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 6, 2020, Yaron Conforti and Jay Pharma entered into a letter agreement pursuant to which Jay Pharma agreed to pay Yaron Conforti
a sum of $83,409, which constituted amounts owed to Yaron Conforti by Jay Pharma, with such sum to be paid in the following manner: (a)
$10,000 paid in cash upon execution of the Original Amalgamation Agreement with Ameri, (b) $5,000 to be paid in cash upon the closing
the transactions contemplated by the Original Amalgamation Agreement, and (c) the remaining $68,409 paid through the issuance of 118,117
shares of common stock of Jay Pharma. In exchange for the payment structured as described above, Yaron Conforti released Jay Pharma from
any claims or obligations related to the $83,409 sum. In July 2020, Jay Pharma agreed to adjust the per share price of $0.8849, of the
Jay Pharma common shares issued under the previous letter to $0.22. Accordingly, Mr. Conforti was awarded 193,169 additional Jay Pharma
common shares pursuant to a letter agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Delinquent
Section 16(a) Reports</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
16(a) of the Exchange Act requires our directors, executive officers and persons who own more than 10% of a registered class of our equity
securities to file with the SEC initial reports of ownership and reports of changes in ownership of our common stock and other equity
securities. Officers, directors and greater-than-10% stockholders are required by SEC regulations to furnish us with copies of all Section
16(a) forms they file.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 55; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
solely upon a review of the Forms 3, 4 and 5 and amendments thereto furnished to the Company, we believe that all directors, officers
and persons beneficially owning greater than 10% of the Company&rsquo;s equity securities timely filed reports required by Section 16(a)
of the Exchange Act during Fiscal 2021, except for the following reporting persons:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">One
    Form 3 was filed late for Mr. Carter Ward with respect to his appointment as Chief Financial Officer.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">One
    Form 3 was filed late for Dr. Facchini with respect to his appointment as an officer. One Form 4 was filed late for Dr. Facchini
    with respect to one transaction.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">One
    Form 4 was filed late form Dr. Joseph Tucker with respect to one transaction.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">One
    Form 4 was filed late for Mr. Bradley Thompson with respect to one transaction.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">One
    Form 3 was filed late for Mr. Douglas Lind with respect to his appointment to the Board. One Form 4 was filed late for Mr. Lind with
    respect to one transaction.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Several
of the late reports were initial reports of ownership related to the new appointees, due to the time delays incurred in obtaining individual
SEC EDGAR codes required to make the required filings. None of these cases involved purchase or sale, but rather non-market transactions
such as a grant or exercise of stock options.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="a_007"></A>Proposal
2:<BR>
Advisory Vote to Approve Executive Compensation</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
accordance with Section 14A of the Exchange Act, stockholders are entitled to cast an advisory vote, commonly referred to as a &ldquo;say-on-pay&rdquo;
resolution, to approve the compensation of our named executive officers, as disclosed in this proxy statement. Accordingly, you are being
asked to vote on the following resolution at the Annual Meeting:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;RESOLVED,
that the compensation paid to named executive officers of Enveric Biosciences, Inc., as disclosed in the proxy statement pursuant to
the SEC&rsquo;s compensation disclosure rules, including the compensation tables and narrative discussion, is hereby APPROVED.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
described more fully in the Executive Compensation section of this proxy statement, our named executive officers are compensated in a
manner consistent with our pay-for-performance philosophy and corporate governance best practices. Our executive compensation programs
for fiscal year 2022 reflect these significant changes to our management team and to our business while promoting our pay-for-performance
philosophy and corporate governance best practices.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that our compensation program balances the interests of all of our constituencies&thinsp;&mdash;&thinsp;our stockholders, our
executive officers, the remainder of our employee base, our business partners and our community&thinsp;&mdash;&thinsp;by, among other
things, focusing on achievement of corporate objectives, attracting and retaining highly-qualified executive management and maximizing
long-term stockholder value. We encourage you to read the compensation tables and narrative discussion related to executive compensation
in this proxy statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 56; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
vote to approve the compensation of our named executive officers is advisory and, therefore, not binding. Although the vote is non-binding,
the Compensation Committee and the Board of Directors value your opinion and will consider the outcome of the vote in establishing its
compensation philosophy and making future compensation decisions. Our current policy is to hold such an advisory vote each year, and
we expect to hold another advisory vote with respect to approve to executive compensation at the 2023 annual meeting of stockholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Vote
Required</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
affirmative &ldquo;<B>FOR</B>&rdquo; vote of a majority of the voting power of the shares present in person (which would include voting
online at the virtual Annual Meeting) or represented by proxy at the meeting and entitled to vote on the proposal. Abstentions will have
the same practical effect as shares voted against this proposal. Broker non-votes will not have any effect on the outcome of the vote.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Board
Recommendation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Our
Board recommends that you vote &ldquo;FOR&rdquo; the approval of executive compensation.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="a_008"></A>Report
of the Audit Committee</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following is the report of the Audit Committee with respect to the Company&rsquo;s audited financial statements for the year ended December
31, 2021.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
purpose of the Audit Committee is to assist the Company&rsquo;s board of directors in its general oversight of the Company&rsquo;s financial
reporting, internal controls and audit functions. The Audit Committee does not itself prepare financial statements or perform audits,
and its members are not auditors or certifiers of the Company&rsquo;s financial statements. In fulfilling its oversight responsibility
of appointing and reviewing the services performed by the Company&rsquo;s independent registered public accounting firm, the Audit Committee
carefully reviews the policies and procedures for the engagement of the independent registered public accounting firm, including the
scope of the audit, audit fees, auditor independence matters and the extent to which the independent registered public accounting firm
may be retained to perform non-audit related services.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company maintains an auditor independence policy that bans its auditors from performing non-financial consulting services, such as information
technology consulting and internal audit services. This policy mandates that the Audit Committee approve the audit and non-audit services
and related budget in advance, and that the Audit Committee be provided with quarterly reporting on actual spending. This policy also
mandates that the Company may not enter into auditor engagements for non-audit services without the Audit Committee&rsquo;s express approval.
The Audit Committee charter describes in greater detail the full responsibilities of the Audit Committee and is available on the Company&rsquo;s
website at www.enveric.com. The Audit Committee is comprised solely of independent directors as defined by Rule 5605(a)(2) of the NASDAQ
listing standards.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 57; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Audit Committee met on four occasions during the year ended December 31, 2021. The Audit Committee met privately in executive session
with Friedman LLP (&ldquo;Friedman&rdquo;) (which merged with Marcum LLP (&ldquo;Marcum&rdquo;) effective September 1, 2022) as
part of each regular meeting and held private meetings with the Chief Financial Officer and other officers of the Company throughout
the year.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Audit Committee&rsquo;s policy is to pre-approve all audit and non-audit related services, tax services and other services. Pre-approval
is generally provided for up to one year, and any pre-approval is detailed as to the particular service or category of services and is
generally subject to a specific budget. The Audit Committee has delegated the pre-approval authority to its chairperson when expedition
of services is necessary. The independent registered public accounting firm and management are required to periodically report to the
full Audit Committee regarding the extent of services provided by the independent registered public accounting firm in accordance with
this pre&ndash;approval and the fees for the services performed to date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Audit Committee has reviewed and discussed the audited financial statements
for the year ended December 31, 2021 with the Company&rsquo;s management and Friedman, the Company&rsquo;s independent registered public
accounting firm for 2021. The Audit Committee has also discussed with Friedman the matters required to be discussed by Auditing Standard
No. 16, &ldquo;Communications with Audit Committees&rdquo; issued by the Public Company Accounting Oversight Board (&ldquo;PCAOB&rdquo;).
The Audit Committee also has received and reviewed the written disclosures and the letter from Friedman required by applicable requirements
of the PCAOB regarding Friedman&rsquo;s communications with the Audit Committee concerning independence, and has discussed with Friedman
its independence from the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on the reviews and discussions referred to above, the Audit Committee recommended to the Company&rsquo;s board of directors that the
financial statements referred to above be included in the Company&rsquo;s annual report on Form 10-K.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">AUDIT
    COMMITTEE</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>George
    Kegler</I></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Douglas
    Lind</I></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Bevin
    O&rsquo;Neil</I></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 58; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="a_009"></A>Proposal
3:<BR>
Ratification of Appointment of Independent Auditors</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Audit Committee (as defined herein) is responsible for the appointment, compensation, retention and oversight of the work of our independent
registered public accounting firm. On June 23, 2021, the Audit Committee approved the engagement of Marcum as the Company&rsquo;s
independent registered public accounting firm. While it is not required to do so, the Audit Committee is submitting to stockholders for
ratification the selection of Marcum as the Company&rsquo;s independent registered public accounting firm for the year ending
December 31, 2022. Notwithstanding ratification of the selection of Marcum to serve as the Company&rsquo;s independent registered
public accounting firm, the Audit Committee will be under no obligation to select Marcum as the Company&rsquo;s independent registered
public accounting firm.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect that representatives of Marcum will be present or available via telephone at the Annual Meeting, will have an opportunity
to make a statement if they so desire and will be available to respond to appropriate questions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Principal
Accounting Fees</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
September 2022, the Board of Directors selected Marcum as its independent accountant to audit the registrant&rsquo;s financial
statements. From June&nbsp;2021 until September&nbsp;2022, our independent accountant was Friedman, which merged with Marcum effective
September&nbsp;1, 2022. Since they were retained, there have been (1) no disagreements between us and Marcum on any matters
of accounting principle or practices, financial statement disclosure, or auditing scope or procedures and (2) no reportable events within
the meaning set forth in Item 304(a)(1)(v) of Regulation S-K. Marcum has not issued any reports on our financial statements during
the previous two fiscal years that contained any adverse opinion or a disclaimer of opinion or were qualified or modified as to uncertainty,
audit scope or accounting principle. In connection with the audit of the 2021 financial statements, we entered into an engagement agreement
with Marcum which sets forth the terms by which Marcum will performed audit and related professional services for us.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth the aggregate accounting fees paid by us for the year ended December 31, 2021 and the year ended December
31, 2020. The below fees for the year ended December 31, 2021 were paid to Friedman and to Marcum, our previous independent accountant
(see &ldquo;&mdash;Changes in the Company&rsquo;s Certifying Accountant&rdquo;). The below fees for the year ended December 31, 2020
were paid to Marcum. All non-audit related services in the table were pre-approved and/or ratified by the Audit Committee.</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year Ended<BR> December 31, 2021</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year Ended<BR> December 31, 2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: justify">Type of Fees</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 60%; text-align: left">Audit Fees (1)</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 16%; text-align: right">170,025</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 16%; text-align: right">15,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Audit-Related Fees (2)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">10,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Tax Fees (3)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">5,150</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">16,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">All Other Fees (4)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">49,935</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt">Total</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">235,110</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">31,000</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Audit
Fees</I> consist of fees billed for services rendered for the audit of our financial statements and review of our financial statements.</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 59; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Audit-Related
Fees</I> consists of fees reasonably related to the performance of the audit or review of the Company&rsquo;s financial statements that
are not reported as &ldquo;Audit Fees.&rdquo;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Tax
Fees</I> consist of fees billed for professional services related to the preparation of our U.S. federal and state income tax returns
and tax advice.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>All
Other Fees</I> consist of fees for other miscellaneous items.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Audit
Committee Pre-Approval of Services by Independent Registered Public Accounting Firm</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
10A(i)(1) of the Exchange Act and related SEC rules require that all auditing and permissible non-audit services to be performed by our
principal accountants be approved in advance by the Audit Committee. Pursuant to Section 10A(i)(3) of the Exchange Act and related SEC
rules, the Audit Committee has established procedures by which the Chairman of the Audit Committee may pre-approve such services provided
that the pre-approval is detailed as to the particular service or category of services to be rendered and the Chairman reports the details
of the services to the full Audit Committee at its next regularly scheduled meeting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
audit committee has considered the services provided by Marcum as disclosed above in the captions &ldquo;audit fees&rdquo; and
&ldquo;all other fees&rdquo; and has concluded that such services are compatible with the independence of Marcum as our principal
accountant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Board of Directors has considered the nature and amount of fees billed by our independent auditors and believes that the provision of
services for activities unrelated to the audit is compatible with maintaining our independent auditors&rsquo; independence.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Changes
in the Company&rsquo;s Certifying Accountant</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Selection
of Friedman</I></FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 23, 2021, the Audit Committee approved the dismissal of Marcum, effective as of June 23, 2021, and the engagement of Friedman, effective immediately, as the Company&rsquo;s independent registered public accounting firm for the fiscal year ending December
31, 2021.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
reports of Marcum  on the Company&rsquo;s consolidated financial statements for the fiscal years ended December 31, 2020 and December
31, 2019, did not contain an adverse opinion or a disclaimer of opinion and were not qualified or modified as to uncertainty, audit scope,
or accounting principles.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the fiscal years ended December 31, 2020 and December 31, 2019, and through June 23, 2021, there were no disagreements, as defined in
Item 304 of Regulation S-K, with Marcum on any matter of accounting principles or practices, financial statement disclosure, or auditing
scope or procedure, which disagreements, if not resolved to the satisfaction of Marcum, would have caused Marcum  to make reference
to the subject matter of the disagreements in connection with its reports on the Company&rsquo;s consolidated financial statements for
such period, and there were no &ldquo;reportable events,&rdquo; as defined in Item 304(a)(1)(v) of Regulation S-K, except that Marcum
 concurred with the Company&rsquo;s assessment of material weaknesses related to the Company&rsquo;s internal controls over financial
reporting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 60; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
its Management&rsquo;s Report on Internal Control Over Financial Reporting, as set forth in Item 4 &ldquo;Controls and Procedures&rdquo;
of the Company&rsquo;s Quarterly Report on Form 10-Q for the quarter ended March 31, 2021 and Item 9A &ldquo;Controls and Procedures&rdquo;
of the Company&rsquo;s Annual Report on Form 10-K for the year ended December 31, 2020, the Company reported material weaknesses in its
internal controls over financial reporting, which constitute reportable events (as defined in Item 304(a)(1)(v) of Regulation S-K). The
material weakness was due to the small size of the Company, and the fact the Company does not maintain sufficient segregation of duties
to ensure the processing, review and authorization of all transactions including non-routine transactions. The Audit Committee discussed
the subject matter of the reportable events with Marcum  and notwithstanding these material weaknesses in internal control over financial
reporting, the Company has concluded that, based on its knowledge, the consolidated financial statements, and other financial information
included in its Annual Reports on Form 10-K for the fiscal years ended December 31, 2020 and 2019 present fairly, in all material respects
the Company&rsquo;s financial condition, results of operations and cash flows for the periods presented in conformity with accounting
principles generally accepted in the United States.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
the time of its dismissal, we provided Marcum with a copy of the above disclosure and requested that Marcum furnish the Company
with a letter addressed to the SEC stating whether or not it agreed with the statements made by the Company above. A copy of Marcum&rsquo;s letter dated June 25, 2021, is attached as Exhibit 16.1 to our Current Report on Form 8-K, as amended, filed with the SEC
on June 28, 2021.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the fiscal years ended December 31, 2019 and December 31, 2020, and through June 23, 2021, neither the Company nor anyone acting on its
behalf has consulted with Friedman regarding (i) the application of accounting principles to any specified transaction, either completed
or proposed, or the type of audit opinion that might be rendered on the Company&rsquo;s consolidated financial statements, and neither
a written report nor oral advice was provided to the Company that Friedman concluded was an important factor considered by the Company
in reaching a decision as to any accounting, auditing, or financial reporting issue, or (ii) any matter that was either the subject of
a &ldquo;disagreement,&rdquo; as defined in Item 304(a)(1)(iv) of Regulation S-K, or a &ldquo;reportable event,&rdquo; as defined in
Item 304(a)(1)(v) of Regulation S-K.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Selection
of Marcum&nbsp;LLP Following Its Merger with Friedman&nbsp;LLP</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on information provided by Friedman LLP, effective September 1, 2022, Friedman combined with Marcum LLP and continued to operate as
an independent registered public accounting firm as a wholly-owned subsidiary of Marcum&nbsp;LLP. Friedman&nbsp;LLP continued to
serve as the Company&rsquo;s independent registered public accounting firm through September 20, 2022. On September 20, 2022,
Friedman was dismissed, and Marcum was engaged to serve as the independent registered public accounting firm of the Company for the
fiscal year ending December&nbsp;31, 2022, effective immediately. The services previously provided by Friedman will now be provided
by Marcum.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
report of Friedman on the Company&rsquo;s consolidated financial statements for the fiscal year ended December 31, 2021 did not contain
an adverse opinion or a disclaimer of opinion and were not qualified or modified as to uncertainty, audit scope, or accounting principles.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the fiscal year ended December 31, 2021, and through September&nbsp;20, 2022, there were no disagreements, as defined in Item 304 of
Regulation S-K, with Friedman on any matter of accounting principles or practices, financial statement disclosure, or auditing scope
or procedure, which disagreements, if not resolved to the satisfaction of Friedman, would have caused Friedman to make reference to the
subject matter of the disagreements in connection with its reports on the Company&rsquo;s consolidated financial statements for such
period, and there were no &ldquo;reportable events,&rdquo; as defined in Item 304(a)(1)(v) of Regulation S-K</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
its Management&rsquo;s Report on Internal Control Over Financial Reporting, as set forth in Item 4 &ldquo;Controls and Procedures&rdquo;
of the Company&rsquo;s Quarterly Reports on Form 10-Q for the quarters ended March 31, 2022 and June&nbsp;30, 2022, and Item 9A &ldquo;Controls
and Procedures&rdquo; of the Company&rsquo;s Annual Report on Form 10-K for the year ended December 31, 2021, the Company reported material
weaknesses in its internal controls over financial reporting, which constitute reportable events (as defined in Item 304(a)(1)(v) of
Regulation S-K). The material weakness was due to the small size of the Company, and the fact the Company does not maintain sufficient
segregation of duties to ensure the processing, review and authorization of all transactions including non-routine transactions. The
Audit Committee discussed the subject matter of the reportable events with Friedman and notwithstanding these material weaknesses in internal
control over financial reporting, the Company has concluded that, based on its knowledge, the consolidated financial statements, and
other financial information included in its Annual Reports on Form 10-K for the fiscal year ended December 31, 2021 present fairly, in
all material respects the Company&rsquo;s financial condition, results of operations and cash flows for the periods presented in conformity
with accounting principles generally accepted in the United States.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">As reported
in our Current Report on Form 8-K filed with the SEC on September 23, 2022, we provided Friedman with a copy of the above disclosure
at the time of its dismissal, and requested that Friedman furnish the Company with a letter addressed to the SEC stating whether or not
it agreed with the statements made by the Company above. As of the date of this proxy statement, Marcum has not provided the Company
with a letter in response to our disclosures. In the event Marcum provides us with a letter in response to the above disclosures, we
will amend the Current Report on Form 8-K filed on September 23, 2022, to include such letter as an exhibit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the fiscal years ended December 31, 2021 and December 31, 2020, and through September&nbsp;20, 2022, neither the Company nor anyone
acting on its behalf has consulted with Marcum regarding (i) the application of accounting principles to any specified transaction,
either completed or proposed, or the type of audit opinion that might be rendered on the Company&rsquo;s consolidated financial
statements and neither a written report nor oral advice was provided to the Company that Marcum concluded was an important factor
considered by the Company in reaching a decision as to any accounting, auditing, or financial reporting issue, except pursuant to
Marcum&rsquo;s engagement as the Company&rsquo;s independent auditor prior to June 23, 2021 and as disclosed above, or (ii) any
matter that was either the subject of a &ldquo;disagreement,&rdquo; as defined in Item 304(a)(1)(iv) of Regulation S-K, or a
&ldquo;reportable event,&rdquo; as defined in Item 304(a)(1)(v) of Regulation S-K, except pursuant to Marcum&rsquo;s engagement as
the Company&rsquo;s independent auditor prior to June 23, 2021 and as disclosed above.</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vote
Required</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
affirmative &ldquo;<B>FOR</B>&rdquo; vote of a majority of the voting power of the shares present in person (which would include voting
online at the virtual Annual Meeting) or represented by proxy at the meeting and entitled to vote on the proposal. Abstentions will have
the same practical effect as shares voted against this proposal.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Board
Recommendation</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Our
Board recommends that you vote &ldquo;FOR&rdquo; the Auditor Ratification Proposal.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 61; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="a_010"></A>Security
Ownership of Certain Beneficial Owners and Management</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth information with respect to the beneficial ownership of our Common Stock (including shares issuable upon the
exercise or conversion of securities that entitle the holders thereof to obtain Common Stock upon exercise or conversion in accordance
with the terms thereof) as of September 14, 2022, by:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">each
    person known by us to be the beneficial owner of more than five percent of our outstanding shares of Common Stock;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">each
    director;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">each
    of our named executive officers; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">all
    directors and executive officers of the Company as a group.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Beneficial
ownership is determined in accordance with the rules of the SEC, which generally attribute beneficial ownership of securities to persons
who possess sole or shared voting power or investment power with respect to those securities and includes shares of our common stock
issuable pursuant to the exercise of stock options, warrants, or other securities that are immediately exercisable or convertible or
exercisable or convertible within 60 days of September 14, 2022.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
as indicated in the footnotes to this table, each beneficial owner named in the table below has sole voting and sole investment power
with respect to all shares beneficially owned and each person&rsquo;s address is c/o Enveric Biosciences, Inc. 4851 Tamiami Trail N.,
Suite 200, Naples, FL 34103. As of September 14, 2022, we had 2,078,271 shares of Common Stock outstanding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 62; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Name of Beneficial Owner</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of Shares of Common Stock Beneficially Owned</TD>
    <TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Percentage of Class</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold">5% Owners</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 60%; text-align: left">Intracoastal Capital LLC</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 16%; text-align: right">129,842</TD>
    <TD STYLE="width: 1%; text-align: right">(1)</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 16%; text-align: right">6.23</TD>
    <TD STYLE="width: 1%; text-align: right">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">Officers and Directors</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Joseph Tucker, PhD</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">31,367</TD>
    <TD STYLE="text-align: right">(2)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.50</TD>
    <TD STYLE="text-align: right">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Avani Kanubaddi</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">15,790</TD>
    <TD STYLE="text-align: right">(3)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">*</TD>
    <TD STYLE="text-align: right"></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Peter Facchini, PhD</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">26,609</TD>
    <TD STYLE="text-align: right">(4)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.27</TD>
    <TD STYLE="text-align: right">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">David Johnson</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">26,955</TD>
    <TD STYLE="text-align: right">(5)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.28</TD>
    <TD STYLE="text-align: right">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">George Kegler</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">320</TD>
    <TD STYLE="text-align: right">(6)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">*</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Douglas Lind, MD</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">182</TD>
    <TD STYLE="text-align: right">(6)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">*</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Sol Mayer</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">320</TD>
    <TD STYLE="text-align: right">(6)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">*</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Marcus Schabacker, MD, PhD</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">320</TD>
    <TD STYLE="text-align: right">(6)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">*</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Bevin O&rsquo;Neil</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD>
    <TD STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">*</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Michael Webb</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD>
    <TD STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">*</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Frank Pasqualone</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD>
    <TD STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">*</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Robert Wilkins, MD</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,507</TD>
    <TD STYLE="text-align: right">(7)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">*</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">All directors and officers as a group of thirteen (13) persons</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">107,370</TD>
    <TD STYLE="text-align: right">(8)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4.97</TD>
    <TD STYLE="text-align: right">%</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*
Represents less than 1%</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
                                            information is based on a Schedule 13G filed August 1, 2022 on behalf of (i) Mitchell P.
                                            Kopin, an individual who is a citizen of the United States of America (&ldquo;<U>Mr. Kopin</U>&rdquo;),
                                            (ii) Daniel B. Asher, an individual who is a citizen of the United States of America (&ldquo;<U>Mr.
                                            Asher</U>&rdquo;) and (iii) Intracoastal Capital LLC, a Delaware limited liability company
                                            (&ldquo;<U>Intracoastal</U>&rdquo;). The principal business office of Mr. Kopin and Intracoastal
                                            is 245 Palm Trail, Delray Beach, Florida 33483. The principal business office of Mr. Asher
                                            is 111 W. Jackson Boulevard, Suite 2000, Chicago, Illinois 60604. According to the Schedule
                                            13G, Mr. Kopin, Mr. Asher, and Intracoastal have shared voting power and shared dispositive
                                            power with respect to shares of common stock beneficially owned by each.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes
    125,000 shares of Common Stock and warrants to purchase 4,842 shares of Common Stock. Excludes warrants to purchase 140,158 shares
    of Common Stock that are not exercisable within 60 days of the Record Date due to blocker provisions limiting Intracoastal&rsquo;s
    beneficial holdings to 9.99% of the Company&rsquo;s outstanding Common Stock.</FONT></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes
    13,823 shares of Common Stock, 3,988 vested options to purchase Common Stock, and warrants to purchase 13,556
    shares of Common Stock. Excludes unvested restricted stock units equivalent to 16,374 shares of Common Stock.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes
    vested restricted stock units equivalent to 15,790 shares of Common Stock. Excludes unvested restricted stock units equivalent
    to 22,556 shares of Common Stock.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes
    12,335 shares of Common Stock, 1,994 vested options to purchase Common Stock, warrants to purchase 12,280 shares
    of Common Stock. Excludes unvested restricted stock units equivalent to 11,522 shares of Common Stock.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes
    vested restricted stock units equivalent to 26,955 shares of Common Stock.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
    share amounts consist of Common Stock.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(7)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes
    vested restricted stock units equivalent to 3,507 shares of Common Stock.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(8)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes
    27,300 shares of Common Stock, vested restricted stock units equivalent to 48,252 shares of Common Stock, vested options
    to purchase 5,982 shares of Common Stock and warrants to purchase 25,836 shares of Common Stock. Excludes unvested
    restricted stock units equivalent to 58,952 shares of Common Stock.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 63; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="a_011"></A>Other
Matters</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
persons designated to vote shares covered by our proxies intend to exercise their judgment in voting such shares on other matters that
may properly come before the Annual Meeting or any adjournment, continuation or postponements thereof. Management does not expect that
any matters other than those referred to in this proxy statement will be presented for action at the Annual Meeting or any adjournment,
continuation or postponements thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="a_012"></A>Deadline
for Receipt of Stockholder Proposals</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to Rule 14a-8 under the Exchange Act, a stockholder proposal submitted for inclusion in our proxy statement for the 2023 Annual Meeting
of Stockholders must be delivered to the Company&rsquo;s Secretary at our corporate office at 4851 Tamiami Trail N, Suite 200, Naples,
Florida 34103 no later than May 26, 2023, or, if the date of our 2023 Annual Meeting of Stockholders is more than 30 days from
the anniversary date of the 2023 Annual Meeting of Stockholders, then the deadline is a reasonable time before we begin to print and
send our proxy materials for our 2023 Annual meeting of Stockholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
you intend to present a proposal at our 2023 Annual Meeting of Stockholders, including director nominations, but you do not intend to
have it included in our 2023 Proxy Statement, you must deliver a copy of your proposal to the Company&rsquo;s Secretary at our corporate
office listed above no earlier than July 10, 2023 and no later than the close of business on August 9, 2023. The proposal
must contain certain information specified in our Bylaws; provided, however, that in the event that the date of our 2023 Annual Meeting
of Stockholders is advanced by more than 30 days or delayed by more than 60 days from the anniversary date of the 2022 Annual Meeting
of Stockholders, your notice will be timely if we receive it no earlier than the close of business on the 120th day prior to the 2023
Annual Meeting and no later than the close of business on the later of (i) the 90th day prior to such annual meeting, or (ii) the tenth
day following the earlier of the date on which a public announcement setting forth the date of such meeting is first made.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="a_013"></A>Annual
Report</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are concurrently sending all of our stockholders of record as of the Record Date, a copy of our 2021 Annual Report. The 2021 Annual Report
contains our certified consolidated financial statements for the year ended December 31, 2021.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
copy of our 2021 Annual Report will also be furnished without charge upon receipt of a written request identifying the person so requesting
a report as a stockholder of the Company at such date to any person who was a beneficial owner of our common stock on the Record Date.
Requests should be directed to 4851 Tamiami Trail N, Suite 200, Naples, Florida 34103.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 64; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="a_014"></A>Stockholders
Sharing the Same Address</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
SEC has adopted rules that permit companies and intermediaries, such as brokers, to satisfy delivery requirements for Annual Meeting
materials with respect to two or more stockholders sharing the same address by delivering a single set of Annual Meeting materials addressed
to those stockholders. This process, commonly referred to as &ldquo;householding,&rdquo; potentially provides extra convenience for stockholders
and cost savings for companies. Because we utilize the &ldquo;householding&rdquo; rules for Annual Meeting materials, stockholders who
share the same address will receive only one copy of the Annual Meeting materials, unless we receive contrary instructions from any stockholder
at that address. If you prefer to receive multiple copies of the Annual Meeting materials at the same address you share with other stockholders,
additional copies will be provided to you promptly upon request. If you are a stockholder of record, you may obtain additional copies
at the same address you share with other stockholders by contacting Broadridge Financial Solutions, Inc., either by calling (866) 540-7095,
or by writing to Broadridge Householding Department, 51 Mercedes Way, Edgewood, New York 11717. Eligible stockholders of record receiving
multiple copies of the Annual Meeting materials can request householding by contacting Broadridge Financial Solutions, Inc. in the same
manner. If you are a beneficial owner and hold your shares in a brokerage or custody account, you can request additional copies of the
Annual Meeting materials at the same address you share with other stockholders or you can request householding by notifying your broker,
bank or other nominee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sincerely,</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/<I>s</I>/
    <I>Joseph Tucker</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Joseph
    Tucker, PhD</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Chief
    Executive Officer</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Naples,
    Florida</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">September
    23, 2022</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 65; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><IMG SRC="proxy_001.jpg" ALT="" STYLE="height: 872px; width: 670px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 66 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="proxy_002.jpg" ALT="" STYLE="height: 868px; width: 670px">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 67; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>proxy_001.jpg
<TEXT>
begin 644 proxy_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" <4!7 # 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MNIX/B38PQ2NL4\<JRH#PX$;,,_B : L?3U%%% @HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *^=?
M'VDQ:[\=%TJ>1XXKIK>)G3&X QCD9KZ*KP7Q%_R<A8_]=[;_ - % &]_PS_H
M?_07U'\D_P */^&?]#_Z"^H_DG^%>N44 >1_\,_Z'_T%]1_)/\*/^&?]#_Z"
M^H_DG^%>N44 >1_\,_Z'_P!!?4?R3_"N4\':'#X;^/D6D6\LDL5MYJJ\F-QS
M;D\X^M?0]>&6/_)SDW^\_P#Z34#/<Z***!!1110 4444 %%%<UK/Q \*Z!<M
M;:EK4$<ZG#1(&E9#Z,$!(_&@#I:*Y_1O'/AC7Y%CTW6K6:5N%B8F.1OHK $_
ME704 %%8>M>,O#OAURFJZO;6\H&XQ;MTF/78N6_2LJT^*G@F]F$46OPJQ[S1
M21+UQ]YU _6@#L:*9#-%<PI-!*DL3C*NC!E8>H(ZU4UC6=/T#3)=2U2Y%O:1
M8WR%2V,D < $GD]A0!>HKF-%^(GA7Q#J::=I>JB>[=2RQF"1,@#)P64#I73T
M %%<K??$CPEIFL2:3>ZNL-['((W1H),*QQU;;MQSUSBNI!# $$$'D$=Z %HK
MGO$'CCPYX6NXK76=1^RS2IYB+Y$CY7)&<JI'4&MFQOK?4K"WOK23S+:XC66)
M]I&Y2,@X/(X]: +%%07MY!IUA<7MU)Y=O;Q--*^"=J*,DX')X!Z5QW_"W_ G
M_0=_\E)__B* .XHKA_\ A;_@3_H._P#DI/\ _$5I:'\0?"_B341I^DZI]HNB
MI<1_9Y4X'4Y90* .FHK/U;7=)T* 3:KJ%O9HW"^=( 6^@ZG\*YN#XL^![B98
MDUZ,,W0R02HOYLH H [2BHK:YM[RVCN;6>*>"0;DEB<,K#U!'!J6@ HHHH *
M*** "BBN;\6^,[#P;'8SZE%*UM=3&(R1#)C.,Y([CZ<_6@#I**I:7JVGZW8I
M>Z9=Q75L_22)LC/H?0^QYJ[0 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !7@OB+_DY"Q_Z[VW_ * *]ZKP7Q%_R<A8_P#7>V_] % 'O5%%
M% !1110 5X98_P#)SDW^\_\ Z35[G7AEC_R<Y-_O/_Z34 >YT444 %%%% !1
M110!B>,+N[L/!NL7=@2+J&TD>-EZJ0IY'TZ_A7R]X.L/#NJZX8?%&J7%C:LA
M*RQ@?,^>C,0=O?DC\17US,T202-.R+"JDR&0@*%QSG/&,5Y#XE^!FG:F\E]X
M<OULVE&];>0;X3GGY6'*C_OKVH&11_!+33=6.J^'-?,]O',DRB;;(LB@@\2)
M@=CV/4?CTOQ:\:W'A+P]%#I[A-1OV9(Y.\: ?,P]^0!]<]J\0M+_ ,2?"WQ:
M;=G:*:%E,]N)-T4Z'!^AR._4>QKO/CW;27,/A_5XU)M71XR?[K,%90?J,_E0
M!@> OA7>>-K=]:U2^DMK&1VVN!OEN&S\QR>@SW.<D'CO7;WGP T%X2++5]2A
ME[--LE7\@J_SK;^#_B"PU3P-9Z?#*@O+!3'/!GY@-Q(;'H0>OKFN_DD2*-I)
M'5$499F. !ZDT 8/@CP_-X6\(66BW$T<TEL9,R1@@,&D9AU]F%>8?'WQ!_R#
M?#T+_P#3W. ?JJ _^/''TKV*PU?3]3L6OK&[BGM%+ S(V4^4X.#T(XZ]*^5=
M<\0VGB#XAS:SJ8FDTY[L%DC4,Q@4@!0"0,E0/S- (=/I^J?#[7]"U-P1*\,-
M]&.F0?O(?U!]C7U9IU]!JFFVU_:OO@N8EEC;U5AD5\]?$[X@>&_&^DV:6-IJ
M,-]:RDH\\484HP^9<AR>H4].U=M\"O$G]H>';C0IWS-I[;XLGDQ,<_HV?S%
M'D_Q*C>;XG:S%$C/(]R%55&2Q*K@"O1/@_\ $<DQ>%=;E(=?DL9Y#_Y"8_\
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M]EO?#GA+X:Z7>^*-.TD0W-K 50FYE;<6P N&8CDD=J\N^ W_ "/UQ_V#Y/\
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MH *\%\1?\G(6/_7>V_\ 0!7O5>"^(O\ DY"Q_P"N]M_Z * />J*** "BBB@
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M S? 7_)6_''_ %T7_P!"-6_C#IVO:AH=C_9,%Q=6<4Q:^M;9B'E3 P..2/O
M@9Z@XXJ5OAWK=IXHU;6]%\7?V<^I2;I(_P"S4FP,Y RS?K@5KOX:\2RZ5#%)
MXTN!J44K.+R.QC164@85HONM@C.?<T <K\+;[P?<:O<)H=I?Z1J*P,L^F3SN
M\9^9<N-Q.6& .QY/'>MSXN:@UCX!NXX-1%G=7#)'$JL0\WS#<BXYY'_U^M3^
M'/ <FE>);GQ'JVLR:MJ\T?E"8VZP*JX ^XI(S@ ?TJUXR\&+XL_LVXBU&73]
M0TV;SK6X2,2!6RIY4D9Y5>_:@1YI\,M>T;1[O4=5:X&DZ1((;-=-,LEQ(]S@
M$N$ +<X8#CN?2NS^+'AZ;4_#D6MZ<"NJ:.XNH74?-L&"P_# ;_@/O5"#X17$
M/B2V\1GQ(LVK1S^?,\NFIY4I]HU8!3[YSGG@\UZ>5#(5<!@1@C'!H \2N];7
MXM^)/#6C0*PTZ"$7VIJ.@<<%/H/N@_[=6?"^FQ?$_P 0:Y>>))9IK"PG^SVN
MF)*T<48^;!(4@YP.OKGV%=UX-\!Z?X,FU26SD,AOI]ZY3'E1C[L8Y.<9//&>
M..*I7_P[>+7[C6_#.N3Z%>W7_'RJ0+/%*2222C$#.3_AU- SDWL(_"_Q*M_!
MD,L]UX;URT/F:?+,S>3D./E.<@?)UST)]!65X@\"^&['XO\ A[0K?3MFFW=N
M7GA\^0[V_><[BVX?='0]J]*\.^ XM(UJ77M3U*?6-;E79]KG4((UQC"(.%].
MO3@8YR_5?!7]I^/])\4_VAY?]GP^5]F\G=YGW^=V[C[_ *'I0!P/QA\/:7X:
M^'FGV&D6OV:V.IB39YC/\QC?)RQ)["MKP7IGA2'Q-!+I?@7Q'I-VB.4N[^&5
M8E^4@@EI&&2"1TKI/'_@K_A.=&M]/_M#[%Y-P)_,\GS,X5EQC</[W7VIVCZ#
MXLLM5AN-3\:?VC9IN\RU_LN*'S,J0/G4Y&"0?PQ0!U5>4?'/_D&:!_V$!_Z#
M7J]>2_'>18M'T.1ONI?[C] M CUJN3\6_$70/"",EY<>??8RMG!AI/;=V4?7
M\ :XB7Q=XR^(]P]GX0M)-*TC.U]2F^5B.^&'0^RY/N*ZKPE\+=#\,NMY.#J6
MJYW-=W(SM;N47M]3D^] ')+IGCKXI,)-4E?P_P"'G.5ME!#RK[C@M]6P.X!K
MT?PSX-T/PE;>5I5FJ2,,27#_ #2R?5OZ# ]JWZ* "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ KYB^,$\UM\4[V:"5XI4CA*O&Q5E/EKR".E?3M>
M+_$[X7:[XC\5MK&D"":.>)%D1Y C(RC'?@@@#]: 1X[_ ,)/K_\ T'-3_P#
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M^8#K].GKFMBB@!D,,5O"D,$:11(-JHBA54>@ Z4^BB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MN> N"%.3GL: (8/!_BO0[2]T7P_J6E)HUS)(T;74<AGM0_4)M^5L<XS5S4/
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MEM%O)(+>V#O;PL,AI,-@9'. 2<4 =C17":G\11#KOAVVTO3;C4+#5D>07$2
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M6YT_P['I%I,FB-=M+:ZG)\L8:3$&=H<%@C'@'G'WAB@#UZBO)H-4L]'T#Q=
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M4QIM.X8QUZ8)J&]\.:JGQ$M_$NFS61A>S6RNXKG>&$?F!RT>W@MQCGBNLHH
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MX0R[6'#;=IQD-GOQ7JM% '$^#/!MQH.J7.HWMIIL4[P"!6M+FYF8KNR<F9B
M.!P!^-9?B_X>ZMXAUS4[I)]-N+:[MUC@^W>87LF"X_=JOR_,>2QY'H>_I5%
M'FUMX+\5:3JUAJ6E7FDB:VT*'2W6X\QE9DQEA@# R 0?P(INF_#C5?#2Z-?:
M'J%G+J=E;26]PMXC"&8.Y<X*\K@L?K@=*]+HH \\?X<W4O@K5["6^A?6]1O#
MJ)N5!2.*XW C;U(7C&>O)IL_PWN+SP);:5<7D)U>._.IS3Y?RYK@LQ8$KM8
MAL9&", UZ+10!R7@CPK-X<%_-=6UC#<W;)N^QW$\P8(#C<TS$YY/0#BNMHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M&>.T=DDC8JRG'4$<@T =!17$ZMXGUNRF\1W,":?]@T-T+1R1N99U,,<C ,&
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MD2H?#^G:P$TF [;V?RQ'F:;E?D;.?PZ4 =#J_@NSU=]0W7^H6L.HH%NX+:1
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MHOS,."QV9..!G X%8%U=W>E?VU9:,UO8>7K&GV4#1VR81)([=3D8^;AB,G)
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M+$C! X QU-3^&_%.JZM=Z3>A[^XM]1=_/M3ICI!:QE69&6;RP&P5522Y!+<
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M/0GKUL>*/MW_  BFK?V9O^W?9)?(\O[V_:<;??T]Z\UGO?#.GZL]QX<MH+J
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M'\&?O=L9SQFN>EL-*U+7H+33XHY?#,NL6XBC@.+=I1;7)E"8X*\1Y X/(]:
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MF\SS^_\ K=FW=^'%8VFB?^PK;RQ-Y/\ 8&E?:O)SO^S_ &F7S<8Y^YNS[9H
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M:A;:59-J,<]QI<5OIVIW M-*U(?Z/,C00,RHO\+!F)7 .-[87GB)XM(B\/\
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M]A;6(T+58(_+OKO7[Z"XG'WFBS=?(3_='EJ<= 1GK6O\/FL;>74-.L/L-W'
MD3'5+,?\?.=W$Q[S#&6.3G<.G2@#N:*** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MX&D;+VUNJ3*@!+@%9%RH)&X^AH [L:E8&P2^%[;&S?;LN!*OEMN("X;.#DD
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110!3M=+L[.]NKR&-OM%T1YLCR,Y(&<*-Q.U1N.%&!R>.:N4
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% %74-.M]3MQ!<^<$#!P89WA8$=PR$$?G1
MIVFVFE6@M;*'RX@Q8Y8LS,3DLS$DL2>Y)-6J* "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M),\8C65\I\O&XD#.">ISQ?OO!5U<W*HDMN+)(+"T12S!O)AE\R48QU;" <]
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MO$O;OR79#&./+=L+N=?F^4'GC /.<4V#QE8SS0$6EZMA<3_9X-09%$$DF=H
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M:R>2R2WM6LHPUOYT+2#E7)?<%R<\@X SFIY_B;);>)Y;*;0-3BL(=*.H2EX
MLZXY)*EL! ,J>^[VYKF]1T7[3XIN-2MUO$M7U;3KR.(Z/?;A%;QNC+_J,9.X
M8'3CDBM3Q)%_:OBB74[+[<MO>Z2^DW:3Z+?;DC9B2\>(L%N>AQTH&=C'XRTZ
M2?P_"(KH-KMN]Q:DHN$58Q(0_P W!P>V>:R;WQY%=Z)KR65O?Z=JEGIDE["M
M[;!&9 IVR*#D$;AW_*N-M+'6_M?A^2ZNY84T6SN+2W>VT._+KOA,:2?-#@MG
M:2. -O?-0Z?H5Y$=4GO9[Z:YO-$FTS<=-U*3=(Q4B1F>(D9.[(4 #C .30!W
M7ASQW%J<.G:>;:^O-1-C;2WMQ# /*A>6(.-YR,9Y/ (K.^'?Q#_MK3=(L-8^
MUMJUXD[+<M;A(9RCL2JE< D)C.!C\:YZWT=TUC0+HQ36O]EPV\<MW:Z-J N+
MA8XE5HV!BVE201GKMQ2:7H]S86'A&$3WL5QHL=^LLR:-?-AIPVQD!@&[:2,@
MXZ4 =N?B/ID1E%WINKV1%I+=PBZM1']H2-=S;/FZXYP<5'%\3M)N(X3;:9K5
MQ)."\,,=GEY(U +2+S@H"<9SR0<9KSN;PYJ5W);S75Q>2W$5I=V[R/8:I*TS
M2P-&KG?$0O+#(4# ]> -/4]#CGBT"X@2^FN]/TN/3IX9M-U*&.0*!\RO%&&'
M.>",$8Z8H WI_B*5\:6?V,7FH:-=:&+R*UL[822O*92,]B,*I!!(''K6S+\1
M]%^QZ?/9PW^H/?0-<1V]G;[Y5C4X9F!(P 01UZCC-<QX>L;70_$UGJ"6MY%:
M0Z.UB8(=)U!MLK3F4E=\1.WYCU;/M61H6DZEX8M=+NM*EE.J064MC<K/HM^8
M61IFE5E(ASD%AP1@XH ZIOB%;_\ "7+<KJ /AO\ X1XZC@1C)D\_9GINSQMV
MYZU#;?$;S_&DS7'VRPT.WT,WLL%Y;!)/,\T ..I(*D8 ..?6N4_X0NT%O]B$
M^IFV.B&Q,IT2]W_:/M/G[MOE8V9XZYJQ=Z/J'B&\NYO$$\Z"?2/[/4V6B7_R
M,LJR*Q#0C()4D\CK@>M '<O\2]'@T^\NKNSU.T:T2*5[>X@"2-%(X19%!;!7
M)YYR/3/%0S_%+2K>3RWTG7-_V0WNS['AA"&*ER"V0OR[LG'!'?BN#NO#+7F@
MZG;-920:A<P16\=PMCJTNY1*DC;O,C;:/DX !Y[UTNO1KJOB75M1A74$@O/#
MTNE1J^CWNX2LQ(8@0XVX/KGVH W%^*'AX2KYZW]M;26[W%O=3VQ2*X5!EMG<
MD#VJU:_$#1Y;:^FNXKW3396ZW4D=]!L=HF.%=0"<@GCUR0,5Y_X@\-Q^(=(\
M*Z=+)J,*:5826]PZZ-?,3(8D52@\D97<O.2.*;#X:M;O2]3MM0M;NUN;FT6W
MCNK73]5G;AUDRPE3 &Y%X'OS0!U'B#XI1Z=X?OKJSTB_34+81L;>^A\O8CMA
M9&PV=AZ<<Y(!QFG0_$&*RN?$NH:F=26TT];,FPDLXT>V\T8X8.2^20QSC Z9
MKDV\-PWFA:O:7-I<6U[=VR017$&G:K-G;(LF&\U#A25' !(R>31J&E:GJ]CX
MK-YYD=[K8LMGDZ3J'EH8"-V<P9Y &.O/I0!Z);?$'19M.U>]G6[LUTG:;J*Z
MAV2 .,H0N3][MW^E2:)XWL-<ULZ/'8ZE:7HM/M;1WEOY>$W!1W/)W \<>^<B
MN%\0:=::E+XTN+F;4+:VU>.T>"5M'O?W+0+R9,P@ $CU/&:S-,\1:_JGBZ[\
M06,EO=SC2ELH[J#2[R2V#^<K,N%C+D[0QR0!D@=J /31XXTQ]:N].AM[Z:.R
M9EN[Y(<VUNRJ68.^>" .< U2@^)NB3132M;:E @M);RW,]OL%W%&I9C%D\\#
M.#BN9CM[BUGUW3+<W+^']:GFGG\W1+\7$)E7#!,1;3VQD]JS)M(U#4K"VM-3
MGG9-+TVXLM.\C0[]3(TD7E!Y28?EP .%S0!VD/Q2TBX81PZ7K<EQ) MS! ME
MEYXC_&G.-HP>20/3-7?^$RCU.'PX^A!)?[8G)_?H1L@C!,IP#PP("CMD]ZYG
M1(ETSQ'I>HS+J#Q6GAV+29 NCWNXRJP)89A^[QZY]JK?#^R_X1G[.VK"^F:T
MLVM;9;?1[Y@N^5Y9&.Z$<G*#Z+0 FA?$;Q%JNA7&KR7GA55BM+FX_L]'D^U?
MNT<K\N_IE03_ +/I5B+XI7[_  XU#6'L[6+7+#R&DMG5O+:.5EV.!NS@HWKU
M'X5SVA:1JFE>'[C1)--L#'+:W,'VY-$U#[5F1'"_-]G'&6 /^SZU+XF\,+J_
MA?1[6P>_M]3MK&&QO&;1[X13Q)M.,B#)PZ@C@?A0!V$?C^ZM?"_B>[U2&V34
M]$N'M_*C#!)">(6P23AB?7L:Y^]^)'BFQO\ 5+:<^'(9M-AMW>UG\U)KAY(P
MS)$-YW$,2.G<>M.U_28-6\>6^KP?VE'I4SP2ZC;-HU[NF>$G9@"'!&-H.2.E
M9VO:3?:CXA\17-M:Q-::QY*B6[T2_>>V")M+(!!@-U[]A0!UFN>+O%6B65IK
M<^FZ6FE3/ GV-GD^V$R 94?P[@2>,'I4-_\ $35+>;4=4AL;)O#NF:D-.N6=
MF^T%@5#.O\(4%AP>OJ*YNXA\2GQ':Z@674H-.18]/CO]*U(>7@ >:RK!@R'&
M223STZ#$UWH\UQ)J&E++=#P]J6I#4;I3H=]YX8E6:-?W6TJ2HP3R/2@#K1XG
M\2V'C'3M%U6STIUU..=K=;21S)#Y:[AYA;C!Z9 ]?2G:?XD\26OC6RT#7K;2
MF^W6\DT;:>TA: +_ ']W4'H",<UR.B2^)[#Q)>ZU?1V]W=W:E/M#Z3J1>% #
MMC0>0 J[L9[GW-6?!0\0:=XH>\U6.*[GU"39=7K:;J E"G[J*6@6-$!QUP !
MUX& #URBBB@04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!
M4U.R;4=,N+1+F>U>5"JSP.5>-NS CT/;OT-<=;Z[J=VEU?:DLMO;^&XI3?K
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M629HU>%D.Y60QHN"" <D$\<T <=>>*]4U2%K.PUK2I)[74[!7O+!&>*5)I0
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MI;F1P98[::S6QGLT*^5-$H8*#D;@5#M@J1^-6M+TB73"=^K:A>IL"(ETT9"
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MMU!'N665I#')YF#LW.V"@W =#FNF\.Z6VB>&]-TMY!(]I;)$SCHS!0"1[9H
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MM^= '-^,[6>?4_#!BU&ZM0=4V8A6,X/D3'=\R-S@$>F">,X(Q-/GU/2=-O\
M5HM2;[,OB*:$V7DIL:.2],;98C=N^<D$,!P!@\UW>IZ39:Q!%%>QNRQ2"6-H
MY7B=' (R&0@@X)'!Z$U&="TUK&2R-M_H\ES]K=-[<R^;YN[.<_?&<=.V,<4
M<K)XBOI/%%DMG<ZA)IMY?2V+.\,"P*RQR9\H_P"L+*\9Y8%#R/2M#X>V\T/A
MMWEOKBYWWMW@3",!2+F4$C:H/S'DYSSTP.*T8_"6B1:FFHI9L+E)FN$/GR%$
MD8'<RINVJ3N.<#D\GFKMAI-GIDER]G&\?VF0RR+YKLFXDDE5)(7)))V@9)YH
M YK6[G5AXDU:#2%3[2NF6DBE(H_-VF>4/M9AR=@.U6.W=VY.=[P]>QZAHD$Z
M7<]T<NCR7,2QRAE8@JZJ  RD8. .E/O-#T^^N)KB:.43S11PO+%/)$VU&9E
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MD(*\H3AL@GG/ P1SG$T[5]5\+>$/#-_+?F\MI],9FLS$BI&L=HTR;6 W9Q&
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 45G:_J4VCZ!?:E!:?:Y+6%IO
M(\S9O"\GG![9/2L:Y\;0"Q\-SV5K]JEUV6-(8O-V^6A7<[DX.=@ZB@#JJ*X2
M3XAWMQ]MN]&\,76I:/92-'->K<I&6V_>,:'EP/J*AU?XD7]G!IU_IOAP7^EZ
MG+%!9W1OUB,DK@_*4VDK@A@23CB@#T&BN'U+QKKNG7.AZ?\ \(JDFK:J)R+3
M^TE C\OG[^S!RO/;'2M^;6+NR\)76LZCIOV:ZMK66XDLQ.'QL#';O QR .<=
MZ -FBN"T7XAWVH:AI-I?^'#8G6+=Y]/D6]699-J;OF 4%!C'.#UZ=:='\2HY
M=)0KI3_V\U__ &?_ &09QN$H/)+[?N!>=V,=J .[HKF_&'BB;PMIUA/#IHO[
MB]O8[*. 3B(;W#$?,5/=<=.]8!^*#P7:Z=>Z#);:HNI6UA/;FY5U03!BKAU!
M#8"],#J/>@#T.BN>N?%45IXS.@36X2)-,;49+MI,!5#E2NW'MG.?PKG_ /A9
M5W_9_P#;G_"*WO\ PC>[_D(>>GF;,XW^3UV^^: /0:*XV^^(=G8^-]+\/M;;
M[;4;9)X[]9?E7>65 5QT) &<]6'%4+OXESQ6DCVNA?:+@:^^B1PF[";W X?<
M4XR<#';UH ]!HK.T2\U.]L3+JVE#3+D.5$ N5GRO&&W #WX]JT: "BN2N_'*
M6_CNQ\,1Z9<L;EG1KN3,<:LL>\A,CY^"N>@&X=:U_$VO0^&?#MYK$\,DT=LH
M/EIU8E@H&>W)'/:@#6HK@Q\2UAL=2-]HTL.I64\%N+2*X259I)AF-5D''3)/
MI[T]OB0EKI^HC4-(FM]8L;B*V;3EF5S))*,Q[7X&",G..,4 =S17/^&O$SZY
M<:C8WFGMIVIZ<Z)<VK2B4 .NY6##&01[50U[QN^FZ[_8VF:6NHWD:+)/YEY'
M;)'N/RKN?[S'&=H__4 =?17#ZQ\0IM-U#4K>UT&:]ATB*.74YEN$3R-Z[@%!
M^^0.>HINJ?$F.UGN3IFD3:G9V-M%=7UPDRIY,<@W+A3]\[><<<4 =U153^TK
M0:1_:GFC['Y'VCS,?\L]N[/Y5Q]I\1_,\/ZCK]YHYMM+MH5EB<7<<DLNX@(&
MC'*$Y'4]Z .[HKB(_B*MHFI+K^D2Z7<V5DM\(1.LWFQ,VT8(QAMV%P>YZU-I
M7C6\O[F[T^Z\/S6FK1V0OK:S-RC_ &B(G PW 4YP"#TS0!V-%<MX?\6W6I^(
M+S0M4T5],U"W@6XVBX6=&C)QG<H&#[5U- !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MI;RXAEFQV ]:PSXOM8;#5;F\L+ZSDTN%;BXMIE0R>6P)4KM<J<[6'WNH.<4
M<+X'\&ZWI?B'1KLZ!'HD=I:O#J$IO%G-\2H PJDA,-SVZUU$?AF9?B_-XA^P
MQBR;2A%]HRN3<;P.F<YV#&<=.*O_ /":626-]<W%C?VQLHXIY89HT#^3(2%E
M #$;>&)R01M.1GBM:WU6"ZU:\TZ))#):)&TLF!LR^2%!SG.!D\="* .;^(WA
MRZ\3:;H]I;VOVF*+5H)KI/,"?N '#G)([-VY]*R_%7PXL6T72]-T#1HQ;C5X
M+B^42X9X0'#$NS;FP&]<\G%=3XLUR[T#1UO+2P>[<W$,1 *X4/*J'.YEY(;
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MA*Z*B .?F 7#%L#()'R\T 9>F>$-5U;4-=UC59[[0;C4YX&2'3[M?,C2*,H
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M=_#-,"Z@>0D0S(9.>-IPIQGDCZT ;]%8.G^*[:_N[2![&_LUO5+V<MU&JK<
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M5EB*B4 J-I#9\WN1C'>HK71=;NKO1_[8>P%OI+>8C6KN6N)-C1JS*5 088G
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M<A2VX'.>,"I/$6IZS9:]X?M=-AM7AN[B1)1-,4WXAD;;Q&V!\N[(Y) '0DT
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M692H"##$X!;GOBJ3>&-=6&#3(I-/_LV#5UU!9FD?S63[1YQC*[< C+8;<<X
MP,Y%Q/&+?\)-'HCPZ<9IWECA6'4A)*K(K./-C"Y0$*>06P<#%4-$\6:W-I]K
M%<6%K=:E>75TENJW11?+BE=7+GR_E5?D4$!BV03@DT =)HVES:==ZS+*\;+?
M7YN8]A.0OE1I@\=<H?7C%/\ $6EOK.@7EC$ZQSR)N@D;HDJD,C'Z,%/X52'B
MNW7PI)KDMM*K1.T,EJ""XG$GE>6#TSOX!XZ@U1O_ !C=Z+;WO]K:1'!=0V,E
M]!'#=^8DZIC<N\H-K LN>".<@F@!8_"]_:Z)HQ@FMFUC3[AKR0N6$4\L@<3
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M@%.U#S@X/8YXU[77[R?Q<VG326MK:E0]M#+"_FW2>6&+I)NV\,2"F"<*3WH
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M=0U"ZN9I;6:269TR6MY"Z<*@ &6P0 .!V.29[SPI8WDE[*TUS'/=74=X)HW
M:"6.-8U9,C'W5Z$$')['%;M% &3HF@0:&U])'=75S->S">>6Y92Q?:%XV@ #
MY>F,#M@8 K7/A.TN9[YVN[Q(;V>&YEMT9-GFQM&0XRNX$^4H(SC&> >:WZ*
M,6^\,6&HW%_/.T^^]C@1BC[?+,+,T;H0,A@SYSST''7*)X<#/9R7FJ:A>R6E
MT+J)IS&/F$;IC"(HQAR>F<XYK;HH I6&EP:=/?RPM(6OKG[3('((#;$3 XZ8
M0>O.:H/X5L7TV2R$MRFZ]DODG1P)(IG=GW*<8X+$ $'C@YK<HH Y]/"-GY;F
M>ZO+FYDNX+N6ZE9/,D:%@R*=JA0HVXP .">YS4:^#+.W\M[&_O[*YC,P^T0.
MF]DED:5D8,A4@,QQQD>O7/244 <_)X.TI[72+=?/C72[D743+)\TCY+'>2#N
M#,=QZ9(%6-"\-:?X=?4'L1+F_N6N9-[ A2W.U< 84$D@>YYK8HH RY]"AGUP
MZJ+FYCD>V^RRQ(5V2H"Q7=E20078C!'OFJG_  B&EO9Z=:3>=-;V.GR:<B.P
MQ)$ZHK;L ?-B,<C'4^V-^B@#,TO2)=,)WZMJ%ZFP(B731D(!Z%44D^[$GWJ"
M?PQ8W%Q=3/).'N;ZWOGPPP)(1&% X^Z?+7/?D\CC&U10!C3>'E-Q?7%IJ=]9
M3WEPEQ+) 8R<K$(PH#HPVX4'D$Y[U6@\&V%HE@+6ZO(&LTEC+JZDSI*X>17W
M*?O,,\8([8KHJ* ,.3PO:MHNE:;%=7<!TL1BTNHV7S4*(8\\J5.5)!!7!STJ
MK!X)L;2SM8K6]OX;FUFFFBO5D1I@96W.#N4JP)QP5/0=ZZ:B@#G;SPC!?M*T
M^I:@6N-/.G7+ QYGC(< M\G# R,05P,]01Q3KWPE:W<TSQ7]_9K<PK#=1VTB
MA;A5&!NRI(..,J5..]=!10!B3>%=.EAU.%3+%%J-@FGR)&0!'$BNJ[..#B0]
M<C@<>KCX<BDU6UO9KZ]FCM'\RWM79/*B?84W#"AB<$\%B.3Q6S10!!96QL[*
M&V:YGN3&H4S3D%W]V( &?PJ>BB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M=WFPXZ<;\?>[_=SVK2\8BR_MG0CK?E_V"#/]H^T?ZCSL+Y7F9XQ_K,;N,XH
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M$A<+CG.?W9SQW%>?ZO91Z5<>(]/TZ!K;2U739KF"U7:%B:603LJCIF-/FQU
M-:?@O^Q/^$P\1_\ "/\ D?8/LUEC[/\ ZG=F?.S'&/7'&=W?- '=45R/B+2[
M/5O'/AV"^MQ/"EK>R>6WW2P:#&1WQUY[@'M7)^$DDO=4TLW"Z3!J_F3?VLCW
MKO=W*LK!TDA,8P VTC+%0%P,YH ]2L;ZVU&V^T6DOF1>8\>[!'S(Y1ASZ,I'
MX58KR?1_[(T1-'G"6=G]@UR\74F150P!OM*0F7'1<,H!/ !&.*5(K#Q+X@1)
M!]HT^Y\2S'N%E4:<I'U4X^A!]#0!ZO2,=JEL$X&>!DUY?<Z7:6TFOZM# J7]
MIX@LX;>4=8D_T52J^@*NP([C&>@KTJ]S]@N,=?*;^1H @L]6M;V9;=#)'<FV
MCNF@EC9'2-R0NX$<'*L".HQS5BYN1:QHYBFDW2)'B)"Y&Y@N2!T SDGL 37F
M_@>TTFUU_19)+:RBO+CPU8O;NT:K))(%D$A4]2VS;G'.,9XKJ_&>?[-T['_0
M7L,_^!$= '1U!>7D&GV-Q>W4GEV]O&TLKX)VHHR3@<G@=J\TLM*M+;0;#68H
M NIOXDV&Y_Y:!&OFC9 >H4J2"O3DGK79^-[.*^\#:Y%);)<$6,SQHR!\.(V*
MD#^\#C'?- &A_:UL=8M],42--/:O=(X V[%9%.><YS(,<>M7Z\[ATC0-<\0>
M'[>*WL[C2AHURT<< 4PEO-A!X7@X)8^S#/45S_VQ[RR\.G78K"XL9-!B,4FJ
MWK6\7GDD.P;RW!EVA""<$9)'4T >R45F^'DNH_#FFI?7"7-TMM&)9XR2LC;1
M\P) )SUY KR_PO\ V&= \(_V-L_X2/S[?[1MS]H\K/[WS._E;,[<_+C;CM0!
M[%5>_OK;3-/N+Z\E\JVMXS)*^"=J@9)P.3^%>8Z7]B$>A^24_P"$R_M!/[2Q
M_P ?&W<?/\WOY>W.W/R_=Q6?+:Z5+X<\0Z58P:9K+II<ERFJVL0:5F!X6<\Y
MFYR#G)P>%H ]FHKR3QKJ&C2Z?-;:8FB06UMIC3Z=.(=[2.2_%KL90C*R EAD
MC(R, U#XO;2GTOQ5)X@V'6'B0Z9Y@^?RO)3'D]\;_,WX]\\4 >PT5Y/XC-Q/
MXGUJ*X.EVVI>;#_9-U?WSQ20H%0@P((FW ONW;6R<D$8%;'CR35#I$BZM;V:
M:0-0MMKVD\CSLGVA.J[!@[<GY23G&,]: /0*AGN1!);H8IG\Z3RP8T+!/E+9
M8C[H^7&3W('>O-GO=,L(O$$N@6]I/X=:*TB8+_QYI,\C+(_R\;50QE\>G-5=
M"D7^T;2&VFM9;./Q*GD&RA,5O@V+EO+4LV%)R>"0<DC&: /3+_5(-.GL(IED
M+7US]FC* $!MCOD\],(?7G%7:\AT@:5]O\([@/\ A)O[1D_M3_GKO\J7=YO?
MK]S/\.=O&:[SQT]['X,U!K!9&FP@81L5;RS(HD(*@D?)NY )'4"@#HJ*\A>T
MMKRQGCLVTF/1[F_TR)K32KUITC<S@,V?+0*64J"!SE<GK6I<6L>E1Z_+90K#
M:Z!J\%[##&N%CB\B(SJH'0%'E.!QD]* /2JI)JD#ZW-I(63[1%;1W+,0-I5V
M=0 <YSE#V[BO,;H.L.BWVJ6EE)IVJ-<ZA<)J=R8+?SI"AA61MCC*Q<*& Y!Y
MR *BCCU"*UN$-S]I5=+LA/+92O(39_;9]P1R S8AXS@$X.* /8**\>\1?V((
M;[_A']G]@>3:?;?[/SY7F_;(=NW;QYFS?G;S]W/.*M7[Q1V?B ^$E1M"*60E
M^R.5AW&4^?L9 <?NMF\J"1R<9% 'J]%<9X#2,3ZK)8OI":8YA,-KI=V;B*&0
M*0YSL0#<-AP!U!)Y-,\7;M/\0V-PGF!-9A.CR-'D%79@8V![%5,QH [:BO%=
M.35I? -Q;>7,USX:>2P+)N4N3,JNRD D;8-PR 2 Y(S7:>!4A^WZE+IS:/'I
MCQPXM-+O#<)'*-VYL^6@4LNW(Y.5R>M ';4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% %'6M1_LC0M0U/RO-^QVTEQY>[;OV*6QG!QG'7%)I^LZ=
MJ:.;2^M9GB \Y(IE<Q'T;!X/7KZ56\6PRW/@S78((GEFET^X2..-2S.QC8
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M69U8Z>K%F6T^V/,"/*2,MA<MGJ<,1VPIY]9[#5-/U6)I=.O[6\C4[6>WF60
M^A*DUQ$FD7^I^%M3U1K";[5J%]%</8R)LD-I#(H6$J>A,:L<>KD=ZUM*!U#Q
MJ^K6EA=6EDFG?9I7N+9H#-)O5E 1@"=BAAG&/GP,T :NMZ_'HCV41L;R]GO9
M6BAAM50L2$+G[[*,84]Z+7Q-I5QI*ZC-=)8PF1X6%ZRQ,DB%@Z')QD;&Z'H"
M>E8GCNV\Z[\/S20:G):PW<C3MIJRF5 87 (,7S %B <>M9&GZ)<MIVAVLFFW
M#:=!X@::VBN8<R);^3*0\H['S">6YY7/)H [Q]9TN.XMK>34K-9[I0UO&TZA
MI@>A09RP^E++JNG0ZA'I\NH6L=[*,QVSS*)''J%SD]#7#ZW8SH/%6G'2;FYO
M-7*_V?<10EHP/*1$#.!B/RW5F^8CKD9S4/B-=;N]3EM6BU$F&_LFMTM;$&*6
M-7B9IGFVD@@[QM5E(P.",T ==KGBG3]&4Q?:+::^$L"&S^T*LNV25(]VWDX&
M_/3G';K4$%]H_A;0AI5I?6\\NF6Q5;>6[B25A&@/S$D!>"I). ,@]*Y/4[*X
M2UO=,DT6]N+^7Q#'>QW$=LSIY1G5A)Y@&/EC^0C.0,\8&:N:GHDSZ#\0)$TZ
M1KV[FD6 B$EYD^SQ !.,L-VX<=\T =5X@\2Z=X?L+N2>ZM3>0VLES%9O<*DD
MVQ2V%!YYVD9 -3W'B#2+%8/M^IV5G)-%YJQW%PB,5QDD D9 ]:X;Q/:RQ6?C
M.RGT6]O[K5!YEE)!:M*K*(555W $*4=6."03GC)-5O$\;:9I/B\:AI=S/_:%
MA&;69("Z($@"D,X&$V.&?#$9SQDT >DW&JZ=:W%O;W%_:PSW/$$<DRJTO^Z"
M<M^%4=3\.IJ\S"ZU*^^Q2%?-L59!#)CL?DWX..0& -<-JVE:I)J.M6MPKQ6V
MIVUO%!,ND37CJJQ 8#QNHB*R;F 88R<Y[5Z)9:E!<7MWIR2-)<V(C6X8K@;F
M7<.?7'..V10!6UO7X]$>RB-C>7L][*T4,-JJ%B0A<_?91C"GO5;69K:[\.17
M^HV6I6ZP3Q70MHXP\X>.0,JD)N&"5&><8/)'4-\66VES0V<FIV>J7 AE9HFT
MY9B\;%2I)\GY@""1Z4F@Q:E_PAKQZ@+AKAEG$2W!W3>46;R@Y[OLVY[YZ\T
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M'Q-I&HWYLK6[WS'=L)B=4EVG#>6Y 5\=]I.*;:>*=%O;MK:"]!=0[!FC9(Y
MGWBCL KX[[2<5SFF:'K#P>'=)NK 6D.AYWWJ2H1/MA>)?+ )8;M^YMP7IWJG
M)X7UK5/#^E^&Y[);&/3+>6%K\2*5F)MW@4Q@$L,[]S;@O3'- &[_ ,)M97FN
M:)8:9)YJ7\T@9I;>2/=&L+ONC+ !AN51D9'/N*Z:XF^SVTLV-WEH7QZX&:XV
M*'7+O5O#!N="^QV^EM(;J=[B)@/]'>,>6%8DH21U /3CJ1T%AJ'_  D/A=;Z
M""2);R!FB23&2IR%/XC!_&@#%L/'L-_X-37EL6CE\Z"&:S>7YHS*Z*IW8Y&V
M17''((Z=K<GB]+:QU$W5FR:E9SBW6Q23<T[N?W.PX&0XYSCC#9^Z:YJ]\(:P
MGAS0%L+9?M?V>PM=4MS(H&V%HW#YS@LA5EX/(;C.!74ZCHC7/CG1=66U1X[6
MVN4EF.,JQV>7QU/!EQCID^M &R\\\6GF=K5I)UCW&WA<$EL<JI;:#SP"<?A6
M;HFO3:QX:_M8Z;(DVZ939QRJ[%HY&3 8[02=GL.>O>MJL/PEI]UI?A];6\C\
MN87-S)MW _*\\CJ<CU5@?QH @T_7]4U?PU!J=AH\!NGGEBDM9[W8$"2.A.\(
M<G*#C'?KQR:1XBU'4M*U&Z;11Y]K<M;1P6UT)!.RX#$.RH  Q(/^Z<9XS!IE
MGK.C^!;FWMK0-JHENV@B,BXS)/(R,3G&,,&/?''7BMO1-*BT31;/386+);QA
M"YZNW\3'W)R3]: ,^RUW4=6\*Z=K&EZ7!+/=QI(UM/=F,(I!)^<(<D''8=:D
M\-:W=ZY;7DEU816AM[I[8>5<&99"F Q#%5X#97IU4U0TBSUG1?AI:65O:!M9
MM[%8DA,BX67&.6SC )R>>W%:FGV#>'="T_3K*W>[$/EPN=X4X)^>4[CSR2Q'
M4]J -:BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "LB#PSI
M4%\MX(IWE1S)&)KJ65(V/4JC,54\GD 5KT4 1P6\%K'Y=O#'#&69]L:A1N8D
ML<#N223ZDU)110 4444 %%%% !1110 4444 %9=[X>TW4;Q;J[BFE8;28S<2
M")MIR-T8;8V/<&M2B@ J.*W@@>5XH8XVF??*R* 7; &3ZG  R>P%244 %%%%
M !1110 4444 %%%% !1110 4444 %%%% %-=+LUU9M3\MFO#'Y0=I&8*O&0J
MD[5SM&< 9P,YQ5B*W@@>5XH8XVF??*R* 7; &3ZG  R>P%244 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 17-M!>6[V]U!'/!(,/'*@9
M6'H0>#4=EI]EIEL+>PL[>T@!)$4$8C7/K@#%6:* "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MK&TLE8+'A> S-E>6S]X^U7?&^@:KJ5S:7&BJ!-/')IMZ^\*4MI<;G&3R4(R
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M$%(R#CKWSBN2\+^&=1M;CP^4\-1:'-I\2I?WBS1;KP"(J4*QD[MSX;+=,>M
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MS4C4@PF/'&S;@G''WL]Z /9**ALYFN+*"9UVO)&KLOH2,XJ:@ HHHH ****
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MM6O(].\,:3-8I.ZVTLDBAGC#':3^^')&#T'T% 'I-%>5_P!N_&3_ *%/1O\
MOZO_ ,?H_MWXR?\ 0IZ-_P!_5_\ C] 'JE%5=,DO9=)LY-1A2&^>!&N8HSE4
MD*C<!R> <CJ?J:XKQ)JWQ+MM?N8?#_A[3+O2UV>1-/(H=OE!;(,J]&W#H.E
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MJ45@>$+OQ->:3+)XJTZVL;X3E8XK=@5,>U<'AVYR6'7MTJIXSO\ QE9?8O\
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M 1OF ;)++T7<>HZ4 :M%>5_V[\9/^A3T;_OZO_Q^C^W?C)_T*>C?]_5_^/T
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M_;OQD_Z%/1O^_J__ !^O2M,DO9=)LY-1A2&^>!&N8HSE4D*C<!R> <CJ?J:
M+5%<!XDU;XEVVOW,/A_P]IEWI:[/(FGD4.WR@MD&5>C;AT'2LK^W?C)_T*>C
M?]_5_P#C] 'JE%>5_P!N_&3_ *%/1O\ OZO_ ,?KO_#<^LW.@6TWB"TAM-4;
M?Y\,)!1?F(7!#-U7:>IZT :M%<!XDU;XEVVOW,/A_P /:9=Z6NSR)IY%#M\H
M+9!E7HVX=!TK*_MWXR?]"GHW_?U?_C] 'JE%>5_V[\9/^A3T;_OZO_Q^N_\
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M?>PP#G&/E';\:Y_3_$WCSQ#K.NV^C1>&TMM,OY;0&\6<.P5B ?E)!X'/3Z4
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M %%%% !1110 4444 %%%% !1110!2UC_ ) E_P#]>TG_ *":X?X<?\D1M?\
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M1L1^ Z]ABO6J* "O!_&EM)9>/%\+1QL+76=9M=20@?+\V4D!_P"!<_A7O%%
M'@^HVLK?$VY\%B-OLM[KD.JL1T:/RR\@_P _W?:NE\=:/8:_\6?">F:G!Y]G
M-;7'F1[V7=A&8<J0>H'>O4Z* /)=.\-Z3X7^.-A9:-:?9K=]':9D\QWRY=P3
MEB3T4?E7*V7_  KS_A*_%O\ PF?_ !\_VQ<>1_Q\?<WMG_5<=?6OH2B@#R[6
M+6SUSXSV5M,OFV=YX<96&,;D9Y.>>AP:Y_P5_:-M\8;31]3RT^CZ;)8K*?\
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M_%4?\+_T#_H$ZG^4?_Q5=C_PK;P;_P!"]9_]\G_&C_A6W@W_ *%ZS_[Y/^-
M''?\+_T#_H$ZG^4?_P 51_PO_0/^@3J?Y1__ !5=C_PK;P;_ -"]9_\ ?)_Q
MH_X5MX-_Z%ZS_P"^3_C0!QW_  O_ $#_ *!.I_E'_P#%4?\ "_\ 0/\ H$ZG
M^4?_ ,578_\ "MO!O_0O6?\ WR?\:/\ A6W@W_H7K/\ [Y/^- ''?\+_ - _
MZ!.I_E'_ /%4?\+_ - _Z!.I_E'_ /%5V/\ PK;P;_T+UG_WR?\ &C_A6W@W
M_H7K/_OD_P"- ''?\+_T#_H$ZG^4?_Q5'_"_] _Z!.I_E'_\578_\*V\&_\
M0O6?_?)_QH_X5MX-_P"A>L_^^3_C0!QW_"_] _Z!.I_E'_\ %4?\+_T#_H$Z
MG^4?_P 578_\*V\&_P#0O6?_ 'R?\:/^%;>#?^A>L_\ OD_XT <=_P +_P!
M_P"@3J?Y1_\ Q5'_  O_ $#_ *!.I_E'_P#%5V/_  K;P;_T+UG_ -\G_&C_
M (5MX-_Z%ZS_ .^3_C0!QW_"_P#0/^@3J?Y1_P#Q5'_"_P#0/^@3J?Y1_P#Q
M5=C_ ,*V\&_]"]9_]\G_ !H_X5MX-_Z%ZS_[Y/\ C0!QW_"_] _Z!.I_E'_\
M51_PO_0/^@3J?Y1__%5V/_"MO!O_ $+UG_WR?\:/^%;>#?\ H7K/_OD_XT <
M=_PO_0/^@3J?Y1__ !5'_"_] _Z!.I_E'_\ %5V/_"MO!O\ T+UG_P!\G_&C
M_A6W@W_H7K/_ +Y/^- ''?\ "_\ 0/\ H$ZG^4?_ ,51_P +_P! _P"@3J?Y
M1_\ Q5=C_P *V\&_]"]9_P#?)_QH_P"%;>#?^A>L_P#OD_XT <=_PO\ T#_H
M$ZG^4?\ \51_PO\ T#_H$ZG^4?\ \578_P#"MO!O_0O6?_?)_P :/^%;>#?^
MA>L_^^3_ (T <=_PO_0/^@3J?Y1__%4?\+_T#_H$ZG^4?_Q5=C_PK;P;_P!"
M]9_]\G_&C_A6W@W_ *%ZS_[Y/^- ''?\+_T#_H$ZG^4?_P 51_PO_0/^@3J?
MY1__ !5=C_PK;P;_ -"]9_\ ?)_QH_X5MX-_Z%ZS_P"^3_C0!QW_  O_ $#_
M *!.I_E'_P#%4?\ "_\ 0/\ H$ZG^4?_ ,578_\ "MO!O_0O6?\ WR?\:/\
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M'_\ %5V/_"MO!O\ T+UG_P!\G_&C_A6W@W_H7K/_ +Y/^- ''?\ "_\ 0/\
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M@W_H7K/_ +Y/^- ''?\ "_\ 0/\ H$ZG^4?_ ,51_P +_P! _P"@3J?Y1_\
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MW_H7K/\ [Y/^- ''?\+_ - _Z!.I_E'_ /%4?\+_ - _Z!.I_E'_ /%5V/\
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M?\:/^%;>#?\ H7K/_OD_XT <=_PO_0/^@3J?Y1__ !5'_"_] _Z!.I_E'_\
M%5V/_"MO!O\ T+UG_P!\G_&C_A6W@W_H7K/_ +Y/^- ''?\ "_\ 0/\ H$ZG
M^4?_ ,51_P +_P! _P"@3J?Y1_\ Q5=C_P *V\&_]"]9_P#?)_QH_P"%;>#?
M^A>L_P#OD_XT <=_PO\ T#_H$ZG^4?\ \51_PO\ T#_H$ZG^4?\ \578_P#"
MMO!O_0O6?_?)_P :/^%;>#?^A>L_^^3_ (T <=_PO_0/^@3J?Y1__%4?\+_T
M#_H$ZG^4?_Q5=C_PK;P;_P!"]9_]\G_&C_A6W@W_ *%ZS_[Y/^- ''?\+_T#
M_H$ZG^4?_P 51_PO_0/^@3J?Y1__ !5=C_PK;P;_ -"]9_\ ?)_QH_X5MX-_
MZ%ZS_P"^3_C0!QW_  O_ $#_ *!.I_E'_P#%4?\ "_\ 0/\ H$ZG^4?_ ,57
M8_\ "MO!O_0O6?\ WR?\:/\ A6W@W_H7K/\ [Y/^- ''?\+_ - _Z!.I_E'_
M /%4?\+_ - _Z!.I_E'_ /%5V/\ PK;P;_T+UG_WR?\ &C_A6W@W_H7K/_OD
M_P"- ''?\+_T#_H$ZG^4?_Q5'_"_] _Z!.I_E'_\578_\*V\&_\ 0O6?_?)_
MQH_X5MX-_P"A>L_^^3_C0!QW_"_] _Z!.I_E'_\ %4?\+_T#_H$ZG^4?_P 5
M78_\*V\&_P#0O6?_ 'R?\:/^%;>#?^A>L_\ OD_XT <=_P +_P! _P"@3J?Y
M1_\ Q5'_  O_ $#_ *!.I_E'_P#%5V/_  K;P;_T+UG_ -\G_&C_ (5MX-_Z
M%ZS_ .^3_C0!QW_"_P#0/^@3J?Y1_P#Q5'_"_P#0/^@3J?Y1_P#Q5=C_ ,*V
M\&_]"]9_]\G_ !H_X5MX-_Z%ZS_[Y/\ C0!QW_"_] _Z!.I_E'_\51_PO_0/
M^@3J?Y1__%5V/_"MO!O_ $+UG_WR?\:/^%;>#?\ H7K/_OD_XT <=_PO_0/^
M@3J?Y1__ !5'_"_] _Z!.I_E'_\ %5V/_"MO!O\ T+UG_P!\G_&C_A6W@W_H
M7K/_ +Y/^- ''?\ "_\ 0/\ H$ZG^4?_ ,51_P +_P! _P"@3J?Y1_\ Q5=C
M_P *V\&_]"]9_P#?)_QH_P"%;>#?^A>L_P#OD_XT <=_PO\ T#_H$ZG^4?\
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M5'_"_P#0/^@3J?Y1_P#Q5=C_ ,*V\&_]"]9_]\G_ !H_X5MX-_Z%ZS_[Y/\
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M_P"^3_C0!QW_  O_ $#_ *!.I_E'_P#%4?\ "_\ 0/\ H$ZG^4?_ ,578_\
M"MO!O_0O6?\ WR?\:/\ A6W@W_H7K/\ [Y/^- ''?\+_ - _Z!.I_E'_ /%4
M?\+_ - _Z!.I_E'_ /%5V/\ PK;P;_T+UG_WR?\ &C_A6W@W_H7K/_OD_P"-
M ''?\+_T#_H$ZG^4?_Q5'_"_] _Z!.I_E'_\578_\*V\&_\ 0O6?_?)_QH_X
M5MX-_P"A>L_^^3_C0!QW_"_] _Z!.I_E'_\ %4?\+_T#_H$ZG^4?_P 578_\
M*V\&_P#0O6?_ 'R?\:/^%;>#?^A>L_\ OD_XT <=_P +_P! _P"@3J?Y1_\
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M2Y=2U.X\BUBP&?:6Y)P!@ GK5^@ HHHH **** "BBB@ HHHH **** "BBB@
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M+?\  G_0=_\ )2?_ .(H [BBN'_X6_X$_P"@[_Y*3_\ Q%'_  M_P)_T'?\
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M07:5@3N9P3U5B ">S'UKWI]/LI+JWNGL[=KBV!6"9HE+Q C!"G&5R..*J_\
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M^P=VS[3N?[3Y&_=Y>S;MSCY=V[ISC-6[OPG>SZ9KMJLUN&U#5X;Z(DMA8U:
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M';Q1N7CB0GG&\HHSSA6[#% '1:SKLUA?V>FZ?8B^U&[5Y$B:;RD2-,;G=L'
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M&L_]_HO_ (W7JE% 'E?_  H/PK_T$-9_[_1?_&Z/^%!^%?\ H(:S_P!_HO\
MXW7JE% 'E?\ PH/PK_T$-9_[_1?_ !NC_A0?A7_H(:S_ -_HO_C=>J44 >5_
M\*#\*_\ 00UG_O\ 1?\ QNC_ (4'X5_Z"&L_]_HO_C=>J44 ?(?CS0+7POXT
MU#1K*2:2WM_+V-.P+G=&K')  ZL>U?7E?+'Q?_Y*EK/_ &P_]$1U]3T#8444
M4""O'OV@O^0%H_\ U\O_ .@U[#7CW[07_("T?_KY?_T&@$=O\-O^2<Z%_P!>
MP_F:ZJN5^&W_ "3G0O\ KV'\S754 %%%% !1110 4444 %?/7A[_ ).3F_Z_
MKS_T5)7T+7SUX>_Y.3F_Z_KS_P!%24#/H6BBB@04444 >7^/M(CN_B7X-#7E
M_']K:Y1O)N63R]J+S'@_(3GDCKQ1 ]_XHU'QA<W6OZCIW]D7#V]K#:S^4D2H
MI(D<#[^[&>>V?;'H%[HFG:AJ>GZC=6_F7>GES:R;V'EEP W .#D =0:S]4\$
M^'-9OGO;[3$DN) %D=9'C\T#H'"D!OQS0!Y[H^L7FO\ BKX::G?C_2IK6^\P
M[=NXJCKNQ[XS^-9/@Z_O9/#?@KP]#?W&GV>IW-X;FXMVV2,$)(16_AR3CCGD
M5[(WAW26U'3;_P"Q(MQIJ-'9E"56%67:0%!"XQQR..U4AX'\-C0H=%_LM#80
MR&6*,R.6C<G)97)W \GD&@#SZ_O->CL/&^CV.LW\YT%X+JTNS*?,"[=\D3L.
M6  (Y].:>?%]W<>*[7Q6FH3KX;6X@T^2 2'RLR0%V<KTRKNHS[5Z7IOAS2-'
MTZ:PL+&.&VGSYRY+&0D8)9B26..Y-45\"^&T\-OX>73 -*>3S6@\Z3EL@YW;
MMW8=Z //H]3UI?#W@S4)M2OEEUCQ$DLJ_:'_ -2[G;'U^YM ^7ISTK.N+_7%
M\&>*?$:>(M46XTK6GAM8A<$QA?,0$,#]X8DX!X&W@=:]?N?#6D7=OI<$UF&B
MTN2.6S42,!$T8PAX/.,=#D56;P9H#Z-J&DM89L=0N#=747G2?O)"5);.[(Y5
M> 0.* .56]O?$7Q"U6RGUF\TVUTNQ@F@CMI?+5F=0S2,/XU&<8.12> /MGB7
MP+HE_?:[J$-Q%J#S,RW)S<;9#B)R3ED[;:T/%G@RXU?5(;JPTW1)3';" 27L
MDZN.O#!/ED3&/E;WYJYH'@#3-+\-:-I5ZOVR32Y_M<4VYDQ/N+;@ >@)Q@Y'
M'- '6T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110!\L?%_\ Y*EK/_;#_P!$1U]3U\L?%_\
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MLV?F!_B!^52!D5TE<7J6F:C/XOM;W3-'GL9EN8_M6HBYC$5S;C[RO&&W,Q'
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MGH&PHHHH$%>/?M!?\@+1_P#KY?\ ]!KV&O'OV@O^0%H__7R__H- ([?X;?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110!E7GAC0-1NGNKW0],N;A\
M;YI[2-W; P,DC)X 'X5JT44 %%%% !7CW[07_("T?_KY?_T&O8:\>_:"_P"0
M%H__ %\O_P"@T CM_AM_R3G0O^O8?S-=57*_#;_DG.A?]>P_F:ZJ@ HHHH *
M*** "BBB@ KYZ\/?\G)S?]?UY_Z*DKZ%KYZ\/?\ )R<W_7]>?^BI*!GT+111
M0(**** "BBB@ HHHH *SM5UW3M%\D7TSJ\Y(BCBA>5WQR<*@+$#(R<<9K1KE
MO&*0 V=P%UB/4(1(;6ZTRU:=HR0N5=0""K87AA@[>HQ0!N6VKV-Y=BU@F+3F
MV2[V%&4^4Y(5N0.I4\=1CD51E\7:'%I]E?&]+PWR[[8102222KU)$:J6P._'
M'>N;M[S6=-UNVUG5M'NY;F\T2&!TLH6E"W*N[%&QG8#O')X'//%4/#%M?>&D
MT+4K_2[]X6T1+*18+9I);:19"_S1@;@&!'('!49H [6[\5:/90VLD]S)FZ3S
M(8H[>1Y67N?+52P [DCBF7'C#0K2>&&>^V/*B2<POB-7^Z9#MQ'GMOQ6.UW)
MIGBR;7IM,U&>QU*PACC>*T>26V9&<E&C +*&W@].H.<5@7VFWDFHZ]#>2^(8
M;'6F69$L].2821O$J%'8QLT;+@C!*@#!'>@#OG\2:5'JYTLW$C7:L%<)!(Z(
M2,@,X4JIQ@X)'45'9>*M&U"*XFM[MO(@C,KSR0R1Q;!U9790K#W!-<S>)-IO
MB2(:);ZP\DL\::E%+:N;6XB"A7EWD;0^U1C:>2,$&LJ;3=3O]*U/1=$MM3;1
M5M8Y8;?4X&B,<J3(WD1LX#,C(K#G(''.#0!W6G>+-%U222.UNVWQQ&8K+!)$
M3&.K*'4;E]QD55C\?>&YX(YH+^29),>7Y-I,YDXR=H"$MCOC[IX.#61J$MQX
MHUK3KBSTO4;:+3X+IIGO+5H2QDB*+&H;[QR<G''RCGI5=K*.R\%^%Q);:U::
MK:Z>@AFTZS>1X7,:;TD0*1AB!D,.J]1B@#O[>>.ZMHKB(DQRH'0E2I((R.#R
M/H:R=.\5Z-JMZEG:W4AGD0O&);>2(2J.I0NH#8SV)I;:ZUL^#4NI[2/^W/L1
MD-MGY3/LR%]LMCOQZUQNFC6-2\4^&;RZDURY,$LS77VO3UMH+=FMY  HV!CR
M<9RPZ<Y(H ZNW\;^';O3I=0@U#?:1[ 9!!)AB^=JI\N7;@C:N2#P0#6IIFJV
M6L6GVJPG\V(,4;*E65AU5E8 J?8@&O.DT758/ 7@V6.*^MI-,=9+F*WMU>>,
M,CKN$;J=S MR-I."<<UUO@^R6&'4+T7&J327MSYDC:C;"W=F"*N0@5<#  Z#
M.* &>*/&FG>'[+4D6Y0ZE;6CS)&T3M&K[28UD91A=Q  !()SQUK7L=6MKN:.
MT,@%Z;2.Z>( \(^0#GIU5AUSQ7">(([RPL/&FF_V/?WTVK[YK26"W:57#0JF
MTL!A2A0D ]>,9)K2>2[T+Q)#J#Z7?7,<VBPVL8M8&D(F1W8HV/N9WCYC@<'G
MB@"]+XWL8]2LY?/C_L6?3'OOM7EON_UL2+QU"_O#G(XZG !KH3J-H-573/-_
MTQH#<"/:?]6&"YSC Y.,9R>?0UYYX;\.W-Q!H=CJ5C<16[^&9[.XWQD;&:2+
MY3GHV,D \\'TK4^&\-]=6MWK&J%6NGV:?&P.08[?*%@?]J0R-^5 '2:MXDTG
M0Y(X]0NC')(I<(D3R,%'5B$!*J/[QP/>JH\1H/$EU:22VRZ;#I<5^+G=V9Y
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MH>*Z3PUI]Q9^(?$LD\<F)9[8).Z$><%MHU)![C.?QS0!N_VE:?VL=+\W_3!
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"O'OV@O^0%H__7R__H->PUX]^T%_R M'_P"OE_\ T&@$=O\ #;_DG.A?]>P_
MF:ZJN5^&W_).="_Z]A_,UU5 !1110 4444 %%%% !7SUX>_Y.3F_Z_KS_P!%
M25]"U\]>'O\ DY.;_K^O/_14E SZ%HHHH$%%%% !1110 4444 %5-2U2RT>R
M:\OYQ# I"[B"223@  9))/0 9JW7+^*3_P 5!X2$V/LIU)]V>GF>1+Y?_CU
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M:87.WEY#_$.X(X*C P!@9KZCXAT+3K[4;.UUPVR:7-+++JL\4H\\ %)$ D;
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M,8@!29@#^\WXX/1>G4$F;1YM>3[#>0PZ\8)[*5[^YU"YC>)B8BR21*LC;/G
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MM7044 4GTBP>&RA%LL<5E(LMO'$3&L; $#A2 1ACP>/:KM%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MY\TKS2!?0,Y) ]@:T+2PM[%KEK=&4W,QGER[-ER "1DG'"C@8%6:* "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ KQ[]H+_D!:/_ -?+_P#H->PUX]^T
M%_R M'_Z^7_]!H!';_#;_DG.A?\ 7L/YFNJKE?AM_P DYT+_ *]A_,UU5 !1
M110 4444 %%%% !7SUX>_P"3DYO^OZ\_]%25]"U\]>'O^3DYO^OZ\_\ 14E
MSZ%HHHH$%%%% !1110 4444 %9/B+3]/U#2C_:5R;2*WD6X2[641M;NO1PQX
M'4CGC!(K6KE?%B+=:UX6L+A0UG/J+/*K=&9(9'0$=_F /X"@!^FZ!I]QHTK:
M7KU[*UW,)I=4@N4DEF8#:,OM*D  # &!BJ<FEVEKINK)IFL_:]7NVCL)[V\N
MD>2'<=H7 P%(#L0@ RQ'K6/?Z]!X4\0>)K:UEM;1KM[,6PE94ACGD1P\C=
M%16/K@=R*A\*V>B7LOC'0=/U2WN5F\EXYH[A7=V$";I\@\D2G)8=&H ]*LK2
M'3["WLK9=D%O$L4:^BJ, ?D*GK)\,:G)K/A;2M2F&);FUCDD&,?,5&?PSFM:
M@#&\566G:AX=N;?5K_[!9%HW>Y\U(_+*R*RG<X*CY@HY'>L;3/#_ (;UN&^8
M:V_B&26$6LMP]XDK1(3N"KY8 3D!LXSE0>U3?$DE? UV5C,A%Q:$(,9;_28N
M.>/SJCJ>I:U';:3#9:<?#L][JJ6LF]8)MT9BD8L A(R"HQGN!U&10!TFE:++
MIDS22:UJ=^-FQ4NY$95&>ORHI)XZG)K/L_ ND6/AZ;1(&N1:RW273,7!?<CH
MRKG'W1Y:KC'W1U[UC^+M>N=%MYQ:>(KN2_T^Q$LEK%IPF65E!):=E0B,,,="
M@')Z58^UZ]KWB;4;2PU@Z;:06-M.BK;QR-YD@D."6!^7Y>>_ P1SD V9-"TP
MP:UI)NG5];\V::/S%\P!HTB=D&.@ 7D@X)]P*UTM85LEM"@>$1^45?G<N,8/
MKQ7ELGBZZDU;PQJPCACO-3T1H?,DR(()'EB^=^X7(X'<E1D9S7J-E!-;644-
MQ=/=S*N'G=54N?7"@ ?@* .*T_0/"^J_\2VP\4SZAI\>&.E1:E'+"$!X4@ O
ML]BV.U=CJ6G0:GH]WIDI9+>ZMWMW,> 55E*G'& <'CBO,/!<$]]H?A.Y32FT
M^VTI6N+G5)VC02)Y;J57!+%3N!);& M7X_$^JC5+*WTK6+K67OXKA(S=:;]G
MM_-6%I$,<FQ<@E0"-S<-G/% '6:UX0TS7;#3K2[,ZK82))#)&P#_ "XX)P<@
MX&1CL/2FR^$XA?W-U9:MJFGK=2>;/!:RH(Y'XRV&0E2<<[2,USD?B74+?0IU
M35KJ?69+BUM#!J%FD364DK[-Q5%&Y.20<L#MZ]:75M1\1>'[_4[5]<:\BC\/
M7=_!)+;1*Z3QE "=J@$#/ QW.<\4 =/<>%+"YN[FY>2X$EQ?6]\^&&!)"$"
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MA0QP?FQG;GM75T44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M.CS9; 6S6Q\QOF9""#D@#G!/3%9L?@B!9+2676M8GDLE=;5I)D'DAHVC. J
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 5X]^T%_R M'_ .OE_P#T&O8:\>_:"_Y 6C_]?+_^@T CM_AM_P DYT+_
M *]A_,UU5<K\-O\ DG.A?]>P_F:ZJ@ HHHH **** "BBB@ KYZ\/?\G)S?\
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MM9(9;33K":%S&5X67<2 58 \\]>M '7^)_%U]HFOZ3HNG:*NI7>I)*T8:[$
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M\RZL-@N4"D>67!*C)&#P#TJ_7EG@G2-&T_XK>+(A;6\%Q;O;_84)PP#QN7V
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ JO-86=S=6]S/:02W%L6,$KQAGBSP=I/*YP,XJQ10!6OM.L=3@\
MB_L[>[ASGRYXED7/T(J-M'TMK6"U;3;,V]O()88C NR)QG#*,8!&3R/6KM%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %>/?M!?\@+1_P#KY?\
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M2-[,>A/M0!W5[J-KI\EHES(4:[G%O"-I.YRK-CCIPK<GTJ/3M5M]3FU"*!9
M;&Y-K*7  +A%?(YZ8<>G(-<OX]TG2[Z_\,RW]E;3%M42!WF0',9BE.TD]MP!
MQZU@76AZ?<Z7\0-7DBW7EI<SO:2ACF!DMHW5D_NG.,D=0!Z4 >JTUW6-&=V"
MHH)9F. !ZFO)]16ZU_Q%J\=W86%U)%9VYM)+S4#;&V5X@QEB4(W/F%LL"#\H
M%=GK5CJM[\,[NQ,BSZK)I9C=H3D2R^7\VT_[1R!]: 'VGC"/4)XOL.BZQ<64
MKA4OD@40L"<;QN8,5YZA>G(KI*Q]%U[1[_2;26RN[=(F146$R -&>!Y9!Y#
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M,T"81#%"S$+NP3,0I&.!Z5N^ HK&#6O%D.FR![2._C2/#;@N(4!4'T4Y4#L
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MER:B-1?3;-KY>ER8%,@_X%C-7:* ,&P\)Z= DC7]M::A<M>378FFME)1G<L
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MTO3IY9['3;.UFF_UDD$"HS]^2!S^-7:* *R:?91PVT*6=NL5J0UNBQ*%A(!
M*#'R\$CCL34L]O#=1&*XACEC)!*2*&!(.0<'T(!_"I** *%MH>D6=M<6UKI5
MC!!<@B>**W15E!&#N &&X)'/K5J.UMX9GFC@B25U5'=4 9E7.T$]P,G [9-2
MT4 4)]#TBZLH;*XTJQFM(,>5!);HR1XZ;5(P/PJ6+3+"'RO*LK:/RI&ECV1*
M-CMG<PXX)W-D]\GUJU10!6&GV2VL-JMG;BW@*M%"(EV1E3E2HQ@8(!&.F*YC
M5? [ZWJ4TU_<Z<]O,V&*:6JW)BS_ *OSRQ.,<$A<X]*["B@"*XMH+NW>WN88
MYH)!M>.10RL/0@\&J]II&F6$9CL].M+9"NPK# J KR<8 Z<GCWJ[10!0L=$T
MG3'WZ?I=E:/@KNM[=(S@D$C@#KM7/T'I4BZ7IZV4MDMC:BUF+&2 0KL?=][*
MXP<]\]:MT4 45T72EU(ZDNF60OSUNA OFGM]_&?UI8]'TN'47U&+3;-+Y\[[
ME8%$C9ZY;&35VB@"G-9O'8SQ:6UO93R,SB0P;U#LV68J"NXDDD\]3FHM#TF/
M0]'@T^.1I?+W,\K#!D=B69B.V6)/XUHT4 0M9VSW<=V]O"US&I1)B@+JIZ@-
MU ..E02:/I<VHIJ,NFV;WR8V7+0*9%QTPV,BKM% %:33K&:_AOY;.W>\A4K%
M<-$IDC!R"%;&0#D]/4U!::#H]A=M=V>DV-M<OG=-#;(CG/7+ 9K0HH K7VG6
M.J6_V?4+.WNX-P;R[B)9%R.AP01FHY-'TN;44U&73;-[Y,;+EH%,BXZ8;&15
MVB@!DT,5S"\,\22Q.-KHZAE8>A!ZUAZIX2TV\\.7^CV-M:Z:MW 8/,M[=1L!
MR>@QD9).,]S6_10!G+H6F01W@L["UM);M66:6"!49R<\L0!GKWJMH/AC3="L
MK)(K2T:]M[6.V>]6W5))=B!<D]><=,FMJB@"N+"S%H]H+2 6S[M\(C&QMQ);
M*]#DDD^I)IMAIFGZ5"8=.L;:SB)W%+>)8U)]<*!5JB@"JNF6"64EDMC;+:2%
MB\ B4(VXY.5Q@Y/)I+#2M.TJ)HM.L+6SC8[F2WA6,$^I"@5;HH JS:987%[%
M>SV-M+=Q*4CG>)6=%(((#$9 ()_,TY;"S1;54M(%6T&+<", 0_+M^3^[\I(X
M['%6** ,\:#HZZB=1&DV(OBV[[2+9/-SZ[L9S^-6;NSM=0MFMKVVAN8'^]%-
M&'5OJ#Q4]% &:_A[1)-/CT]]'T]K*-MR6S6R&-3ZA<8!YJT+"S6.WC%I $MF
M#0*(QB(@$ J/X3@D<=B:L44 5GT^RDAN87L[=HKHEKA&B4K,2 "7&/FX '/8
M"LE/".F2:SJ6HW]K:WS7<\<T:W%LK^05B2/Y2<\G9G/'Z5OT4 4]0TC3=66-
M=2TZTO%C.4%S"L@4^HW XJ:.SMH9?-BMX4D\M8MZH =BY*KGT&3@=!DU-10!
MFS^'=$NEC6XT?3YA$S-&)+9&V%F+,1D<$DDGU)S3KC0M(N[K[5<Z58S7&S9Y
MTENC/MQC&2,XQVK0HH J3:5IUQ<07$]A:RSP*5AE>%6:,$8(4D9 QZ5'<Z'I
M%[:06EUI=E/;6X AAEMT9(P!@!5(P...*OT4 0BTMA+#*+>(20(8XGV#,:G&
M54]@=J\#T'I3HK>"!I6AACC:9_,D** 7; &XXZG  R>P%244 4;G1=*O+V.]
MNM,LY[J+'ESRP*SICIAB,BK0MX!<M<B&,7#((VE"C<5!)"D]< DG'N:DHH K
MWMA9ZG;&VO[2"Z@)!,4\8D4D=#@C%)_9]D(+B#[';^3<Y\^/REVRY4*=PQ\V
M5 '/8 59HH H7VAZ1J?E?;]+LKORAB/S[=)-@]LCBKRJJ*%50JJ,  8 %+10
M!G/X?T634!J#Z18->AMXN6MD,@;UW8SFGW.BZ5>7L=[=:99SW46/+GE@5G3'
M3#$9%7J* (A:VXFEF$$7FS*$D?8-SJ,X!/<#<< ^I]:8MA9HMJJ6D"K:#%N!
M& (?EV_)_=^4D<=CBK%% &!X<\(Z9X>L+&-;6UFO[6 0F_\ LRK*X QUY(&.
MV35Z/0-&BNGNH](L$N)&#O*ML@=F!# DXR2" <^HS6C10!6.GV1@: V=N87E
M\YH_*7:TF[?O(Q][=\V>N>>M4+;19E\23ZS>7BW$GDFWM8TAV"",MN8$Y.YB
M0O/'W>E;%% %&[T72K^[BN[S3+*XN8L".::!7=,'(PQ&1S5JXMX+NWDM[F&.
M:"12KQR*&5@>H(/!%244 0R6EM+-YTEO$\OEM%O9 6V,02N?0X&1["JMIH6D
M:?\ \>6E6-M]X?N;=$ZXST'? S]*T** *\=A9PFW,5I AMHS%!MC \I#C*K_
M '1\J\#C@>E1S:3IMQ:26D^GVDMM(YD>%X59&<G)8J1@DDDD^M7** *']AZ1
M_9O]F_V58_8,Y^R_9T\K/^[C'Z5-9Z?9:>C)96=O;*V-RPQ*@. %&<#L !]
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M65O%]G1DA\N)5\I6QN"X' .!D#K@5:HH SX-!T>UGGGM])L8IIP5FDCMT5I
M>H8@<Y]ZNPPQ6T$<$$210Q*$CCC4*J*!@  <  =J?10 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !5/5-+L]:TRXT[4(1-
M:W"[)$)QD?7L0<$'VJY10!PJ?#**&-8X/&'BZ&)!M2./4\*@[ #;P!6UX;\'
MZ=X8:ZFMY;N[O;H@SWE[-YLT@'0%L#@?3ZYKH** "BBB@ HHHH *Q/$GA73O
M%%O;I>-<0SVS^9;W5K)Y<L+=RK?@/R'I6W10!PS?#174JWC/QBRL,$'5,@C_
M +YKJ=$T2P\.Z3#IFFP^5;19P"<EB>2Q/<DUH44 %%%% !1110 5R6K?#W3=
M2UB;5;;4=7TB\N !</I=UY/G8Z%A@Y-=;10!PX^%^G32Q'4]=\0ZM;QN)!:Z
MA?\ F1,PZ$KM&:[BBB@ HHHH *\>_:"_Y 6C_P#7R_\ Z#7L->/?M!?\@+1_
M^OE__0: 1V_PV_Y)SH7_ %[#^9KJJY7X;?\ ).="_P"O8?S-=50 4444 %%%
M% !1110 5\]>'O\ DY.;_K^O/_14E?0M?/7A[_DY.;_K^O/_ $5)0,^A:***
M!!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MDY&"Q'S (I/\6><UOZ*(F\-6OC#6M8OB[6XOI1'=.L$2E=VP1*=I ''())%
M':U2N-6L;:TGN7N%:*"012F(&0JY(&TA<G.6''O7&:;<72>+(+9UUNVL;RPN
M'F&IW@+.5,>'C57+1$!FZ!>HXR.,S187TWP[X<GM[C4!<ZQ>_;IPUW*^Z)1)
M.1@L1R BG^]GG- 'J=%>;7,M_P#\('#XN;5KW^U[A(KF"&.X809D8;(!$/E8
M88+D@MG)S3=0:]GT7Q;XA;5]2C-O=31Z;#!<LL<;1 1@[0<,&D7E3D>V2: /
M2ZPK?QAH5UJ/V"*];SS,UNI>WD1'D4D%5=E"L<J>A/2M*YNSI^D37ET5)MX&
MEE(X'RKD_P J\UM;/7(?A[87&I06=G9:;'_:S.L[2S7$HS,HV[0$RY&>6/;O
MF@#U6BO/K/3-2M=0T;P_<ZWJ;S7-BUSJ%RUTQ=_+V*(XS_!EI,DCYB%'/)-4
MM0N[VWU&\\-V6LWJ02:G96\%T\YDEA9E:66,.V2WRQKPQ/\ K,'@XH ].HKS
M?6K^_P##.NR:9I6H7<JW5M"K/>3M<?99I;A8DDRY.,JSG;TR@XK0U"TO](U[
M3M/T?5[V2YU"WNED%[<-.J%8\I-M.=N)-@PH .[I0!W%1W%Q%:6TMS.X2&)#
M(['^%0,D_E7"V.HVEKI=Q97$FO\ ]K2SI9S6:WC33><$\P^4S-M563YMP*C'
M]TUGO=WTGA?Q)I$QO8_-OX=.MH;NX6>>)9UB#*SAFR/G<C+$@=: /2;:XCN[
M6*YA8M%*@D0E2"5(R.#R/QJ6J-_=OI=G&UMIEU>X8((;3R]RC!Y^=E&.,=<\
MCBLS_A)K[_H4=>_\EO\ X]0!T-8FK>+M%T34!8WUQ,MR8A-LBM)9<(20"2BD
M#E3U]*ETW6;F_NC#+H.IV*A2WFW7D[/I\DC'/X5RVMW&NVWQ%O9=!L[.ZN%T
M*)FCN963.)IL!< Y.>Q(^M ';V-]:ZE90WME.D]M,H>.1#D,*?+=00300RS(
MDD[%(D8X+L%+$#UX!/X5YWIT^G#PCX?TVUFUN^N+J.6[6+3)/LTC$N3(7.]0
MBJ[XQNZ\<XK/L8)-?'@>YU&ZU$7#W=[;.5O71PL2SA<E&QOPH!8<GD9(H ]'
MN=?TRSM+RYN+@I%9S""8F)R1(0I"J ,L3O7&W/)QUJ:SU2TOY6C@:0NL4<S*
M\+H0LF=N=P'/RGCJ.X%><:W"^K?;/M=Y>D0>+;>WB$=U(@1&^S\ *1C&20>Q
M)(P2:M:OJ%_:>*;G1;?4;N&VGDTRR\TS%GA1Q<%F5FSAVV*NX\Y(/4"@#TFH
MKBZ@M$1[B9(E>18U+G&78A54>Y) KD]8M['1K:TTH7/B.[GNYFEA@M;Z1YY
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M%FE;<[I'*RJ6/<X &>^*@\&_\?OBK_L-R?\ HF&@#?T[4;35;-;NRE\V!G=
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M&Y8GDG@X/I5V_;4M'G\00V.H:A/#HOV+4HXYKEY'9#YGG1EF.64HA.TD\]*
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M %Q3_P!!% %FBBB@ KQ[]H+_ ) 6C_\ 7R__ *#7L->/?M!?\@+1_P#KY?\
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M-6+C0=+O'OGN;..8W\20W(?)$B)NV@CH,;FY'/Y"M&B@#+TKP]INBR22627
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M1,#+=S/(C@8#+(6+*<<<$5N44 9,/AG1X-(N-*2R4V=R29TD=G:4GNS,2Q/
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%>/?M!?\@+1_^OE__0:]AKQ[]H+_ ) 6C_\ 7R__ *#0".W^&W_).="_Z]A_
M,UU5<K\-O^2<Z%_U[#^9KJJ "BBB@ HHHH **** "OGKP]_R<G-_U_7G_HJ2
MOH6OGKP]_P G)S?]?UY_Z*DH&?0M%%% @HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "O'OV@O\ D!:/_P!?+_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !7CW[07_("T?\ Z^7_ /0:]AKQ[]H+_D!:/_U\
MO_Z#0".W^&W_ "3G0O\ KV'\S755ROPV_P"2<Z%_U[#^9KJJ "BBB@ HHHH
M**** "OGKP]_R<G-_P!?UY_Z*DKZ%KYZ\/?\G)S?]?UY_P"BI*!GT+1110(*
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ KQ[]H+_D!:/_U\O_Z#7L->/?M!?\@+1_\ KY?_ -!H!';_  V_Y)SH
M7_7L/YFNJKE?AM_R3G0O^O8?S-=50 4444 %%%% !1110 5\]>'O^3DYO^OZ
M\_\ 14E?0M?/7A[_ ).3F_Z_KS_T5)0,^A:***!!1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>/?M!?\@+1_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH *\>_:"_Y 6C_ /7R_P#Z#7L->/?M!?\
M("T?_KY?_P!!H!';_#;_ ))SH7_7L/YFNJKE?AM_R3G0O^O8?S-=50 4444
M%%%% !1110 5\]>'O^3DYO\ K^O/_14E?0M?/7A[_DY.;_K^O/\ T5)0,^A:
M***!!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %>/?M!?\ ("T?_KY?_P!!KV&O'OV@O^0%H_\ U\O_ .@T CM_
MAM_R3G0O^O8?S-=57*_#;_DG.A?]>P_F:ZJ@ HHHH **** "BBB@ KYZ\/?\
MG)S?]?UY_P"BI*^A:^>O#W_)R<W_ %_7G_HJ2@9]"T444""BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\>_:"_
MY 6C_P#7R_\ Z#7L->/?M!?\@+1_^OE__0: 1V_PV_Y)SH7_ %[#^9KJJY7X
M;?\ ).="_P"O8?S-=50 4444 %%%% !1110 5\]>'O\ DY.;_K^O/_14E?0M
M?/7A[_DY.;_K^O/_ $5)0,^A:***!!1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %>/?M!?\@+1_^OE__0:]AKQ[
M]H+_ ) 6C_\ 7R__ *#0".W^&W_).="_Z]A_,UU5<K\-O^2<Z%_U[#^9KJJ
M"BBB@ HHHH **** "OGKP]_R<G-_U_7G_HJ2OH6OGKP]_P G)S?]?UY_Z*DH
M&?0M%%% @HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "O'OV@O\ D!:/_P!?+_\ H->PUX]^T%_R M'_ .OE_P#T
M&@$=O\-O^2<Z%_U[#^9KJJY7X;?\DYT+_KV'\S754 %%%% !1110 4444 %?
M/7A[_DY.;_K^O/\ T5)7T+7SUX>_Y.3F_P"OZ\_]%24#/H6BBB@04444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7
MCW[07_("T?\ Z^7_ /0:]AKQ[]H+_D!:/_U\O_Z#0".W^&W_ "3G0O\ KV'\
MS755ROPV_P"2<Z%_U[#^9KJJ "BBB@ HHHH **** "OGKP]_R<G-_P!?UY_Z
M*DKZ%KYZ\/?\G)S?]?UY_P"BI*!GT+1110(**** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KQ[]H+_D!:/_U\O_Z#
M7L->/?M!?\@+1_\ KY?_ -!H!';_  V_Y)SH7_7L/YFNJKE?AM_R3G0O^O8?
MS-=50 4444 %%%% !1110 5\]>'O^3DYO^OZ\_\ 14E?0M?/7A[_ ).3F_Z_
MKS_T5)0,^A:***!!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %>/?M!?\@+1_\ KY?_ -!KV&O'OV@O^0%H_P#U
M\O\ ^@T CM_AM_R3G0O^O8?S-=57*_#;_DG.A?\ 7L/YFNJH **** "BBB@
MHHHH *^>O#W_ "<G-_U_7G_HJ2OH6OGKP]_R<G-_U_7G_HJ2@9]"T444""BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH *\>_:"_Y 6C_ /7R_P#Z#7L->/?M!?\ ("T?_KY?_P!!H!';_#;_ ))S
MH7_7L/YFNJKE?AM_R3G0O^O8?S-=50 4444 %%%% !1110 5\]>'O^3DYO\
MK^O/_14E?0M?/7A[_DY.;_K^O/\ T5)0,^A:***!!1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>/?M!?\ ("T?
M_KY?_P!!KV&O'OV@O^0%H_\ U\O_ .@T CM_AM_R3G0O^O8?S-=57*_#;_DG
M.A?]>P_F:ZJ@ HHHH **** "BBB@ KYZ\/?\G)S?]?UY_P"BI*^A:^>O#W_)
MR<W_ %_7G_HJ2@9]"T444""BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MMFR**+.U6,FS.6/10O8\\9J.7QU+Y5C%;:-)-J-Q>RV$MH9PODS(A8Y;!!7
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MM--N+C3;NP-TMR@CPP+1[9!EP0BASGC=DC (H D\8>%3X@GTR\CM["ZFL&D
MMM04F&5' # D E2"JD'![\<U13P=//IT.EOI^D:9IT]P9-1@TYG'G1J!LCSM
M7.6^\>.!@9R36C:^-]/NIK8K9WZ6-U-Y%MJ#Q 02N3@ '=N )& 2H!]>15O1
M_$UOK>H7MK:V5ZJ6<LL$MS)&JQ>9&^TH#NR2?O# QCJ0>* .6?P7K;W%I]N3
M2=9MK.$VL$&H2R;0@<E)2NP@R;2%((_ASNY.)]%\':SX92SN=-DTV:[CAFMI
MX)"\4+QM.\J%"JL4*[R,8(YQVS78ZKJEKHVF3:A>N5@B SM4LS$D * .I)(
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MBMQ'* G) +?,Y)X'7%=/;^-+*72I=6FL=0M=.6-98KF:-=MPK$!=BJQ8ELC
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MEY>?8XXYUCW!MC.&.UR-N%(R"3GM3;_Q9INFW=]:SK.9K18/D2/<9FF+!$C
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M&IB6.3.'+%AQQ]>1@'G !E>&-%FCU6*\O](U2VNK>!D6>\U8W29;;N$:F1B
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M-L_O@.H)7W&10!RT.CZ_<>'M+\*7.EK%;V<L"S:BLZ>7)%"ZLI10=X=MBCD
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MUS&T5V2"$98U8X?=@EB%.,@YK1\#6E_IGA6STO4;)K::R00;C(CK*!_&NTG
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M6&$,%R0268G 50,EB>P )K UCQYIEEX6U#5[)I+F2U!3R#;R*RR;25$BE=R
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MW'N!@5G0^%M<71?#BRZ;>";1%EM98;;4%@>X1PO[R.1'& "H^5BN<GI7J-%
M'/\ A72UT^VNYCI][93W4V^1;V]^TROA0H8MN8=!C&3P!70444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MT4%SKEW?>4\?-O&UNRH9!_"2R[O8L!UKT>B@#D_B22/ UV5A\XBXM,1<?/\
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M\ *.U>ET4 >56VB7>MZ=#8W%SX@6_M=.G@AAN]/CAMX7>!HMOF+&H8<\88]
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M%24#/H6BBB@04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !7CW[07_("T?\ Z^7_ /0:]AKQ[]H+_D!:/_U\O_Z#
M0".W^&W_ "3G0O\ KV'\S755ROPV_P"2<Z%_U[#^9KJJ "BBB@ HHHH ****
M "OGKP]_R<G-_P!?UY_Z*DKZ%KYZ\/?\G)S?]?UY_P"BI*!GT+1110(****
M.2L?#^BZMK_B6?4=(L+R9=0C027%LDC!?LEN<98$XR3Q[UH_\(7X5_Z%K1O_
M   B_P#B:-"_Y#'B?_L)I_Z26];E &'_ ,(7X5_Z%K1O_ "+_P")H_X0OPK_
M -"UHW_@!%_\36Y10!A_\(7X5_Z%K1O_   B_P#B:/\ A"_"O_0M:-_X 1?_
M !-;E% &'_PA?A7_ *%K1O\ P B_^)H_X0OPK_T+6C?^ $7_ ,36Y10!A_\
M"%^%?^A:T;_P B_^)H_X0OPK_P!"UHW_ ( 1?_$UN44 8?\ PA?A7_H6M&_\
M (O_ (FC_A"_"O\ T+6C?^ $7_Q-;E% &'_PA?A7_H6M&_\  "+_ .)H_P"$
M+\*_]"UHW_@!%_\ $UN44 8?_"%^%?\ H6M&_P# "+_XFC_A"_"O_0M:-_X
M1?\ Q-;E% &'_P (7X5_Z%K1O_ "+_XFC_A"_"O_ $+6C?\ @!%_\36Y10!A
M_P#"%^%?^A:T;_P B_\ B:/^$+\*_P#0M:-_X 1?_$UN44 8?_"%^%?^A:T;
M_P  (O\ XFC_ (0OPK_T+6C?^ $7_P 36Y10!A_\(7X5_P"A:T;_ , (O_B:
M/^$+\*_]"UHW_@!%_P#$UN44 8?_  A?A7_H6M&_\ (O_B:/^$+\*_\ 0M:-
M_P" $7_Q-;E% &'_ ,(7X5_Z%K1O_ "+_P")H_X0OPK_ -"UHW_@!%_\36Y1
M0!A_\(7X5_Z%K1O_   B_P#B:/\ A"_"O_0M:-_X 1?_ !-;E% &'_PA?A7_
M *%K1O\ P B_^)H_X0OPK_T+6C?^ $7_ ,36Y10!A_\ "%^%?^A:T;_P B_^
M)H_X0OPK_P!"UHW_ ( 1?_$UN44 8?\ PA?A7_H6M&_\ (O_ (FC_A"_"O\
MT+6C?^ $7_Q-;E% &'_PA?A7_H6M&_\  "+_ .)H_P"$+\*_]"UHW_@!%_\
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MZ%K1O_ "+_XFC_A"_"O_ $+6C?\ @!%_\36Y10!A_P#"%^%?^A:T;_P B_\
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M6'_PFGA7_H9=&_\  ^+_ .*H_P"$T\*_]#+HW_@?%_\ %4 ;E%8?_":>%?\
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M ,50!N45A_\ ":>%?^AET;_P/B_^*H_X33PK_P!#+HW_ ('Q?_%4 ;E%8?\
MPFGA7_H9=&_\#XO_ (JC_A-/"O\ T,NC?^!\7_Q5 &Y16'_PFGA7_H9=&_\
M ^+_ .*H_P"$T\*_]#+HW_@?%_\ %4 ;E%8?_":>%?\ H9=&_P# ^+_XJC_A
M-/"O_0RZ-_X'Q?\ Q5 &Y16'_P )IX5_Z&71O_ ^+_XJC_A-/"O_ $,NC?\
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MPFGA7_H9=&_\#XO_ (J@#<HK#_X33PK_ -#+HW_@?%_\51_PFGA7_H9=&_\
M ^+_ .*H -=_Y#'AC_L)O_Z27%;E<E?>(-%U;7_#4&G:O87DRZA(YCM[E)&"
M_9+@9PI)QDCGWKK: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@##\6?\@>W_ .PG8?\ I7#6Y6!XRFBMM CG
MGE2*&+4+%Y))&"JBB[B)))X  [T__A-/"O\ T,NC?^!\7_Q5 &Y16'_PFGA7
M_H9=&_\  ^+_ .*H_P"$T\*_]#+HW_@?%_\ %4 ;E%8?_":>%?\ H9=&_P#
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MO_BJ/^$T\*_]#+HW_@?%_P#%4 ;E%8?_  FGA7_H9=&_\#XO_BJ/^$T\*_\
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M%!^%?^@AK/\ W^B_^-UKG3Y=%\5>$EAU[4[I;QYQ<QSWCR)<8MW8.%)P!GG
MXY'' K*T;[?:^$?"NOMK6J7%]=W=I#/Y]TS1O'(X0J8R=N<'[V-V1G- #?\
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M\'Z-;C6YK6\TL7TZ65WB:1@D0"*[R*4C&XG:A'; QF@"7_A0?A7_ *"&L_\
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M:/\ ]?+_ /H- ([?X;?\DYT+_KV'\S755ROPV_Y)SH7_ %[#^9KJJ "BBB@
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MGS.<Y&<GIC';%>"_\(G\9/\ GYUG_P '2_\ QVC_ (1/XR?\_.L_^#I?_CM
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M;SK=U=E9&P1U!&002"#P>X-> ?\ ")_&3_GYUG_P=+_\=H_X1/XR?\_.L_\
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M_P"#I?\ X[0!]%T5\Z?\(G\9/^?G6?\ P=+_ /':/^$3^,G_ #\ZS_X.E_\
MCM 'T717SI_PB?QD_P"?G6?_  =+_P#':/\ A$_C)_S\ZS_X.E_^.T ?1=%?
M.G_")_&3_GYUG_P=+_\ ':/^$3^,G_/SK/\ X.E_^.T ?1=%?.G_  B?QD_Y
M^=9_\'2__':/^$3^,G_/SK/_ (.E_P#CM 'T717SI_PB?QD_Y^=9_P#!TO\
M\=H_X1/XR?\ /SK/_@Z7_P".T ?1=%?.G_")_&3_ )^=9_\ !TO_ ,=H_P"$
M3^,G_/SK/_@Z7_X[0!]"7EI!?V<UI<IO@F4HZ[B,@^XY%9-MX-T&UM[R&.R9
MA>0-;SO-<22NT3=4WLQ8 Y[$>M>(_P#")_&3_GYUG_P=+_\ ':/^$3^,G_/S
MK/\ X.E_^.T >K^(_"ESJ=^#::9I30^0L FFO)XGVC/RO&@VRJ.RL<=?6MS1
MO#=AHUMIRQ(7GL;+[$DY)!*$J6R,XY* UX9_PB?QD_Y^=9_\'2__ !VC_A$_
MC)_S\ZS_ .#I?_CM 'N%QX2T2YC"/9LI6>6X5XIY(W$DIS(0ZL& 8GD9QTXX
MH;PCH1TI-,6Q\NTCG-PB12O&4DY^964A@>3T/?%>'_\ ")_&3_GYUG_P=+_\
M=H_X1/XR?\_.L_\ @Z7_ ..T >VZGX,T#6)GEOK$R-)&(I )Y$$B@8&\*P#$
M9X)R1VK1CTFQBO6NTMU$[6Z6I8DD&)2Q5<=.K-^=> _\(G\9/^?G6?\ P=+_
M /':/^$3^,G_ #\ZS_X.E_\ CM 'N.G>$]&TF[2YL;:6)H\^6GVF4QID8.V,
ML47J>@J;5]*:^N-/O+>18[NQN!(C-T9#\LB'V*D_B%/:O"/^$3^,G_/SK/\
MX.E_^.T?\(G\9/\ GYUG_P '2_\ QV@#W.U\*Z+9Z?=V,=B'M[S_ (^!/(\S
M2\8&YG)8X'3GCM3+?PCH=K;7MNEFS+>PFWN&EN))'>(@C9O9BP7!/ (KP_\
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M3^,G_/SK/_@Z7_X[1_PB?QD_Y^=9_P#!TO\ \=H ^BZ*^=/^$3^,G_/SK/\
MX.E_^.T?\(G\9/\ GYUG_P '2_\ QV@#Z+HKYT_X1/XR?\_.L_\ @Z7_ ..T
M?\(G\9/^?G6?_!TO_P =H ^BZ*^=/^$3^,G_ #\ZS_X.E_\ CM'_  B?QD_Y
M^=9_\'2__': /HNBOG3_ (1/XR?\_.L_^#I?_CM'_")_&3_GYUG_ ,'2_P#Q
MV@#Z+HKYT_X1/XR?\_.L_P#@Z7_X[1_PB?QD_P"?G6?_  =+_P#': /HNBOG
M3_A$_C)_S\ZS_P"#I?\ X[1_PB?QD_Y^=9_\'2__ !V@#Z+HKYT_X1/XR?\
M/SK/_@Z7_P".T?\ ")_&3_GYUG_P=+_\=H ^BZ*^=/\ A$_C)_S\ZS_X.E_^
M.T?\(G\9/^?G6?\ P=+_ /': /HNBOG3_A$_C)_S\ZS_ .#I?_CM'_")_&3_
M )^=9_\ !TO_ ,=H ^B)HDGADAE7='(I5AZ@C!K!T[P-X<TJY@N+73SYEOCR
M#-<2S"+ P-H=B%_"O%?^$3^,G_/SK/\ X.E_^.T?\(G\9/\ GYUG_P '2_\
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M_P#!TO\ \=H ^BZ*^=/^$3^,G_/SK/\ X.E_^.T?\(G\9/\ GYUG_P '2_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
+"BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>proxy_002.jpg
<TEXT>
begin 644 proxy_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" <4!78# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M.:<?/S_X']:W"7EY?\$V_B1_R3K7?^O5OZ5XG.?!VJ?#_3-,TBS\_P 7N(U
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MVO9])F+26JGYG0D'C\B/7FL#Q'/XB\5^*_".H#PQJ5EI]I?(6\Z(F0$LI9F
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MP^N[:PM)[JX:6(B*",NQ <9X'-<O\1]%UR"#0]:T&QNIKX6+:?<I!"SN$:/
M) &1C+<]CBDFU>W73\-/QL-J]E_6_P#E<XJ\C;6/$%GXOEW?\3#Q"L-OGIY*
M$8/\A^%>[>(+KQ/'<06_AW3[";>C-)<7LK*D9R,#:O)SS^5<%XB\*7NG>'?
MFFV5C<7!LKV)[DP1,X0\%V; X&2>35GQQIVJ7'C>&?4](U36?#/V<*EII[GB
M7/)=0PS^/&,>AJK67*NC?X)?F*]WS>7ZO]#8T3Q?K^K3ZYH4NGV-KXCTU%9
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M22?<2XN$C+?0$C-69KRVMK;[3/<0Q0<?O7<*O)P.3QR2/SH FHKE_$GCO1=
MTR]F34=/N;VV&/L0O$61FR!C')!&?2M[3]2LM5M1<V%Y;W4)./,MY5D7/<9!
MQFA:Z@]"U156^U*PTN'SM0O;:TB)QON)5C7/U)%$.IV%S8&^@O;:6S"EC<)*
MK1@#J=P.,"@"U152#5=.NKIK6WO[66X6,2M%',K.$/1B <X.1S[TRSUK2M0N
M9+:RU.RN9XO]9%#.KLGU .10!>HHK.&OZ,=0^P#5[ WI.W[/]I3S,^FW.: -
M&BH8KNVFGF@BN(I)H"!+&K@M&2,C<.HR.>:8=0L@;@&\MP;;'GCS1^ZR,C=S
M\O'/- %FBJ.GZUI6K%QINIV=YL^_]FG63;]=I.*YGQ/>7=KX$\2W$.N"ZGB:
M7RI;;;&UKR,190YW+ZG!YH&E=V.THJA/JVGZ98PS:EJ%M:(RC#W,RQ@G'JQ%
M9'B[4U?X?:OJ&EWP;%H[PW-K+G!QU5E/\J'H*.MO,J:QX/UR_P!1N9[#QGJ%
MA;7+9>V6)9 HP!A&)!3IVK5\*^%;#PCHXT^P,CAG,DLLIR\CGJ3^53V6N:6[
MV]@VJ6;:@8E)MS<*92<#^'.:S;FZN%^)EA:">46S:7-(T(<["PD0!BO3.">?
M>G:SY5_5K_Y"O=7_ *Z?YG3T51N=;TJSO8[.ZU.R@NI/N02W"J[?12<FKU(8
M451U#6])TDH-2U.RLR_W1<W"Q[OIN(JIK_B73]!T";59KFV*B)G@5YU07#!2
M0JD]2<=LTF[*XTKNQLT5FZ'K=EKVF0WEG=6T^Y%,JP3+((W(!*DCH1GO6E5-
M6=F2G=704444AA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MS1YY4EE*,,C."/<5G^#--@D\6ZIK=C)=7%D]M';K>W1):[D#%F<$@94#:HP
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M%!51Q]<GWK3JY.\FS."M%(****DH**** "BBB@ HHHH **** "BBB@ HHHH
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M.% '!5Q^%'?^O/\ 5!_7Z?F=917#>#O$VI2-XAM/$<Z&[TR03DA @6!TWJ.
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M>.:[DFN8Y&D",&"($)ZD#);'':NRHH6@NAQ&H^%+WQ1?:A?:GNLY;?\ =:.
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MBKM%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 445YMJ>B_%B75KR33O$^
MDPV+SNUM%)&I9(RQV@_N3R!@=3]30!Z317E?]A?&3_H;-&_[]+_\8H_L+XR?
M]#9HW_?I?_C% 'JE%5=,CO8M)LX]1F2:^2!%N98QA7D"C<1P."<GH/H*XKQ)
MI/Q+N=?N9O#_ (ATRTTMMGD0SQJ77Y0&R3$W5MQZGK0!W]%>5_V%\9/^ALT;
M_OTO_P 8H_L+XR?]#9HW_?I?_C% 'JE%97AN#6;;0+:'Q!=PW>J+O\^:$ (W
MS$K@!5Z+M'0=*Y7Q)I/Q+N=?N9O#_B'3+32VV>1#/&I=?E ;),3=6W'J>M '
M?T5Y7_87QD_Z&S1O^_2__&*/["^,G_0V:-_WZ7_XQ0!ZI165X;@UFVT"VA\0
M7<-WJB[_ #YH0 C?,2N %7HNT=!TK \7Z;X_O-6BD\*ZY86-B( LD5P@+&3<
MV3S$W&"HZ]NE ':45Y7_ &%\9/\ H;-&_P"_2_\ QBC^POC)_P!#9HW_ 'Z7
M_P",4 >J45@>$+3Q-9Z3+'XJU&VOKXSEHY;=0%$>U<#A%YR&/3OUK*\7Z;X_
MO-6BD\*ZY86-B( LD5P@+&3<V3S$W&"HZ]NE ':45Y7_ &%\9/\ H;-&_P"_
M2_\ QBC^POC)_P!#9HW_ 'Z7_P",4 >J45@>$+3Q-9Z3+'XJU&VOKXSEHY;=
M0%$>U<#A%YR&/3OUK*\7Z;X_O-6BD\*ZY86-B( LD5P@+&3<V3S$W&"HZ]NE
M ':45Y7_ &%\9/\ H;-&_P"_2_\ QBC^POC)_P!#9HW_ 'Z7_P",4 >J45RO
M@RP\967VW_A+M6L]0W^7]F^S(%V8W;\XC3KE?7H>E'C.P\97OV+_ (1'5K/3
M]GF?:?M*!M^=NS&8WZ8;TZCK0!U5%>5_V%\9/^ALT;_OTO\ \8H_L+XR?]#9
MHW_?I?\ XQ0!ZI17*^#+#QE9?;?^$NU:SU#?Y?V;[,@79C=OSB-.N5]>AZ4>
M,[#QE>_8O^$1U:ST_9YGVG[2@;?G;LQF-^F&].HZT =517E?]A?&3_H;-&_[
M]+_\8H_L+XR?]#9HW_?I?_C% 'JE%<KX,L/&5E]M_P"$NU:SU#?Y?V;[,@79
MC=OSB-.N5]>AZ5;\7VGB:\TF*/PKJ-M8WPG#22W"@J8]K9'*-SDJ>G;K0!OT
M5Y7_ &%\9/\ H;-&_P"_2_\ QBC^POC)_P!#9HW_ 'Z7_P",4 >J45Q?A#3?
M']GJTLGBK7+"^L3 5CBMT 82;EP>(EXP&'7OTK5\7VGB:\TF*/PKJ-M8WPG#
M22W"@J8]K9'*-SDJ>G;K0!OT5Y7_ &%\9/\ H;-&_P"_2_\ QBC^POC)_P!#
M9HW_ 'Z7_P",4 >J45Q?A#3?']GJTLGBK7+"^L3 5CBMT 82;EP>(EXP&'7O
MTK?\20:S<Z!<P^'[N&TU1MGD33@%%^8%L@JW5=PZ'K0!JT5Y7_87QD_Z&S1O
M^_2__&*/["^,G_0V:-_WZ7_XQ0!ZI17 >&])^)=MK]M-X@\0Z9=Z6N_SX88U
M#M\I"X(B7HVT]1TKJO$D&LW.@7,/A^[AM-4;9Y$TX!1?F!;(*MU7<.AZT :M
M%>5_V%\9/^ALT;_OTO\ \8H_L+XR?]#9HW_?I?\ XQ0!ZI17 >&])^)=MK]M
M-X@\0Z9=Z6N_SX88U#M\I"X(B7HVT]1TKJO$D&LW.@7,/A^[AM-4;9Y$TX!1
M?F!;(*MU7<.AZT :M%>5_P!A?&3_ *&S1O\ OTO_ ,8H_L+XR?\ 0V:-_P!^
ME_\ C% 'JE%<!X;TGXEVVOVTWB#Q#IEWI:[_ #X88U#M\I"X(B7HVT]1TKM=
M3CO9=)O(].F2&^>!UMI9!E4D*G:3P> <'H?H: +5%>5_V%\9/^ALT;_OTO\
M\8H_L+XR?]#9HW_?I?\ XQ0!ZI17FVF:+\6(M6LY-1\3Z3-8I.C7,4<:AGC#
M#<!^Y')&1U'U%=_J<=[+I-Y'ITR0WSP.MM+(,JDA4[2>#P#@]#]#0!:HKRO^
MPOC)_P!#9HW_ 'Z7_P",4?V%\9/^ALT;_OTO_P 8H ]4HKS;3-%^+$6K6<FH
M^)])FL4G1KF*.-0SQAAN _<CDC(ZCZBO2: "BO*_["^,G_0V:-_WZ7_XQ1_8
M7QD_Z&S1O^_2_P#QB@#U2BO*_P"POC)_T-FC?]^E_P#C%>J4 %%>5_V%\9/^
MALT;_OTO_P 8H_L+XR?]#9HW_?I?_C% 'JE%>5_V%\9/^ALT;_OTO_QBO5*
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M&5[]B_X1'5K/3]GF?:?M*!M^=NS&8WZ8;TZCK7*_V%\9/^ALT;_OTO\ \8H
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MY._)^YG.,=.M5-0T*PU.=9[A)TG5=@EM[F2!RO7:6C921['BE_7Y_P"8^_\
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M ,+^\.?] O5?^^8__BZ/^%_>'/\ H%ZK_P!\Q_\ Q==E_P *\\'_ /0NZ?\
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M&_\ "_O#G_0+U7_OF/\ ^+H_X7]X<_Z!>J_]\Q__ !==E_PKSP?_ -"[I_\
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M_0+U7_OF/_XNC_A?WAS_ *!>J_\ ?,?_ ,779?\ "O/!_P#T+NG_ /?H4?\
M"O/!_P#T+NG_ /?H4 <;_P +^\.?] O5?^^8_P#XNC_A?WAS_H%ZK_WS'_\
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MZK_WS'_\779?\*\\'_\ 0NZ?_P!^A1_PKSP?_P!"[I__ 'Z% '&_\+^\.?\
M0+U7_OF/_P"+H_X7]X<_Z!>J_P#?,?\ \779?\*\\'_]"[I__?H4?\*\\'_]
M"[I__?H4 <;_ ,+^\.?] O5?^^8__BZ/^%_>'/\ H%ZK_P!\Q_\ Q==E_P *
M\\'_ /0NZ?\ ]^A1_P *\\'_ /0NZ?\ ]^A0!QO_  O[PY_T"]5_[YC_ /BZ
M/^%_>'/^@7JO_?,?_P 779?\*\\'_P#0NZ?_ -^A1_PKSP?_ -"[I_\ WZ%
M'&_\+^\.?] O5?\ OF/_ .+H_P"%_>'/^@7JO_?,?_Q==E_PKSP?_P!"[I__
M 'Z%'_"O/!__ $+NG_\ ?H4 <;_PO[PY_P! O5?^^8__ (NC_A?WAS_H%ZK_
M -\Q_P#Q==E_PKSP?_T+NG_]^A1_PKSP?_T+NG_]^A0!QO\ PO[PY_T"]5_[
MYC_^+H_X7]X<_P"@7JO_ 'S'_P#%UV7_  KSP?\ ]"[I_P#WZ%'_  KSP?\
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M_P 779?\*\\'_P#0NZ?_ -^A1_PKSP?_ -"[I_\ WZ% '&_\+^\.?] O5?\
MOF/_ .+H_P"%_>'/^@7JO_?,?_Q==E_PKSP?_P!"[I__ 'Z%'_"O/!__ $+N
MG_\ ?H4 <;_PO[PY_P! O5?^^8__ (NC_A?WAS_H%ZK_ -\Q_P#Q==E_PKSP
M?_T+NG_]^A1_PKSP?_T+NG_]^A0!QO\ PO[PY_T"]5_[YC_^+H_X7]X<_P"@
M7JO_ 'S'_P#%UV7_  KSP?\ ]"[I_P#WZ%'_  KSP?\ ]"[I_P#WZ% '&_\
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MKSP?_P!"[I__ 'Z% '&_\+^\.?\ 0+U7_OF/_P"+H_X7]X<_Z!>J_P#?,?\
M\779?\*\\'_]"[I__?H4?\*\\'_]"[I__?H4 <;_ ,+^\.?] O5?^^8__BZ/
M^%_>'/\ H%ZK_P!\Q_\ Q==E_P *\\'_ /0NZ?\ ]^A1_P *\\'_ /0NZ?\
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M  KSP?\ ]"[I_P#WZ%'_  KSP?\ ]"[I_P#WZ% '&_\ "_O#G_0+U7_OF/\
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M_A?WAS_H%ZK_ -\Q_P#Q==E_PKSP?_T+NG_]^A1_PKSP?_T+NG_]^A0!QO\
MPO[PY_T"]5_[YC_^+H_X7]X<_P"@7JO_ 'S'_P#%UV7_  KSP?\ ]"[I_P#W
MZ%'_  KSP?\ ]"[I_P#WZ% '&CX_>',C.F:KC_<C_P#BZ[GPSXST+Q; SZ3>
MB21!F2!QMD3ZJ>WN,BJLOPW\'31/$WAZR"L,$HFT_@1R/PKQ;QKX:NOA5XMT
M_6-"N)?LDK%X=YR4(QNB8]U(/'<C/IF@9])454TK4(M6TBSU&#/E74"3(#U
M8 _UJW0(**** "BBB@ HHHH **** "OG_1?^3EI?^ONY_P#1+U] 5\_Z+_R<
MM+_U]W/_ *)>@#Z HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ KR']H#_D6M*_Z_#_ .@&O7J\A_: _P"1
M:TK_ *_#_P"@&@#N?AZ2?AYH.3G_ $./^5=+7,_#S_DGF@_]>:?RKIJ "BBB
M@ HHHH **** "BBB@ KY_P!%_P"3EI?^ONY_]$O7T!7S_HO_ "<M+_U]W/\
MZ)>@#Z HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "O(?V@/^1:TK_K\/_H!KUZO(?V@/^1:TK_K\/\ Z :
M.X^'G_)/-!_Z\T_E735S/P\_Y)YH/_7FG\JZ:@ HHHH **** "BBB@ HHHH
M*^?]%_Y.6E_Z^[G_ -$O7T!7S_HO_)RTO_7W<_\ HEZ /H"BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M><<]/PJW\7_#&L^*-"T^VT:S^U30W7F.OFHF%VD9RQ'<U0M=8^,$0@A;PKI
MB7:I;S5SM'&?]?Z40Z^O^0I=/0Q_C8]S'XM\*/91K)=*S&%'Z,^]-H/(XSCN
M*R/$.H^(_$WBK1_#7CV./1K224.BVD882,?E'S;V]QD$XSTKN/B-X4UO7O%O
MAB^TVR\^WLI0UP_FHNP;U/1B"> >F:L?%GP9?>*='LY](A\W5+*;,:AU0LAZ
M@%B!P0#U[4HZ)-]W_P .-ZO3L<W\=H([71_#EO"H6**9D11V 50!47QG*_\
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M10[?.V<_O5[Y'05Z=XD\,OXT\%IIFJ$6E[(B2EHQN$,P'.!DY&21UZ=Z\_\
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MX.?N$^W6E89UM%%%( HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\A_: _Y%K2O^
MOP_^@&O7J\A_: _Y%K2O^OP_^@&@#N/AY_R3S0?^O-/Y5TU<S\//^2>:#_UY
MI_*NFH **** "BBB@ HHHH **** "OG_ $7_ ).6E_Z^[G_T2]?0%?/^B_\
M)RTO_7W<_P#HEZ /H"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HKRKXC_%'4_"N
MOII>BVEI<M'!YUTT\;OLR>/NL,<<G/J*]$T+5H==T&QU2#&RZA63 _A)'(_
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M!M45D>(I]87PW<3>'H$FU,JIMXY"H!R1G.2!TSWJ3P])JLN@6;ZY$D.IE/\
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M7D/[0'_(M:5_U^'_ - ->O5Y#^T!_P BUI7_ %^'_P! - '<?#S_ ))YH/\
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MXQN-+\]F-K;6L9"  D?, PXR#USZUZ;XET2/Q'X<O](E?8+J(H'QG:W53^!
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M/NQ8&VVBZ,+>43Y0&-^,=>.M9TVF>)?A]\1-3UK2]#GUC2M3)9DMLEE+-NZ
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBFR2)#$\LKJD: LS,<  =2: '45YC=_&.&XO9K;PUX<U+7?).'D@4A
M?J,*QQ]0*U_"OQ.TKQ)J;:3/;7.F:JN?]%NA@L0,D ^OL0#0M=@>FYV]%%%
M!16?::YI=_J-QI]I?03W=L,S11-N,?.,-CH<]NM:% !117!Z[XUU+3/BAHWA
MF&"T:RO8U>21T8R DN."&Q_".QH6K2[AT;['>4444 %%%% !116)XI\2P>%M
M)%_-:75WOE6&.&V0,[,V<=_:ANP)7-NBO+D^,JVFI0V^O^%]3T>WF;$<\X/(
M]2I5>/H377^+O&>F>#]'CU"]WS"9@D$4."TAQGC/&,=Z'HK@M78Z*BO,8OC#
M]EN+;_A(/"^I:1:7+8AN9,LI'J057],UZ:K*Z!E(*L,@CN*=NH"T45R/BOQS
M_P (UJ$&G6VAZCJM[-%YRQVD>X!<XY(R>OM4W&E<ZZJVH0376G7-O;7!MYY8
MF2.8#)C8C ;\#S7$^%?BG:Z]K@T/4=)NM'U1@=D-P<AB!G&2 0<<\BM/QAX\
ML_"<MK9+:3ZCJEW_ *BRM_O,.F3UP,\=":;6GJ"W]#E[WP;\2M4M'TJ]\7V+
M:;(I221(<2NOH0%''_ N:[KPIX9M/"7A^#2;-F=8\L\C#F1SU8_YZ5B>%/B+
M;^(=7ET6^TRYTC6(UW&UN>=P[X. <XYZ#CFH/$/Q(FTK6+O2M,\+ZKJ]S:;?
M-:!#Y8)4,.5#'H1VIWM\Q6O\CO**X[P5\1-/\9RW%JEM-9:A;#,EM-R<9P2#
MWP>#P*S-9^*%Q9:E>V>E^$M7U0V<IBFFC0B,$=<%5;]<4GH"U/1**Y7P5X\T
MWQM:3O:1RV]S;D":WEQE<]"".HX-=53:L%PHK@?&_P 5M)\'S"SBB_M'401O
MMXY=@C'^TV#@^V,_2NMT351J_A^QU5HA MU;I.4+[MFX9QG SCUQ26JOT!Z.
MQHT5YC=_&.+S[J72O#FH:EI5FQ6XU"+A%]P-IX^I%=YH.NV/B31H-4TZ0O;S
M#C<,,I'52.Q%"U5P>CL:5%07EW;Z?937EU*L5O ADD=NBJ!DFO-#\:(PIOQX
M7U0Z")/+_M'MG./NXQ_X]1UL%M+GJ5%94_B/2K?PV?$#W2_V;Y(F$HYRIZ8'
MKVQZUP4?QGC0PWE]X8U.TT6=]D6H-R&]\8Q^3'H:.M@Z7/4J*9#-'<01SPNL
MD4BAT=3D,",@BGT %%>8K\9+)O'?_"._V;_HWVK[+]N^T\;LXSLV]-W'WO>O
M3J%JE+H#T=@HKR6/XWQ_\)3_ &//H)BA%[]E:Z^UY"_/MW;=GXXS7J5]>1:?
MI]S>SG$-O$TKGV49/\J+^[S=!V][EZEBBO+?"/QC/BKQ/::-_8!M1<AR)C=[
M\;5+=-@STQUKU*FTTKBZV"BO./%/Q2N] \7/X>LO#,VJW 177R9R'?*[CA!&
MQX%6_#?CS7M;U-[6]\#ZEI<2PO()YR^TL!PO,:\GZU*=U<;5M#O**\AO_C+K
M>E6XN-1^'VH6<);:)+B9XU)],M"!G@UM>&_B-KNO:O96LW@;4;*SN>?MKL[1
MJNTD-DQ $'COWJDK[">AZ)1112 **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\A_: _Y%
MK2O^OP_^@&O7J\A_: _Y%K2O^OP_^@&@#N/AY_R3S0?^O-/Y5TU<S\//^2>:
M#_UYI_*NFH **** "BBB@ HHHH **** "OG_ $7_ ).6E_Z^[G_T2]?0%?/^
MB_\ )RTO_7W<_P#HEZ /H"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KA/C#>S67
MPWU#R&*F9HX6(_NLPS^8X_&N[K$\7^'T\4>%K[2&<(TZ?NW/17!RI/MD"IFK
MQ*@[2,GX6Z7;:9\/=*^SHH:YB%Q*X'+,W//T&!^%<-\<+=-+UCP]X@M,1WZR
ME2R\%MA5E)^F2/QIGAGQ[?\ PZTK_A'_ !;H>HA;1BMO<0(&#*3G&6(!&3P0
M?;'%)+;ZQ\6_&>GWDFEW&G^'-/.X-<K@R<@G'J6P!QD #K6C]ZHI+:]_E_6A
M$?=BU+L_F=/XZ\>:KIVL:;X;\-VT4FLWRJY>496,'../7@G)Z 5>TO2OB(FG
MW\.I^(=/>YEA'V6>*!<PR;N<C8 1CCI7-?$/3=4T#XA:5XVL;"6^M(4$=Q'$
MI+)C(/T!5N#TR*[#PG\1-+\8WTEKIUI?QF*+S'>XB"J#D#;D$\\U,=5YZC>C
M7;0\G\":;XKN/'?B.+3=>@M;V&8_;9FMU83GS#G *G;DY/&.M=YXF\;:]=>,
MQX/\(Q6WVY$W7-W<C*Q<9X'L".<'DXQ7*:;KJ?#?XF>))==L;P6^HRLUO+#'
MD,"Y88R0#P?7@BM#6H=0\!?%.?Q=_9US?:-J$969K=-S19 SGTY4'G (/6A:
MJ%]K?C;8<E:4K;]/334N2^,/&'@37-/M/&,EGJ.FWK;%O;=-C(<C.< #C/3'
M3H:R/B1>7=E\9] N-/MA=78MHQ#$3@.Y:0#)],FF^)=2N/B_JVDZ;H6FWL>E
MV\IDN+VXCVJ,X!P>1P,\9R2>E.^(LUY8?&3P_/IUHUW<6]K&Z6Z_>D"M(2![
M[0::WBY=W]U@Z2MV_&Y>U[Q/\0_ =U9ZEKUQIVH:9<R!)(;>/:(CC)4' .<9
MP23TK?\ &GCN]L[[2-$\."V.HZH@F6>Y/[N&,]&/Y'\NAKC/'GBR7XD167AK
M0-'U$3BX66X^TP[/+." #@G &223CI5SXC>"WM-2T'6&TJ;5]+LK6.SO;:%F
M#[4SAAM(/?\ 3GK2Z*_?\+?YAUTWM^-_\C1?Q;XJ\':SID?B+5=,UG3+Z40O
M-;*J/ Q]E X_ Y /2I_'OCC6O#7Q TJPL&,UI<6I/V(1H?.F8NJ#<1N'S;>A
MKG--A^%^K:E:6>D^$-6N+B694?YYPMODC)<^8<8Z_A6IXY4?\+R\(+@$!(^#
M_P!='II7<4^_X6%>RD_+]4>@>$(O%":=-)XJGM9+N67?'';@!8DP/EX'/.>Y
M^M= 0#C(!QR/:EKB/BAXQN?!OAE;BRB5KNZD\B)VZ1'!.['?IQ4RE;4<5<Y#
MXRZDFOZEI/@W3$%QJ+7 DDV\^62" #Z<$D^@ K3^+FA6R^"M-N7U*&VN=)*B
M S9(G.T J ,Y8[0>G;GCFN"\ >./"OA>2?5-5M]6OM=N23)<"*-E0$\A27!)
M/<UUWQ1MKWQ5X?\ #GB;2+&>[LHCY\EH4R^UMI!95S_=(.,XS3M:*]4V^W_#
M G>7R:MW_P"'.7USQK/X_;0M%\0V\>A6;2K/+=R!R)N, H"OR@Y/<CWXKZ&@
MC2&".*+_ %:*%7Z <5X3XX\70_$?2++0]"T#4)-06=68R0@>1P05R"<=>IP,
M"O0-8\6?\('IOAO1Y;234;^ZC2V54E"Y90JYR0>I-4MK=W]_]?<2]UZ?<=U2
M':N7.!QRQ]*!G R,'N*\7^-/CF^L+D>%[,M;Q30K)<SJ<LZ,2-@]!QSZ]*AN
MVA25R.WN%\=_'6'4-,7=I^D(!)<J.'V[L'/NS8'J!FK=H_V_]I*Z\\;A9VQ$
M0/\ #^Z7_P"+;\ZK> OB)X*\/6EGH6F:?JYGN9422XD@B!DD8@9;$G YZ=A5
MSQA;WO@WXIVWC2.QN+K2YXO+NS NYD.W:<CMP%(SQP:I6BX]E?7S:$_>4N[M
M]R9'X^;[!\;/"5Y",2R^7&Y'<&0K_)C7K=Y=VNFV4]Y=2)#;Q*9)9&X  '4U
MY%IKW'Q)^*EAXAMK&Z@T/2XQLEN$V^8P)(QVR6(Z=AS7.?%+QQ+K'BF3P[=/
M/:Z)93[+@6X#R3$=3@D#Z#/OS4ZJ*CU=_NN5HY-]$D=%\+DF\1_$7Q!XPCA,
M-@^Z*(8QN+%?U"J"?<UZOJ^JV6@Z3<ZE?2+#;0*7<^I]!ZDG]37 ^ _B-X3N
MKC3_  MH.FZC; JPB\Z*,+PI8EB')).#SCK7F_CGQRGB?Q@;#6#=6^@6%PR&
MWM K22%206.2!D_H#WIRZ1C_ %YB6K<I?UY';?!>RN;[4_$'BF2'R+>_F*PH
M.ARY9L>PR!^=>OUP'@7XB>&M>NHO#^AZ??6BP0%D66)%0*N!CY7)SSZ5W]4^
MB6Q*U;;W/'OBKX0T30O!>JZE862QW=[>1O)(>2,MR%]!GG%;\ES)9_ 59HB5
M<:*H!';,8']:9\;?^2<3_P#7Q%_.M71-,&M?".QTPMM^U:2D0;T)CP#^=9V_
M=S2\OR+O[T7Z_F9/PDLX&^%$",@*W)G\T8^]EBO/X 5S'PAFU9_ 'B6ST=\7
MT4I-H6VX$C+_ +7'\(ZU6\->-KOP'X8NO"FJ:-J']KQ/*MFL<65DW<]>X!).
M0#D5T_@'3;GX>_#&_P!5U.U<W3;[R2W)VL%  "GT.!G\:TDTW*72R_0E)I*/
M6_\ F4O&T_B2S^"=PGB.4-JLLZQS,FP H9,C[@ Z "MB*R@_X4'Y&P;#HIDQ
MC^+9OS^?-.OYF^*GPHNI;.U-O-<9,,3N&^>-\@9XZXQ^-<0OCNZ3X=GP4=$U
M/_A(?LYLA%Y/&S[N[U^[QTZU$KVG'J[?D5&UXRZ*YBWVIW!^ &F6VX[#JC0G
MGJHW.!^?\J]0\<6%NOP3FMP@$<%C 8QZ%=F*Q]2^'-\?@K;:)%'OU6V87AB4
M_><DED'OM8CZBL+5O'5WXE\"P>#K/1=2.O2)%;W"-#@*%(R>N1G'<#'-.>O-
M%;W7Y(F&CC)[:_FW^1Z1\++J2[^&NBR2$EEB:,$^BNRC] *T?&VO#PWX/U'4
M]P$L<16'/>1N%_4U/X4T8^'O"NFZ4Q#/;0A7(Z%^K8_$FO,_C'=SZ[KVA>"[
M!LRW$@FEQS@GY5S[ ;B?PIU?>DTNK"EHKOIJ<KI_A![[X)7.MH&-]%>M>HX^
M\47Y6Y_!C^%>X>#-=7Q)X1T[5,@R2Q!90.TB\-^H-<!#\'-=M;#[#;_$+48K
M0*5%O'$ZQX/4;1-C!R>U5?@KJ$^DZMK7@^_.V:WE:6-3ZJ=KX_\ '2/QIIIM
MI>J^6C$TTD_ZUU.*31?[7T_X@2QKF>QO%NHSW 627=_XZ3^5=_XR\7F^^"EC
M<1/F[U98[4A>26'^L_\ 02/QJO\ ":WCN_$OCNWF4-%+.4<'N"\H-<EX0TB_
MN_B)I_A.\):RT.]GN-I] 0<_0E5_[Z-3%748/9J+^Y:_@7)V;GV;_';\3;T;
M1UT#XU^'-+4 &WTU5?'=_)<L?S)KW>O']0_Y.3TW_KT_]I/7L%.]X)^OYLBU
MI->GY'@OB[Q!:>%_CTFKWL<TEO! NY85!<[HBHP"0.I]:](\(?$K1O&NHSV6
MFVU_%+#%YK&YC101D#C:QYYKS?Q=X@M/"_QZ35[V.:2W@@7<L*@N=T148!('
M4^M>@^%?BIH?B_6AI>GVFHQ3F-I-UQ&BK@=>CD_I2IZP2]?S95323?I^2,GX
M[_\ (A0?]?T?_H+UW/A?_D4]'_Z\H?\ T 5PWQW_ .1"@_Z_H_\ T%Z[GPO_
M ,BGH_\ UY0_^@"B'PR]5^03WCZ/\S6HHHH$%%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%>0_M ?\BUI7_7X?_0#7KU>0_M ?\BUI7_7X?_0#0!W'P\_Y)YH/_7FG\JZ:
MN9^'G_)/-!_Z\T_E734 %%%% !1110 4444 %%%% !7S_HO_ "<M+_U]W/\
MZ)>OH"OG_1?^3EI?^ONY_P#1+T ?0%%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MQ7P%=S_$+XAP^(;N-A!H]C'$H;H9B,$_F7/X"O;*=K+7^ET_S)O=_P!;]?\
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MJE]!:1SV;NL:P(P4X0-SEB>OO6)X>^)_BCQ/9V<.DZ%;7=^9";V50R001[L
M<M]X@$_>_ U4^#/_ "3OQ'_UUD_]%"M+X"(H\%7KA1N:_8$^N$3%7;WGY),A
M_#\VB_?^/->U3Q)>Z)X,TBVO'L#MN;N[D(C5NF  1W!'7L>,"M'PAXWNM8UF
M^\/ZYIJZ;K5FH=HT?<DB<<J?Q'<]:\H@TC3-$\=:WIWBK6-8T99YS-:W%G+Y
M<<REB<L=I[$<]N0:[;P/HW@V7Q=<W.@^(=7U34(;9EEDN) R;6^7&XH"3Z8.
M.*F/PI^7X_\ #Z%3T;7F23_$GQ!KWB"[TOP1H=O?1VC;9;NZ<A#SCCYEP.#C
MG)]*C^(=[XSF^';-<:9I]O%) W]IH9"SQ8<!?+(;!R.>_6N?^''B&Q^'6JZU
MX?\ $Q:RE:8/'.T;%7QD=@>",$'IR:[[Q=J-KXK^%.KWFBNUW!+ VQE1@6V-
M\V 0#V/:IG_#NM=AQ_B6VU,7X2WGB.'PO9G4(-.B\.16TCQ7"L?.R')^;YL8
M^]V["FP?$;Q9XHGN9/!OAJ"XT^W?8;B\EVF3'8#<N"?QQQFJ_@+6-,\0_"\^
M$;2]"ZPUC<1F$HP*Y)P<XQCYAWJC\,_&^C^$-!NO#_B21]-OK.X=BLD+'<#C
M^Z#S_,8Q6D]9O\/,B.D5IU^X[;P1X^7Q3<7FF7UBVG:S9$^?;,V00#@D'V/4
M>XZUREC\5/$>J2ZAINFZ);7VL1W;Q0QQ*RQQPKQOD);UP.HJ+X>I-XF^*>M^
M,+:"2+2F5HHG==OF'"@?HN3Z9%/^"R+_ ,)%XQDVC>+E1GVWR4DKM7[7_$;T
M3MW_ $-C7_B%K=OXDL_"VB:3:W&N20*\YN),11N5W$#!&0!SG/YUUOAFZ\17
M-G-_PDFGVMG<H^U/LTFY)%Q][J2.>,&N)^(%I\/]0UV0:UJTFEZW;Q*PG@+*
M^WJO8@GZ<T?!;6-;U33=334+JXO+""55M+JXSN?KD9/)'W3[9Q1'5/\ KKT"
M2M;Y?D>I4444@"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M*\A_: _Y%K2O^OP_^@&O7J\A_: _Y%K2O^OP_P#H!H [CX>?\D\T'_KS3^5=
M-7,_#S_DGF@_]>:?RKIJ "BBB@ HHHH **** "BBB@ KY_T7_DY:7_K[N?\
MT2]?0%?/^B_\G+2_]?=S_P"B7H ^@**** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MG_T2]?0%?/\ HO\ R<M+_P!?=S_Z)>@#Z HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M>SSTVD;-PRO)&#D>E6Z\]L]2OK7XC>*K;3=,^W7+BU<^9,(8T41X^9\,<G/
M /?I75Z!KAUJ&Z6:T:SO;.8P7-NSA]CX!&&'W@000<"A:I,'HVC7HK.U;0-)
MUZ.)-5T^"\6(DH)EW;2>N*\\\->'O#MCH>OZQ)H=I/-INHWCPY7! B.54'G&
M,<>E*^]^@[7M;KH>J45B7/B'[/X*?Q%]EW;;'[9]G\S&?DW;=V/PSC\*AO\
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M2>:#_P!>:?RKIJYGX>?\D\T'_KS3^5=-0 4444 %%%% !1110 4444 %?/\
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MKJ+I<9M(])FV_:Y&=O.90V615VXP0 ,ENYXKH%4*H50  , #M3O>[?5_\/\
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MTUIJ6L,,#5;Z2YB'_3( )&?Q50?QIOCC7M-L-"O],FN1_:%Y9R);6J@M),S
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M2O#NFZ?.R--:VL<+LA)4E5 .,@<<54U#1KB[\7:-JT;Q""QBN$D5B=Q,@4#
MQCL<Y(K63]]M=_\ /_,B/PV?;_(Q?[0M/%7C?1KC1YA=6>EI/+<747,>YUV+
M&&Z$]20.F!5?PWKNG>$=/GT/7KE;&YMKF9HVF! N8W<NKH<?,?FP0.<BN^HJ
M-M%_6MQ[[GE.HP3OX1U?5IH)+>/4]<MKB"*12K",2Q(K$'D%MN<>XKJ;3_DJ
M^I_]@BW_ /1DE=;136G]>5@>O]>=SDM*_P"2F>(_^O*S_P#:E5_AQJ%HFA_V
M(TZ+J=I-<&>U)P\8\YB"1Z$,.?>NUHI+3[OU;_4'K_7E8Y/XE\^ =1_WH?\
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M]O:FMUVNO_;7^H/1/T?X77Z'H%<_XM\667A33/M$\ML;AF416\MPL;."P4L
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M#)M\R0C\2@_"AM)-]K_E?_@#2OI_6]O^"=.^MZ5'J(TY]3LEOFZ6S7"B0_\
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M.:"10R21L&5AZ@C@BO.[R:74?#_P_O+Y%:ZGOK9I69>6)B?K]>M>CJJHH50
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MG<J8W'.,#&1U-6Z/,/(Y^]\)6]QJDVHV6HZCI=U< "X:RD0"; P"RNK#('<
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MZ%)/+9S.A"3&8_(%/0[%9UXZ9%:-M+<>$M=U@7&FWUUIVHW/VR&>RMVG*.5
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MN=%BMM&8D6U]I\.HVF>S%%$RC_@6&_X&:[;78WF\/ZE%$C/(]K*JJHR6)4X
M'<UR-QIVH6G@/PWJ=I93/JNC00R?90A$DB[ LL6,9R03QZJ*2=KM^7Z_\ IJ
MZ2]?T,GXFG^VEOHP<VFB)"[8Z&YDD4 ?\!3/_?8KL=3UC4GUN/0]$CM?M2P"
MXN+B[#-'"A.%&U2"S$@]QC%<YJ&B:BOPJO%DM9IM7U"5+RYBC0L_F/*C%<#G
MY5 'T6IO$N@VJ>,$UK4O#YUG3KBT6WD$=MY\EO(K$A@G4J0V#C/2BUO=??\
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M/2A.\DWY_E_2':R:7;]?Z98EUG6=5UJ^L- 2QBAT]A'<7=ZCR!I2 VQ$5EZ
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M[OE^49! )P#CC- &Y4-W:PWUG-:7"EX)T,<BABN5(P1D<CCTK"?QYX;1"_\
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MNYA!!E20SD$A<@8' /7%)=ZG9V5W:6EQ-LGO&9($"DER%+'H., =3Q0!,;2
MWBWAB4W"QF-9#U"D@D#ZD#\A4U<YIFN:)IGAK3[@ZS/<64\ABAO+TLSR-EC\
MQ*C&,,,D 8%8^M?$K38+>RDTMYIQ+>Q0RNVGW&WRV/S%3M +8Z 9SV!HZV"W
M]?UZ'=T5FP:]IUQ<65NDTBSWL3RP1R0.C,J8W$AE&W&1P<&IWU.S35H]+:;%
M[)"TZ1[3RBD G.,=2.,YH MT5@3^-- MKI[>:]="DGE/*;>7RE;.,&7;L'/'
M)JCJAS\3?#I'3[#=_P XZ%K;^NEP>ESK:*X?P-JEG:6\UC/-LN;S5[\0*5.'
M*R$L,XP#CG!-=;+J=G#J=OIKS8O+A'DCC"DY5<;B2!@=1UH[?UT#N6Z*H:IK
M-CHT*2WTK()&VHJ1/(SGK@*H)/Y55@\5:/=:=<7T%Q++%;,$F1+:4RQD] 8M
MN\=?3WH V:*Y;P1XM7Q1I0EF5UO TA<+:RQQA1(57#,,$X R 2>O2MVWU2SN
MM0N["&;==6>SSXRI&W<,J<D8((],T[ 7**SK#7=,U/4;^PL[M9;JP<)<QA2/
M+)Z<D8/0],U%#XETBXUIM(BNRU\K.OE^4X!9 I8!B-I(#+P#WI :U%9TFNZ9
M#KT.B27:KJ4T1FC@VG+(.ISC'8\9SQ46H^)M(TF_BL;V[\JXEV%5$3L!O;8N
M2 0N6XY(H UJ*SM6UW3-#%J=2NEM_M4ZV\.5)W.>@X!Q]3Q4]YJ5I82VL5S-
MLDNY?)@7:27?!..!QP"<GB@"U15.XU2SM-0L[&>;9<WF\0*5.'*C+#., XYP
M346HZI86\W]GW%T\-Q/;RRJ(U;<$4?,P(!QC(Z]^F:3=E<:6IHT5SL'B/0M(
MT32S/K$DEO/:^9;W-UN9YT502S''WB".H!)/ K*U7XB6-M>Z*EE]HDM[R<K.
M[:?<9$>QC\GR<MN XP3C/'>J:UL+I<[>BJ%OK5A<W\=C%,WVJ2V%VL3Q.A\H
MG )R!@Y['GVJ1-3LWU672UFS>10K.\>T\(Q(!SC'4'O2 MT5@)XUT![M+87S
MJTD@C21[>58F8\ "0KL)S[UGO(D/Q7DED=4C30MS,QP !,<DFC^OPN'?^NMC
MKZ*Q=.\6:-JUVEM97$TCN"48VLJ(X'=790K?@:Y7PEXHT?1M.U*"]NF$HU2\
M=DB@DF*+YK?,P13M'!Y.!1_7X@>B45GSZWIMOI*:H]VALI I26,%P^[IM"@D
MY]JBTKQ'I6M32PV5PYGB 9X9H7AD"GH=KJ#CWQB@#5HK"M/&.@WU]#96M_YM
MQ,7"HL3\;2P.X[<+RK8W8SCC-)#XT\/W%ZMK%J(9WD\I)/*<1._3:LNW83[
MT ;U%<+<:O8:/\3]1FOI_+5]*MU155G=SYDAPJJ"S'V -=7I6M:=K=N\^GW
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MUF-RPL9W8%54KL*KAAR<E0<>U'8#L:*16#H&&<$9&1BEH **** "O(?V@/\
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M6C7[-$-/TN&0QQ;B6,S *#C&,!<\YSDT=EZ?E_P [OU_/_@DOC/_ )$?7?\
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MMHL[$W%L9))Y))ZDT?Y+\ ?ZO\3G?&W_ !^^%?\ L-1?^@/2_$#_ )!.E_\
M87L__1HKH;[3+/47M7NX?,:TG%Q"=Q&R0 @'@\\$\'BC4-,L]5BBBO8?-2*9
M)T&XKAT.5/!'0]NE):6];_E_D#_2WY_YG-:7#&WQ4\0S% 9$L;55;'(!+Y'Z
M#\J3P5;0QZWXOE2-5D?52K,!R0(T./S8_G731:99P:G<ZE'#MN[E$CEDW$[E
M3.T8S@8R>@HL],L]/ENY;6'RWNYO/G.XG>^ ,\GC@#@<4+;Y6_$'K?U7Y'E,
M?VD>#_#:PR6\4"^()E9KF,O$I\R7R]R@KQNQCD<XKMCH.OWFOZ5J6I:EIA6P
MD=@MK9R1NX9"I4EI&XZ'IV%;">'=)CT>32/L,;6$K.SP2$N"68L3R2>I)]NU
M0:9X4T?2+M;JS@F$RJ41IKJ6;8#U"AV('X4T_P"ODE^@2U_KS;_4R_&&W^WO
M"GVK'V#^T&\S=]WS?+;RL_\  NGOBCQ[M\K0_*Q_:']K6_V7'WOO?/\ ALW9
MKI;_ $^TU2RDL[ZWCN+>08>.1<@UGZ;X4T72;P7=K:,;E5*++//),R*>H4NQ
MVCZ8I+2WK?\ K^M@?Z6_/_,R/"L$0\:>,K@(/-:[@0OWVB%2!^II_@L!-2\5
MQJ,(NL.0HZ F-"?U.:Z*UTRSLKN\NK>'9->.))VW$[V"A0<$X' '3%%EIEGI
M\MW+:P^6]W-Y\YW$[WP!GD\< <#BA:?=8'U];G-6\R:7\4=0BNF"#5K.%K5V
M. [1;@R#WPP.*F^(=Y'#X.O;(8>[U%/L=K"/O22/\HP/;.3]*V]6T73=<M/L
MNIV<=S"#N <<J?52.0?<52TSP?H.D7HO;2Q)N@-JS3S23NH]%,C,5_"C=),=
M[.Z,:RB6W^)<=O>D-)'HT:V);H<,1+M_VON9]JM?$K_DGFL?]<E_]#6MO5M#
MTW7(8XM1M1,(VWQL&9'C;U5E(93]#4-OX;TJVTRZTY;=Y+6ZSYR7$\DQ?(P<
MEV)Z>]#;?]>=Q1M%_P!=K&)XCV_\)?X/^U8^Q>;-C=]WS_+_ '>??[^/>G>-
M=O\ :7A?R,?VA_:J>5C[WE[6\W_@.WK^%:Z>%]'31WTEK0S63MN,=Q,\Q!XP
M0SL2,8&,'CM1IGA;1]'NC=6EJWVDKL\Z>>29POH&D8D#V%-;KR=_Z_K873Y6
M_K^MS \"?9/[=\8;-GVO^UF\S^]LVC;^&=WZURNI>:MIJ!LWMX],_P"$KCRT
MR%X1\J[BP!&5\W&>1S7H=SX+T"[GEG>Q9)II&DEE@GDB=RV,Y9&!(X''3VJ^
MFBZ8FC_V0MC -/V>7]GV#85],4EI;R2_"W^13U;\_P#@_P"9@S:#XAU#5M)O
M-0U/2MEA<><OV6RDC=@5*E=S2L,$'T["HO -O%'-XGG5 )9=;N [8Y(&,#]3
M^=:VF^$=%TF[CNK2VF$L0(C,MU+*(P1@[5=B%X/85HV&F6>F?:?L</E_:9VN
M)?F)W2-]X\GCIT'%-:?UYK_(73[OU_S&:OJ]GH>F2W]]+LAC'899B>BJ.Y)X
M K&\-Z7>W&H3^)-:C\K4+J,106V<_9(,Y"?[Q/+'UX[5I:YX;TKQ'%;QZK;O
M,MO)YL6V9XRC^H*,#FJ]AX/T;3+V.\M8[P31YVF34+B1>1CE6<@]>XI+S!['
M,)H<'CGQ'J]UJ=S-;G39WL((;1_)D";02[N/F;=G(&=N.QYK5\#/)9-JOAW?
M'-;Z/,D,$\<:IN5D#;6"X&\9Y('.:U-4\(Z'K%Y]LO+(_:BNTS0320NP]&:-
M@2/K5;5?"Z+X,O=!\/Q6UC]I0QY)( #'#L2,DMMSUZFA:+^OO&]6=)7(:_>W
M'B*_E\+:1(43 &J7J?\ +O&?^6:G_GHP_(<^E=/8V<.G:?;V5NH6&WC6)%'8
M 8%<^OP\\-)+-)':7<332-+)Y6HW"!G/).!(!FAI7\A)Z>94\9VL&E:#HDD$
M8BL=+U*U=E7@)$#LS]!N!_"IOB$RS^'+>PC8&>^OK:*%0>6/FJQ(^BJ36_;:
M/8VNE'3$A:2S*LK1SR--N#=02Y)(Y[FJ&F>#M!T>]6[LK#;.BE8VDFDE\L'J
M$#L0@_W<4[ZZ][_E_D'33M;\_P#,K>(]:NFN4\/Z&5;6+E,O(>5LXCP96]_[
MH[GVK4TG3;+PWH4-E"VRVMD):21N3W9V/J3DDUG7/@3P]=ZE<ZA):W*W5TP:
M:2*^GCWD# R%<"K \):-_8ESH[03R6-R<RQRW<SENG\3,6 X' -+6WF/2_D8
M^GK+XSUJWUN9&30[%R^G1L,&YDZ>>1V4<[1^/I79US,7@#P]#L$<-\H3&T#4
M[G QTX\RI[K09KWQM8:Q.T1L["UD2"/)+^<Y 9B,8QM&!SGDT]-$+NQOC;3Y
M=0\+71MAF[M=MW;8Z^9&0X_/&/QK+T2]A\5>+7UJ$A[.QL$A@/;S9@)'_$+L
M'XFNU(!&#T-9VCZ%IGA^R:STNU6VMVD:0HK$Y9NIR234]_ZUM;\@>W]>OYGF
M5M;Q77PY\%03H'B?6HPRGH1YDG%=CX]XM-"]!K5I_P"AUKQ^&='BT^QL4M,6
MUC.+BV3S'^20$D'.<GECP<CFK6J:59:S8O9:A )K=B"5W%2"#D$$$$$'N#FJ
MO^=_R_R&]7]_XN7^9SVKD)\3/#;,<![2\12>[?NSC\@:AO+N%?BS:KO!>#19
MGD4<D R)C^1K<N/"^D76F0:=<6SRP0-OB+SR&1&YY$F[>#R><TFG^%=%TJ\6
M\L[+9=*C1^<TKN[!B"=Q8DL?E7DY/%+]+_C<7?SM^!Q>M:GKVO?#G4M9>XTN
MPTFXLI)([<P--*R$' 9]ZJK'V4X/K6A;L7\6^"V8DL='G))[_+%6U_P@OAO=
M+G308Y-Q,!FD,(+=2L>[8I]P :TUT73TO+*Z6WQ-90M!;MO;Y$. 1C.#]T=<
M]*:LG_79K]1/7^O-/]#SF*WD'@B_U6W0M<Z1KUS?1@=2J3-O'XH6%=)X7GC\
M0>)]8\11L)+5 EA9N.A11ND8?5FQ_P !J_J0M/#>C7%OI^E7=RUX\KK!;Q/,
M'E?).X\A 2>I( J?PCH2^&_"NGZ4 N^&(>:5Z%SRQ_,FE';[OOLD_P OQ&_\
M_NNVOS*^M:SJ2^(+30M'CM!>30/<O/=ABD<:D+PJD%B2>F16/X9^V)\1_$,5
M]>V]W<+96OF-;P&%0<O@%2S<@'KGN*ZC5O#^F:V86O[=GD@),4L<KQ2)GKAT
M(8 ^F:--\/:5H\[S6%FD$LB".1P22X!)&XD\G)/)YYH7^?X@_P#(QOAM_P B
M/:C_ *;W'_HYZK>(+R+PQXRM]<F.VTO;&6VG/;?$#)'^)'F"NAT_P[I>E7T]
MW8V[PRSEC(HF<QY8Y)"%MJDGN *DUC0]-U^T2UU2U6XA25954L1AUZ'((-#U
ML_ZVLQ]7_76YYXKGP7XRTS4[P[(M6TIUO"!P;E!YA)]SD@5HZCIDFA>&-%UJ
M08O+"]%[>$>DS$3#Z /_ ..BNQU;0=,UP6HU*T6X%K,L\(+$;7'0\$9^AXJU
M>V=OJ-C/97<0EMYT,<B$D;E(P1Q3OV_I7O;\T+U^?W6/-=:;=$/'$9S]CUE2
MK ?\NB_N' ]B=S?C6I)I \4Z3XIOT.9+YC!9./X5@^X0?^N@8_E75KH&EKX?
M_L$6BC3/)\CR-S8V8QC.<_CG-6;"PM=+T^"PLHA%;6Z"..,$G:HZ#)Y/XTNC
M2^7X?JKA?5/^OZU//#CXC1.R\+;Z,-I_N7<PS^:[!_WU6AX?U+_A+?$6EWQ'
M[O3--$DJG^&YE^4CZJJ-_P!]5U>DZ%IFA)<IIMJMNMS,UQ* Q.YVZGDG'T'%
M-T[P]I6DQWL=C:+"M]*TUP ['>[=3R>/H,"G?6Z_IZ_Y_@@MI;^K:?Y?F97C
MN%TT.+5H5)GTBX2]7'4HIQ(/Q0M6=:NFM7_B?7D8/;QVIT^T<<@JJ%I"/JS8
M_P" UU=CHVGZ=HR:1:VX2P2,Q+"6+#:<Y&223U/>F:=H6FZ3HJZ18VHAL%5D
M$09CPV<\DYYR>]3)74DO.WS5AIZIO^K.YY_IEO%<R_# 3('"64LB@C^(0K@_
MA72^+?\ D8_"'_82?_T2];,/A[2[=M,,5KM.EQM%9_O&/E*5"D=>> .N:DU;
M1K#7+9+?4(#*B.)$*NR,C#HRLI!!^AJY2O*Z[M_B2EI;RL8).SXN+NX\S1,)
MG^(B;G'YBJ4FJVUA\1/$=ZQ\Q+'18GF5.2-K.V/K@C\ZZ*]\+Z1J%K:6]S;.
MXM!B"03R++&,8XD#!^>_//>ET_PQHVE322V=BD<DL7DR,69O,3)/S9)R<DY)
MY/K4]-//\2M+Z^7X'!^,;OQ#>_#BXU2_N]*L[.>.*2.TBMWDD^9E*CS2X&[I
MR%_QK:OK"'5?B+<V%SN\FY\.F*3:<'#2D'!_&M5? 7AD1/$=-WPL"!%)/(Z1
M@_W%+$)_P$"M*YT'3+R[ENI[;?-+:_9';S&&8LYVX!QU[]?>GI^?Y6$F_P"O
M5/\ 0PK"^U7PUJFF:%JLL%]9W>8+.\B7RY5*+D+(G0_*/O+^(%-^'=M#'I>L
M2I&H>;6+LR-CEL2$#/X"M?3?"FC:5>B\MK:0W*J426XN99V13U"F1FV_ABK^
MGZ99Z5#)#90^5'+,\[C<6R[G+'DGJ31?>_\ 6HK=%_6AY_X<UN[TWPMI&FZ;
M!!)>WVH7<%N;@D11*DDC$G')P!P!C-7+<:G%\5=.CU/4+.YN#I<Y*VMLT(1=
MZ8!R[%N0<=.AKI9/">B2Z4NFM8C[*DS3HHE<,DC$L65\[E.6/0]Z?8>%]&TR
M[2[M+/;=(K*)WD=Y"&QG<S$EN@ZD]*2WO_6UAO6]OZUN<3HUO)#\(=?DT]-M
MW,U^Y9!\S,'<9^N!BK<>AZ[X@\$6^GP:IH2:9/:QB)H+"4,B@ J5/G8!&!SC
MJ*[?3M,L])L_LEE#Y4&]WV;BWS,Q9CDDGDDUD+X&\.I<>='8/'^\\WRDN95A
MW9SGR@VSK[4+_+\!M]5Y_B9ME:H?BS>2R@23PZ+ JR$>LCYQ]<5F:S]J35_'
MR6&X3MI,#J$ZE]D@R/? _05WB:99QZM+JBPXO)85@>3<>44D@8SCJ3VHBTRS
MAU.YU&.'%W<HD<TFXG<J9VC&<#&3T%#U5O)_B"T=_3\+&39_V/\ \(!#CR?[
M(_L\9SC9Y>SG-<CX8^U?VEX$^U[O._L>Y^_UQ^[VY_#%=:W@7PVTYE.FC:7\
MPP":00%LYR8MVSKS]VM:32[*74K;47AS=6T;QPN&(VJV-PQG!^Z.H[4V[MOO
M_P '_,FUH\O]=/\ (YOX>"$>#")]GG_:;G[;N_YZ^8V[=^&.O;%<-89_X0OP
MY_9\EM'8_P#"0R[7N(R\(&^3RMR@C(SM[CG%>FWG@[0;^^DO+BQS+-@S!)I$
M2;']]%8*_P#P(&IXO#>CPZ-+I"6$1T^5F=[=\LI+-N/7IR<^W:EUOZ?@4^WK
M^-_\S).@Z_>:_I6I:EJ6F%;"1V"VMG)&[AD*E26D;CH>G85!\/+>*+2]9F1
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M_P!$O0!] 4444 %%%% !17.^(=5OTU33M#TEXX;V^#R-<2)O$$28W,%SRQ+
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MG@MS%:Q.9 KD ON7H.%P,'@DGFIE\9:@WA."000?VY+J!TH+SY0G#E2^.NW
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M58DL#MS@$X!/XU=\6:->:A_9NH:;'#+?:;<><D,QPLR,I5TSV)!X/J!71T4
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\A_: _
MY%K2O^OP_P#H!KUZO(?V@/\ D6M*_P"OP_\ H!H [CX>?\D\T'_KS3^5=-7,
M_#S_ ))YH/\ UYI_*NFH **** "BBB@ HHHH **** "OG_1?^3EI?^ONY_\
M1+U] 5\_Z+_R<M+_ -?=S_Z)>@#Z HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KR']H#_ )%K2O\ K\/_
M * :]>KR']H#_D6M*_Z_#_Z : .X^'G_ "3S0?\ KS3^5=-7,_#S_DGF@_\
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M7'^*/%=]HGC'PSI%M%;/;ZI*Z3M(K%U *_=(( Z]P:["ETN'6P4444 %%%%
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M=N5 X]B:%KKZ_@#T_#\3<HHHH **** "BL[2==TW78)Y]+NENHH)3"[H#C>
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M110 4444 %%%% !1110 5\_Z+_R<M+_U]W/_ *)>OH"OG_1?^3EI?^ONY_\
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M$,MY;N9HE)R  /E.,]ZJ7Q.WR_4F.R_KT,OQ!XWUC5=(\(V.BSK8WWB  RW
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MJ-QH,[Q132=9>H4,?J.O7FNF\(>$[_0/$OB?4KJ6V>'5;D30+$S%E&7/S9
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M%^M6WB#SCYFF7(\N!QDX4*5QR/<'VKLM'\):MI?BKQ5JZW-HHU4+]D(+,8V
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M&XBD@?<[N20L:ICDDCKGO1MH&^IVU9EYX@TNPUFRTBYNME_>@FWB\MCOQUY
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M)^]U!)U0VOS*!\I&6SDCCI2D[*XXJ[L==JVK6.AZ9-J6HS^1:0@&238S;<D
M<*">I':IK.\@U"Q@O+5_,MYXUEC?!&Y2,@X/(X]:\GU?5-7U3X%WSZMIDEJ4
MM;813R7(F-TI*?O#CE2>N#SS4^E_$I]!\(Z)-+X<U!]&2WAMY-1W!1N"@':G
M4C((R<9QQ56LVNS7ZBW2:ZW_  L>L45S7B/QG9Z!!8"*VFU"]U%@MG:V^-TO
M .<GH.1S[U6T+QM)?Z[_ &%K&C7&C:JT/G112RK*DJ]]KKU/M[&DM= Z7.NH
MKS;XX_\ )/?^WR+^M<1=:;HNEZEH#?#S4KB;5Y9T^T06T[2IL_B+]@,\'/8F
MB/O.WG8):*_DW]Q] 45ROB?QO;^']0M=)MK"XU/6+H;HK.WP#M_O,3]T<'\J
MA\/^/$U/7#H.K:3<Z-K'E^8EO.P=9%_V''7OV['TH6NP/3<["BN/U?Q?K-C>
MW<=AX/O[^UM&Q)<B9(PP R2@/+^G'O45Y\1K-/AV?%]C9O<PAE4V\DGEL&+A
M2"<'IG\:.EQVUL=K5#6=:T_P_IDFI:I<?9[2(@/)L9\9.!PH)ZGTKDX/B=:O
MI^I:K<:3>V^CVD2M%>.IQ=.3C;&" #ST.?RKC/B!XXO=;^'D\=[X9OM.M[YH
MVM+EW5T<!@WS8P5) )'K2E=!%7/:K>>.ZMHKB%MT4J!T;!&5(R#S4E9V@?\
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M5=.U 66E>&;S57$0E:1)4BC4$D8W-U;CI[BJ&G_$.VU'PSK>J)I\\-YHZO\
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MTE7C^!/BV*4.LJ:B0ZNVYE.Z+()[FOH"BE;W6O*WXW&I>]?SN>3^,0!^SW:
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M/_)PL_\ V"!_,5T/Q*L+G4OA[K%K9PM-.T2LL:#);:P8X'<X!KJZ*35XJ/\
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M[^=_R_R/!KC0+_0?@#J@U*)H)[R[2Y\AA@QJ70 $=CQG'O71_$M0OP5L0H
M6TP!VX%>K44WK?U7X?\ #"6Z;\_Q/*/'*>$&FL9-6FU.PUF.S0VUY8QON;(.
M%!4$$YSP<'GK72?#"XU^Z\&12>(O.-SYK")K@8D:+C!;/.<YZ]L5V=%.^_G_
M )BMHEV_R/)/$VN7J^/KO3]?U/6M)T58T^P?V7&P-RV!G+JI;.<\#T[=\'PZ
MC1:1\3XY%O%;[-N O7W3[2DA!<_WL$9KWFBI2TMY6*OK?T/*8% _9Q(  _XE
MS'C_ 'S6-KEA>KX$^'_B"VM);N'21%+<0QKN.WY3G'_ <?C7M]%4V^9R7=/[
MB8JT5'U7WGA_CCQ;:>*]4\)RZ9:W1LXM1C+74T)C&]B,(N>O )...E>QZQ_R
M!+__ *]Y/_035VBIDKP<>]_Q*3]Y2[?YG@:?\FSR?]?'_M<5TWQ+4+\%;$*
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M3.[0'D$#*G&,CISQZ5TVL"7QI\69_"]_=W,.C6%H)FMX9#']H8A3\Q'4?/\
MI[T6O:W7_*X=[]/\['JU%>4:6DG@CXLV?AG3KNYFT?4;4RBUFE,GV=@&Y7/0
M?)^OL*R/!?A.W\5:UXQAU*ZNOL$>I2 6T,IC5G+-\[8ZX & >.M&^J[-_<[
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M#T3_ *Z'L"W7B(^,GMFL+<>'A;;ENMP\PR_W<;NG7^'\:W*\SA/_ !D).?\
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MR.JYYJ/X@Z%IVM^#[_\ M" R_9();F'#LNV14;!X(S]#Q7#>!/#^F6?P?O\
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M\QON8'&W./QQ6+H__)N&L?\ 7R?_ $9'52]V_DE^8H^\TN[?Y,][HKPC7_#
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M@N[HW5S'&JRSE=OF,!RV.V?2K5%'D!R?B_P2/$UWI^HVFIS:9JE@28+F- X
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MF<?A6WJ%A;:II]Q87D0EMKA#'(A[@U9HJI/F;N*.AYO_ ,*KN18G1U\7ZF-
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MVZZ1A=:BXE^?J(P,(/RR?QKN[S2]/U$QF^L;:Z,1W1F>%7V'U&1Q5L    8
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MT]ZS/C//KL'A"=K%[2/3"$%TY9Q/DN  F.,>N:U/AKJ-\^@0Z-J&B7^G3Z9
MD3/<QE4EZC*'OTY^M6OB3HM[X@\!ZCI^GQ^9=-L=(\XW;6#$#WP**VNJ%2TW
M.*\6'7#\#;C^VUT\-MM?LWV/?_JLIC?N_B^G%6)/'GB?P[X<T?5[C0;5?#[1
MQ0G,Q-Q@J '(' !QD#GJ.E-U^YU7Q)\'KO3U\.ZK;7UJ+: V\ENQ>4JRY9 !
MDKQUK1^(>EZA>_".TLK2QN9[M5MLP10LSC &?E SQ52=G)^:)@M(I]F;7BGQ
ME<Z;J.F:-HEG%>:MJ2F2,3R;(XHP,[V/7UX]C^,6@>+]5;Q2WAGQ)96<&H-;
M_:()[*0M%,O< -R#P?R/X\[X]\%3ZEJNAZ[_ &,^L6MO;+;WNGI*8Y"O)#+@
M@Y!)XSV%6?!.@:&GB*.]T[P)JFC&&)B+N^GD4[C\NT1ESG()Y/I26[^?_ &]
MEZ+_ ((SP_\ $#Q5XBU&6RL-%M)A:Z@T5W<Y*1Q6X8 8!?YG(#=/0<5;B\;^
M)O$%Q?S^%]+TV33+&9H?,O9V5[EE'/EA>!VQG_\ 4[X5:7>Z?:^(5OK*XM3-
MJ<CIYT3(70C@C(Y'O7$VW@.S\.WM[::_X(U'7(VG+6E]I\KG<AZ*ZJZ[<>I]
M:E;+T7WZ?U]Y;MKZ_AJ>@K\3=.'P\'BJ6W=6W>2;0-\WG9QLSZ=\XZ=JS+OQ
MOXST&PBUS7O#MBNC2%-Z6T[&>!6Z%L\'J.!C\*KZIX!&K_##[!HVBOHUTMT;
MR*QGN#(2PRO+,3@LO..@/XFH/$.J>*_&7AK_ (1F+PC?V5Y/Y:75U<X6! ""
M2K?Q<CM^M4]W;?3]/^#Z"5K*^VO_  /P^\I_&"[U>^L]$N;8Z>^BSW4,EH_S
M^:TI4D;NVS![<UZMHAU@Z7'_ &Z+(:AD[Q9;O*QGC&[GI7G_ ,0_#EY%X/\
M"^E:;:W-[]AO(%8PQ,Y"JA!8@ X%=EXFU[4=$.G_ &#1+C5/M-P(I?)W?N%_
MOG"GCZXHT2:7?_(G5M-]O\S?HHHI#"BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "O(?V@/^1:TK_K\/_H!KUZO(?V@/^1:TK_K\/_H!H [C
MX>?\D\T'_KS3^5=-7,_#S_DGF@_]>:?RKIJ "BBB@ HHHH **** "BBB@ KY
M_P!%_P"3EI?^ONY_]$O7T!7S_HO_ "<M+_U]W/\ Z)>@#Z HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K
MR']H#_D6M*_Z_#_Z :]>KR']H#_D6M*_Z_#_ .@&@#N/AY_R3S0?^O-/Y5TU
M<S\//^2>:#_UYI_*NFH **** "BBB@ HHHH **** "OG_1?^3EI?^ONY_P#1
M+U] 5\_Z+_R<M+_U]W/_ *)>@#Z HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KR']H#_D6M*_Z_#_ .@&
MO7J\A_: _P"1:TK_ *_#_P"@&@#N/AY_R3S0?^O-/Y5TU<S\//\ DGF@_P#7
MFG\JZ:@ HHHH **** "BBB@ HHHH *^?]%_Y.6E_Z^[G_P!$O7T!7S_HO_)R
MTO\ U]W/_HEZ /H"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "O(?V@/\ D6M*_P"OP_\ H!KUZO(?V@/^
M1:TK_K\/_H!H [CX>?\ )/-!_P"O-/Y5TU<S\//^2>:#_P!>:?RKIJ "BBB@
M HHHH **** "BBB@ KY_T7_DY:7_ *^[G_T2]?0%?/\ HO\ R<M+_P!?=S_Z
M)>@#Z HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M*\A_: _Y%K2O^OP_^@&O7J\A_: _Y%K2O^OP_P#H!H [CX>?\D\T'_KS3^5=
M-7,_#S_DGF@_]>:?RKIJ "BBB@ HHHH **** "BBB@ KY_T7_DY:7_K[N?\
MT2]?0%?/^B_\G+2_]?=S_P"B7H ^@**** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\A_: _Y%K2O^OP_P#H
M!KUZO(?V@/\ D6M*_P"OP_\ H!H [CX>?\D\T'_KS3^5=-7,_#S_ ))YH/\
MUYI_*NFH **** "BBB@ HHHH **** "OG_1?^3EI?^ONY_\ 1+U] 5\_Z+_R
M<M+_ -?=S_Z)>@#Z HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ KR']H#_ )%K2O\ K\/_ * :]>KR']H#
M_D6M*_Z_#_Z : .X^'G_ "3S0?\ KS3^5=-7,_#S_DGF@_\ 7FG\JZ:@ HHH
MH **** "BBB@ HHHH *^?]%_Y.6E_P"ONY_]$O7T!7S_ *+_ ,G+2_\ 7W<_
M^B7H ^@**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH *\A_: _Y%K2O^OP_^@&O7J\A_: _Y%K2O^OP_^@&@
M#N/AY_R3S0?^O-/Y5TU<S\//^2>:#_UYI_*NFH **** "BBB@ HHHH ****
M"OG_ $7_ ).6E_Z^[G_T2]?0%?/^B_\ )RTO_7W<_P#HEZ /H"BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O(?V@/^1:TK_K\/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "O(?V@/^1:TK_K\/_H!KUZO(?V@/^1:TK_K\/_H!
MH [CX>?\D\T'_KS3^5=-7,_#S_DGF@_]>:?RKIJ "BBB@ HHHH **** "BBB
M@ KY_P!%_P"3EI?^ONY_]$O7T!7S_HO_ "<M+_U]W/\ Z)>@#Z HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ KR']H#_D6M*_Z_#_Z :]>KR']H#_D6M*_Z_#_ .@&@#N/AY_R3S0?^O-/
MY5TU<S\//^2>:#_UYI_*NFH **** "BBB@ HHHH **** "OG_1?^3EI?^ONY
M_P#1+U] 5\_Z+_R<M+_U]W/_ *)>@#Z HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KR']H#_D6M*_Z_#_
M .@&O7J\A_: _P"1:TK_ *_#_P"@&@#N/AY_R3S0?^O-/Y5TU<S\//\ DGF@
M_P#7FG\JZ:@ HHHH **** "BBB@ HHHH *^?]%_Y.6E_Z^[G_P!$O7T!7S_H
MO_)RTO\ U]W/_HEZ /H"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH S];UO3_#VE3:EJ<XAMHAR<
M9)/8 =R:XJW^)6L:A"M[IO@35;C36Y$YD578>JI@[OP-9OQM8>7X:6ZS_9AO
M_P#2?3MU_P" [Z]4B\OR4\G;Y6T;-O3';'M1'5-^=AO1I>5Q8V+Q(Y4J6 .T
M]1[4ZO*=8$OC3XLW'A:_N[F#1["T$S6T,AC^T,0I^8CJ/G_3WI-+23P1\6;/
MPSIUW<S:/J-J91:S2F3[.P#<KGH/D_7V%-:V\[V_'_(35K^6_P"'^9ZO37<1
MHSMT49->)^"_"=OXJUKQC#J5U=?8(]2D MH93&K.6;YVQUP , \=:TO .GQ>
M)O NM:%KKRWUI87[QP^9*P;"C(Y!SP>U2W[M_*X[:V\['H7AWQ-9^*M'DU+2
MEE,*R/$GFKM+,O?&>G-)X5N?$%WHWF^)K&WLM0\QAY5NP*[.QX9N>O>O.?@Q
MX>TQ?"DVOBW/]I$S0&;S&^Y@<;<X_'%8NC_\FX:Q_P!?)_\ 1D=5+W;^27YB
MC[S2[M_DSWNBO"-?\,#3?A9IWBU-3OSK<,5O(D_GD!5;: BKT  (Z>E;OCNX
M>[U?X;7,N/,FNXY&QZDQ$T^7WN7SL).ZOY-_<>M45YCX_(_X6?X#&1GSY#C\
M4KF]=U1-?^(FM6FM:3X@U;3M/*PV]EI2,50]W?:0<DC@_P"%0M;?/\+?YCZO
MY?C?_(]RK'\67USIGA'5[ZSD\NYM[222)]H.U@I(.#P?QKS/0M<U_0_!WBXM
M9:S;6MFGFZ6^J0LLB*V1MRW7;P>IJB/!-LWPCG\2_P!J7W]KW%DUS-.;EBLH
M.<QL,X(QQZYHEL_1?B5'=>OY'J/@74[S6?!.E:C?S>==3P[I)-H7<<D=  !7
M0UR7PQ_Y)MH?_7#_ -F-9WC^?PY/J-AI^KMJMY<E':/2],+EI@<?,P4CIM.,
MD=ZNII*R,Z>L4V=]17D7PZO)++X@ZQH=K#JEII9LQ<166I']Y"P*C@;FX.X]
M_2L3X>>#;;Q3X1U>34KR\\F&ZE6VABF*)&^T$O@?>/3KGI4O17\K_C8M+\[?
MA<]XKDOB7K6H>'_ M[J6EW'V>[B:,))L5\9< \,".A]*\YM_%FL6_P  6NEN
MYC>?:C9K<;B75"?7KG'&?I3?'/@2RT#X9+J-EJ%Y]H<0F[WW#,ET6(Y*GC(.
M"/I2FK7\K?C9A#6WS_#0]HTB>2ZT6PN)FW2RV\;NV ,L5!)XJEJ/B?3],\0:
M9HDPE:\U'=Y(1<J  22QSQTJSH'_ "+FE_\ 7I%_Z *\F\9>#-"D^+>@VK69
M,.K&:6\7S7_>-R<YSQSZ8JY_Q+>;_4BG_#N^R_0]JHKR?Q'$^H_$#0_ ,5U<
M6.APV0D>."4JTP4-A-W4@!1^M,EL_P#A7?Q'\/Z?HMS<G2]6W136,LID5""!
MN7/3J#^!I+5KSV_KY%/1/RW/5YV*6\KJ<,J$@_A7&_"O7]3\2>#1?ZM<_:+K
M[3(F_P M4^48P,* *[&Z_P"/2;_KFW\J\.^&G@>R\5>!;B;4KZ[PEQ(MM%%.
M42W8 '?@=6R>_8"I3MS>GZ@UMZ_H>[45X%!XWUN'X+RXNYVNUU'^SENU),GE
ME=W!]<9 -!$^DW6FWWA7PQXTM;Z*=#>/=VTC)=1]&WC)Y_#^E5;WK>GXZ_J#
MNEKY_@>^T4G)7(X)'&:\#MH+?1-=FF^(UAK/VR6[/V?5DG<P*,Y &TX XSCG
MCL,4EK*P?9N>P7=UXC3Q?8VUKI]M)H#PL;JZ9AYD<GS8 &\<<+_">M;M>7ZZ
MP;X^>&&4@J=/D(([\2UF>'M*C^(OC/Q'?:Y=W9CTVZ^SV=M#.T8A + ,,=#\
MOYDT+5+Y_@[#E9/[OQ1['17CGP]CE@U'XBPS7+74D3&,SOC<^T2C)QWXYK'\
M+>#H-8^$-QJU[?7AGM8YY+)(YBJ6^S+<*."2V<D^M)NROY)_>'+KR];V/>Z*
M\2U/Q=K"?!70)5N;G[7J$_V26XAR9BBLX^4_WB% JK!Y^DZWI%WX5\,>,;)U
MN5%^+VWD:.XC/#%N3\WX ?E5\OO<OG8F_NW^9[O7"Z!XAU2]^*GB31;BZWZ?
M9PQM!#Y:C82%S\P&3U/4US4.FKX_^*FOVNM7-S]@TD*EM:QS-& >F[CZ$Y]Q
M2_#K3VTKXM>*K%KN:[\F!%6:9]SE<K@$]R!@?A4PU:?=-CGHFNS1Z]17*?$C
M7;OPYX%U#4+ [;D!8XWQG868+N_#/YUQ%[X%MK#X?'Q1!J^HC7H[-;PW_P!J
M8EVQNV]>G.*5]&WLAVV75GL5%>'^,=4OO$?@SP%?M+]GOKF]0>:%^[)]W>!]
M1FKNO:''X&\>>$[K2+V^+ZC=?9[SS[AI/.&5!+9[_,?;I5):V?>Q-[JZ[7/8
MZ**\1\%>&/\ A*/$GB1;V^NHM/L=9>=+>!@HEEWG!?(.0 HP/>DM78;T5SVZ
MBO Y-3B\3>*M=FU[1?$NKQ6MTUO:0Z6CF*V"DC)VL/GXS5L:3KGB'X5ZM:ZC
M::G'=:1=&YTU]0A9)FB SCGJ<;AQWQ23]WF?K\OZU';WK?+^OR/<:*\:\3Z^
M?'.A^#M!M9/WNLNDUYM/W4CX?_QX,?\ @-0>+M12_P#B++X?OM-UN_T33;1
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M HHHH **** "BBB@ KR']H#_ )%K2O\ K\/_ * :]>KR']H#_D6M*_Z_#_Z
M: .X^'G_ "3S0?\ KS3^5=-7,_#S_DGF@_\ 7FG\JZ:@ HHHH **** "BBB@
M HHHH *^?]%_Y.6E_P"ONY_]$O7T!7S_ *+_ ,G+2_\ 7W<_^B7H ^@****
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M$8E48PJ@$! .3WSFM'6? C7>O2:[HFLW.BZI,@2:2*-9(Y0.FY&X)X%=A12
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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ML_\ @Z7_ ..T?\(G\9/^?G6?_!TO_P =H ^BZ*^=/^$3^,G_ #\ZS_X.E_\
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M?_!TO_QV@#Z+HKYT_P"$3^,G_/SK/_@Z7_X[1_PB?QD_Y^=9_P#!TO\ \=H
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M1_PB?QD_Y^=9_P#!TO\ \=H ^BZ*^=/^$3^,G_/SK/\ X.E_^.T?\(G\9/\
MGYUG_P '2_\ QV@#Z+HKYT_X1/XR?\_.L_\ @Z7_ ..T?\(G\9/^?G6?_!TO
M_P =H ^BZ*^=/^$3^,G_ #\ZS_X.E_\ CM'_  B?QD_Y^=9_\'2__': /HNB
MOG3_ (1/XR?\_.L_^#I?_CM'_")_&3_GYUG_ ,'2_P#QV@#Z+HKYT_X1/XR?
M\_.L_P#@Z7_X[1_PB?QD_P"?G6?_  =+_P#': /HNBOG3_A$_C)_S\ZS_P"#
MI?\ X[1_PB?QD_Y^=9_\'2__ !V@#Z+HKYT_X1/XR?\ /SK/_@Z7_P".T?\
M")_&3_GYUG_P=+_\=H ^BZ*^=/\ A$_C)_S\ZS_X.E_^.T?\(G\9/^?G6?\
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M/^?G6?\ P=+_ /': /HNBOG3_A$_C)_S\ZS_ .#I?_CM'_")_&3_ )^=9_\
M!TO_ ,=H ^BZ\'^.OB.UU"[T_P /63K//;R&6?R_FVN1A4X[\G(^E9\?@OXO
MW1:&>^U..-A@F;6-RGVP'/\ *NR\!?!R+P_?Q:OKEQ'>7\1W10QY,<;?WB3R
MS#MP /?@T >@>%]-DTCPII.G2@"6VM(XY,?W@HS^N:UJ**!!1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
61110 4444 %%%% !1110 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
